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Stellingen behorende bij het proefschrift van Ellen van den Bogaard
From skin development to disease 
pathogenesis and therapeutics 
‘The power of 3D skin models’
1. Een knock-out muis kan een vertekend beeld geven van de werkelijkheid. 
(dit proefschrift)
2. 3D huidmodellen zijn een goed alternatief voor het gebruik van proefdieren. 
(dit proefschrift)
3. Koolteerzalf herstelt de huidbarrière en remt de ontstekingsrespons bij 
eczeempatiënten door activatie van de arylkoolwaterstof receptor, (ditproefschrift)
4. Nu de werking van koolteerzalf bekend is kunnen we gericht op zoek naar een 
beter en patiëntvriendelijker alternatief, (dit proefschrift)
5. De farmaceutische industrie zou er goed aan doen om de arylkoolwaterstof receptor 
te beschouwen als een farmacologisch target in plaats van een graadmeter voor 
toxiciteit, (dit proefschrift)
6. Je moet schieten om te kunnen scoren. (Johan Cruijff)
7. Waarom aan één project werken als je er ook tien naast elkaar kan doen?
8. Your skin is in 3D... so why is your cell culture not?
9. Het succes van een 3D kweek heeft veel weg van een verbouwing: je bent 
afhankelijk van goede kwaliteit materialen, vakmensen en een flinke portie geduld.
10. Als je werken leuk vindt, hoef je nooit te werken. (Mahatma Gandhi)
11. Vakantie is een hinderlijke onderbreking van het werk. (Joost Schalkwijk)
12. De combinatie van stelling 10 en 11 maakt dat dit promotieonderzoek is een grote 
vakantie is gebleken.
13. Whoever said diamonds are a girl's best friend... never owned a dog!
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"It seems to me as if  these stripes 
I follow  on the road 
were sim ply put there 
ju st to lead me back to you"
Douwe Bob 
- Stone Into The River -
Preface
We can simply describe our skin in a few key words: largest organ, barrier function, host defense, 
and esthetic appearance. For many people the last one may be the most important, but from a 
scientific point of view, barrier function and host defense are fascinating aspects of skin biology. 
Dysfunction of these biological processes invariably leads to disease and compromised esthetics. 
The implications are therefore not only of medical significance but may also have a strong psycho- 
social impact. To perform experimental dermatological research we need model systems in which 
normal skin biology and the effect of disease-related factors can be studied. The search for 
appropriate skin models has started decades ago and is ever rising due to limited availability of 
human skin, and ethical issues with regard to animal experimentation. The development and 
application of in vitro cultured human skin models by academia and the pharmaceutical industry 
is therefore of utmost importance to move the field of skin biology forward. As described in this 
thesis, in vitro cultured 3D skin models are a powerful tooi for studying skin biology, disease 
pathology and therapeutics.
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General introduction
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1. Skin structure and function
Many reviews have been published about epidermal morphogenesis, skin function and skin 
diseases. In this introduction, the most relevant topics will be briefly highlighted.
The skin is the largest organ of the adult body, accounting for 15% of the total body weight. 
It is composed of a cellular epidermis and underlying dermis made of connective tissue. The 
basement membrane separates the two compartments and provides a strong adhesive layer for 
the epidermis. The dermis does not only provide strength and elasticity by the presence of collagen 
and elastic fibers, respectively, but also contains the hair follicles, sweat- and sebaceous glands, 
blood vessels and nerves. The epidermis is comprised of various cell types, e.g. melanocytes, 
Merkel cells, Langerhans cells and circulating lymphocytes. However, the majority, up to 95%, 
are keratinocytes 1. These keratinocytes form a stratified epithelium in which different layers can 
be distinguished. From the inside to the outside: the stratum basale (single cell layer), stratum 
spinosum (5-15 layers), stratum granulosum (1-3 layers) and the stratum corneum (5-10 layers) 
(Figure 1.1). These layers are formed due to the mitotic divisions of stem cells in the basal layers 
and the migration of daughter cells (transit amplifying cells) towards the skin surface. During 
this process the keratinocytes undergo a process called terminal differentiation or keratinization. 
During this differentiation process the keratinocytes will lose their nuclei and organelles to 
become corneocytes. The corneocytes are organized in lamellar layers and will eventually be shed 
from the skin surface, which is known as desquamation. In normal skin the journey from the basal 
layer to the shedding of the corneocytes will take about 30 days to complete2'3.
The skin is a master regulator of body temperature and serves as a barrier between our body 
and the often hostile environment. From the outside in, it protects against diffusion of water 
soluble molecules, chemical exposure, UV radiation and penetration of pathogens. From the 
inside out, outward passage of water and electrolytes is prevented thereby protecting the body 
from dehydration. The stratum corneum exerts most of the defensive functions of the epidermis4. 
However, in case of a barrier defect and penetration of potentially harmful stimuli, the Langerhans 
cells together with keratinocytes and the residing immune cells in the dermis will join forces to 
eliminate the potential threat and thereby providing a secondary defense mechanism.
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Figure 1.1 The morphology of normal skin. The epidermis of human skin can be subdivided into 
different sublayers or strata, depending on the differentiation stage of the keratinocytes. The stratum 
basale contains proliferating stem cells that continuously provide the stratified epithelium with new 
cells. During the differentiation process, the keratinocytes express distinct epidermal differentiation 
proteins which is useful to detect the different layers within the epidermis. In the final stage of terminal 
differentiation the keratinocytes will lose their nuclei to become corneocytes. These corneocytes form the 
main outer barrier of the skin, the stratum corneum.
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Recent studies have highlighted the importance of the skin as a microbial reservoir. The mapping 
of the skin microbiome in both health 5 and disease 6J has attracted global attention of scientists, 
and the importance of the composition of bacteria and fungi for skin homeostasis is nowadays 
widely accepted. The composition of the microbiome varies within the different layers of the 
stratum corneum and is altered upon skin barrier disruption 7. Characterization of the skin 
microbiome under dynamic conditions will generate deeper insights on the complex interaction 
between resident bacteria and epidermis.
2. Epidermal proliferation
The epidermis cannot properly differentiate without keratinocyte proliferation to replenish the lost 
cells. Within the basal layer, the presence of self-renewing highly proliferating cells, or stem cells, 
is vital. Methods to investigate stem cell properties and function have greatly evolved over the 
last decade resulting in elegant lineage tracing mouse models8-9 and inducible gene transduction 
strategies using tissue specific promoter driven Cre recombinase 10-11. From these studies, we 
know that stem cells are mainly present in three different areas of the skin: in the basal layer 
of the interfollicular epidermis, the hair follicles, and sebaceous glands. Most of the stem cell 
research in mice has focused on the hair follicle stem cells and led to the identification of a stem 
cell nice called 'the bulge'. These bulge cells are normally quiescent and become only activated 
just after the start of the growth phase. After self-renewal for a few days they return to their 
quiescent state 12. These bulge stem cells, after isolation and culture, can regenerate hair follicles, 
epidermis and sebaceous glands when engrafted onto recipient mice 13-14. Although, much of 
the present knowledge on human epidermal stem cells is attributed to the results obtained 
from mouse models, the human skin is different from murine skin. In mice skin, hair follicles are 
abundant and the primary source of epidermal stem cells, whereas in humans the hair bulge is 
less distinct and interfollicular stem cells appear to be the more abundant stem cell. Therefore, in 
human keratinocyte stem cell biology in vitro studies have set the paradigm. In the late 1980's, 
differences in proliferative potential of keratinocyte cultures prepared from the human epidermis 
were characterized, identifying populations of cells, called holo-, para- and metaclones 15. The 
holoclones gave rise to the largest colonies in clonal growth assays and are rich in markers of 
the epidermal basal layer, including (31 -integrin 1È. Subsequent studies revealed that these cells 
are rich in a6-integrin and express low levels of CD71 (transferrin receptor), and display many 
characteristics of stem cells including quiescence and long-term growth capacity and they are 
generally detected at the downward tip of the rete ridges17.
Amongst others, the transcription factor p63 has been suggested as a putative stem cell marker. 
p63 is a member of the p53 gene family including p53, p63 and p73. p53 is recognized as a 
prototypical tumor suppressor gene, with many p53 loss-of-function mutations found in various 
types of cancer '8. p63 and p73 play a role in morphogenesis with p63 being the master regulator 
during ectodermal and epidermal development. The human p63 gene is located on chromosome 
3q28 and upon protein translation, two classes of proteins are generated based on their different 
N-terminal ends. The TAp63 form contains an N-terminal transactivation (TA) domain, which is 
lacking in the N-terminal truncated (ANp63) isoform. The latter is the major isoform expressed in 
the epidermis. The ANp63 isoform is mainly expressed in the basal layer and downregulated in 
suprabasal keratinocytes '9. There are many indications that p63 is required for the proliferative 
potential of the epidermis, although its requirement of the maintenance of stem cells is debatable.
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Nevertheless, epidermal cells lose their donogenic potential upon p63 knockdown in vitro 20. In 
addition, p63 knockdown in embryonic stem cells prevents ectodermal cells from differentiating 
into epithelial cells, whereas overexpression of ANp63 enhances differentiation of ectodermal 
cells into keratinocytes 21. The crucial role of p63 in epidermal formation is furthermore 
demonstrated by the phenotype of p63 knockout mice, who have no epidermis and are devoid 
of epidermal appendages. Moreover, these mice have truncated limbs and abnormal craniofacial 
development22. These features recapitulate with the phenotype of several ectodermal dysplasia 
(ED) syndromes in human, where a heterozygous mutation in the p63 gene is responsible for 
abnormalities in ectodermal structures such as hair, teeth, nails, craniofacial structures and digits 
23. The ectrodactyly, ectodermal dysplasia, and cleft lip/palate (EEC) syndrome is one of seven 
clinically different diseases in which p63 mutations are reported 24. Within these p63-related 
diseases great clinical variability is present probably based on the type of p63 mutation present. 
Mutations involved in DNA binding as well as global protein structure or stability may influence 
the transcription of p63 target genes causing a large variety in clinical phenotypes23. Therefore 
the study on patient-derived keratinocytes with defined genotypes may shed further light on the 
effect of individual mutations on the expression of p63 target genes and the subsequent effect 
on epidermal development. This work is part of Chapter 7 of this thesis.
3. Epidermal differentiation and skin barrier function
3.1. Proteins involved in epidermal differentiation
When the newly formed cells in the basal layer start their journey to the surface of the epidermis, 
they undergo a tightly controlled process of morphological and biochemical changes that 
transform them from keratinocytes into corneocytes (Figure 1.1). The first change in keratinocyte 
structure is the strengthening of the keratin intermediated filament network to anchoring 
desmosomes in the cell membrane. Large amounts of new sets of keratins, K1 and K10, are 
synthesized to replace the K5/K14 heterodimers which are characteristic for basal keratinocytes. 
25-26. The keratin intermediate filaments, together with microtubules and microfilaments, form 
the skeleton of the epithelial cells to provide mechanical strength. The transition of the spinous 
cells towards the stratum granulosum is characterized by the presence of keratohyalin granules 
in cells of the stratum granulosum. This last living cell layer of the epidermis plays a key role in 
the development and maintenance of the skin barrier. The keratohyalin granules secrete proteins 
and lipids that form a lipid-enriched extracellular matrix in which the corneocytes are embedded 
27'29. The corneocytes are formed by the programmed cell death of the cells of the stratum 
granulosum whereby nuclei and other organelles are lost due to the release of proteases and 
other lytic enzymes. The corneocytes form a stable and insoluble cornified envelope (CE) which 
consists of more than 20 proteins crosslinked together in a orchestrated manner by calcium (Ca2+) 
dependent transglutaminases (TGases)30. The presence of Ca2+ is important for the initiation of 
epidermal differentiation and within the epidermis a concentration gradiënt is present, with the 
highest concentrations found in the stratum granulosum, while the stratum basale has a very low 
Ca2+ concentration 31.
The first terminal differentiation protein to be incorporated in the CE is involucrin. Involucrin can 
already be detected in the stratum spinosum but maximum staining intensity is reached in the
13
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stratum granulosum and inner stratum corneum. The incorporation of involucrin in the CE is 
mediated by a cross-linking reaction catalyzed by TGase 1 28'32. Involucrin is cross-linked to almost 
all other CE proteins and serves as a principal substrate for attachment of ceramides to form the 
lipid envelope 33.
The main component of the CE, is loricrin. About 70-85% of total protein mass of the cornified 
layer is attributive to loricrin 29'32. Loricrin is expressed only at the very end of the terminal 
differentiation program 32-34 and immunoreactivity is therefore only observed in the stratum 
granulosum. Loricrin is cross-linked, like involucrin, by TGases forming bridges mainly between 
two loricrin molecules. The small proline rich proteins (SPRRs) are also cross-linked to loricrin. 
These SPRRs are characterized by a variable number of amino acid residue proline rich repeats, 
hence its name. TGase 3 is known for cross-linking the SPRR members into short oligomers35-37 
after which TGase 1 connects the SPRR's to the CE 36.
A very important and intensively studied protein of the CE is (pro-) filaggrin, a member of the 
S100-fused type gene family. Profilaggrin is a large (>400kDa), insoluble protein, that forms 
the major component of the keratohyalin granules. Upon dephosphorylation and degradation, 
monomeric filaggrin is produced in the stratum corneum which is then further proteolyzed to 
release its component amino acids. Filaggrin contributes to the protein-lipid CE which replaces 
the plasma membrane of differentiating keratinocytes and is extensively cross-linked by TGases, 
forming a barrier to water loss and minimizing the entry of allergens and micro-organisms 2. 
The profilaggrin molecule is composed of an N-terminal domain which has calcium-binding 
and nuclear localization components, followed by 10, 11 or 12 nearly identical filaggrin repeats 
which have keratin binding properties, plus a C-terminal domain of unknown function 3S. The 
N-terminal domain is cleaved from profilaggrin and translocates to the nucleus where it may play 
a role in the enucleation of keratinocytes in the outer stratum corneum3S. The S100-like calcium 
binding domain 39 may play a role in the regulation of calcium-dependent events during terminal 
epidermal differentiation40-41 or conversely, calcium may be involved in the control of profilaggrin 
processing3S. Although the exact function of the C-terminal domain is still unclear, its requirement 
for the processing of profilaggrin to filaggrin was demonstrated by Sandilands et al. Loss-of- 
function mutations within filaggrin (FLG) exon 3 resulted in a truncated profilaggrin molecule 
lacking the C-terminus and almost complete absence of filaggrin monomers was observed 42. 
These monomers are vital for proper CE formation as monomeric filaggrin binds to keratins 1 and 
10 and other intermediate filament proteins within the keratinocyte cytoskeleton to form tight 
bundles 43, facilitating the collapse and flattening of cells in the outermost stratum corneum. 
Ultimately, filaggrin is deaminated and degraded on the skin surface to produce a mixture of 
hygroscopic amino acids, the so-called 'natural moisturising factor' 44, which contributes to 
epidermal barrier function and hydration. The pH of the skin is also regulated by filaggrin due to 
the acidity of its breakdown products. The acidic pH modulates serine protease activity 45 which 
is necessary for coordinated epidermal differentiation and cornified cell envelope formation. In 
addition, the 'acid mantle' of the stratum corneum has a well-known antimicrobial effect46.
The importance of filaggrin in the skin barrier formation is exemplified by the presence of 
filaggrin loss-of-function mutations in patients with ichthyosis vulgaris and/or atopic dermatitis, 
which are skin diseases characterized by a disturbed skin barrier function and will be discussed 
later in this chapter.
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Hornerin is a recently discovered member of the S100-fused type family is and is structurally as 
well as functionally most similar to profilaggrin 47. In initial studies, hornerin was not detected in 
normal skin but only in regenerative skin upon wounding 4S. However, two recent independent 
studies indicate otherwise. Hornerin mRNA expression has been detected in skin biopsies from 
different sites as head, trunk, legs, hands, and feet. Furthermore, Ca2+-dependent differentiation of 
cultured human keratinocytes transiently induced the expression of hornerin, providing evidence 
for its role in epidermal differentiation 49. Immunoreactivity in healthy epidermis was observed at 
the periphery of keratohyalin granules in the upper stratum granulosum and at the corneocyte 
periphery in the whole stratum corneum49'50. Recently, it was shown that hornerin is a substrate 
of TGase 3 50. The expression of hornerin has also been analyzed in skin with a disturbed barrier 
function (e.g. atopic dermatitis and psoriasis) where a clear downregulation of protein expression 
was seen 49-51. For atopic dermatitis, cytokines involved in the inflammatory process reduced the 
expression of filaggrin-like proteins in vitro, providing a rationale for the contribution of hornerin 
to the atopic dermatitis-related epidermal barrier dysfunction 51. A recent study suggests a role 
for UVB irradiation in the expression profiles of hornerin in keratinocytes, and postulates hornerin 
to be a marker for acute UV damage in skin 52. However, more data are needed to confirm 
this observation as it is unclear how the mechanism of UV exposure and associated hornerin 
expression occurs at the cellular level.
The role of the late cornified envelope (LCE) proteins in the formation of the CE has been studied 
by our group, and few others, over the last years. The LCE cluster is located within the epidermal 
differentiation complex on chromosome 1q21 and comprises a total of 18 members, divided into 
six families (LCE1-6)53. The LCEs are expressed at a late stage during gestation in mice epithelia 
and are crosslinked by TGases54 to involucrin and trichohyalin in the CE 55. Expression anaiysis of 
16 LCE genes of LCE groups 1, 2, 3, 5, and 6 in vivo and in vitro indicated that the members of 
the LCE3 group are distinctly expressed in comparison to the other LCE groups. The LCE3 group 
showed increased expression in lesional psoriatic epidermis and after superficial injury of normal 
skin, whereas expression of members of other LCE groups was down-regulated under these 
conditions 56. Therefore, Bergboer et al. suggested that LCE3 proteins are involved in barrier 
repair after injury or inflammation whilst the other LCE proteins are involved in normal skin barrier 
function. These findings provided a rationale for the LCE3B/C gene deletion associated with 
psoriasis57, where deletion of these genes may cause insufficiënt barrier repair after skin injury 
resulting in putatively antigen exposure and subsequent inflammation.
3.2. Receptors involved in keratinocyte differentiation
Epidermal differentiation is a tightly controlled process in which a variety of receptors in 
keratinocytes regulate downstream signaling cascades leading to gene transcription. Detailed 
description of all receptors known to be involved in skin development is beyond the scope of this 
introduction, but the most relevant and intensively studied receptors are the epidermal growth 
factor (EGF) receptor and type I and type II nuclear hormone receptors. More recently, the aryl 
hydrocarbon receptor (AhR) and its nuclear partner aryl hydrocarbon nuclear translocator (ARNT) 
have been suggested to play a role in the regulation of epidermal differentiation and skin barrier 
function.
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The EGF receptor farmily consists of four receptor types: ErbB1 (also universally identified as EGFR), 
ErbB2, ErbB3, and ErbB4. EGFR, ErbB2, and ErbB3 are expressed in human skin, but expression 
levels are dominated by EGFR 58. These receptors are activated in an autocrine manner by 
keratinocyte-derived EGFR ligands, including transforming growth factor (TGF)-fS59, amphiregulin
60, heparin binding (HB)-EGF 6', and epiregulin 62. In addition, the EGFR can be activated by 
transactivation from a variety of G-protein-coupled receptors, integrins, and cytokine receptors. 
EGFR signaling is involved in a wide variety of cell-cell functions, including changes in proliferation 
rate and keratinocyte differentiation, cellular shape, attachment and motility, and regulation of 
proinflammatory activation 63'64.
Nuclear hormone receptors (NRs) have the ability to directly bind to DNA and regulate the 
expression of adjacent genes, and are therefore considered being transcription factors. NRs 
can be divided into two broad classes according to their mechanism of action and subcellular 
distribution in the absence of a ligand. Type I NRs are located in the cytosol and include the 
androgen receptor, estrogen receptors, glucocorticoid receptor (GR), and progesterone receptor, 
of which the GR is mostly studied in epidermal differentiation. The GR has been shown to be 
required for skin homeostasis and epidermal barrier competence in mice 65-66. Mice with epidermal 
inactivation of the GR showed thickened skin with increased keratinocyte proliferation and
16
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impaired differentiation67, and GR loss provoked skin barrier defects and cutaneous inflammation 
6a. In human skin diseases with a disturbed barrier such as atopic dermatitis and psoriasis, 
glucocorticoids have been successfully used. It is, however, unknown whether this therapeutic 
effect relies on the repair of the perturbed skin barrier or is due to the known anti-inflammatory 
effects of GR activation, by antagonism between ligand-activated GR and the pro-inflammatory 
NFk B, and signal transducer and activator of transcription (STAT) signaling pathways in many cell 
types64.
Type II NRs belong to the superfamily of steroid-thyroid receptors and are located in the 
nucleus. Endogenous ligands for NRs known to be present in the skin are: all-trans retinoid 
acid (RA) for the RA receptor, 9-cis RA for the retinoid-X-receptor, 1,25-dihydroxyvitamin D3 for 
the vitamin D receptor, fatty acids/lipids for peroxisome proliferator-activated receptor (PPAR), 
oxysterols for liver X receptor and triiodothyronine for thyroid receptor. Type II NR signaling 
contributes to the renewal of the epidermal cell layers and maintenance of the epidermal barrier. 
Due to the variety and importance of NRs in epidermal differentiation, the potential of these 
receptors as therapeutic targets has been widely recognized and NR ligands are currently used to 
treat skin diseases with disturbed epidermal differentiation 69.
In mammals, the AhR is constitutively expressed in tissues like the lung, liver, kidney and also skin 
70'71. The AhR is part of the basic helix-loop-helix (bHLH) family of transcription factors and resides 
in the cytoplasm in its inactivated state. There, it is located in a complex with two members of the 
90 kDa family of heat shock proteins (Hsp90), the co-chaperone p23, and the immunophilin-like 
XAP2 protein. XAP2 enhances and stabilizes cellular AhR levels, as its over-expression has been 
shown to enhance cytoplasmatic AhR levels. Upon ligand binding, the AhR dimerizes with ARNT 
in the nucleus and binds to the xenobiotic response element (XRE) in the promotor region of its 
target genes to regulate their expression 72 (Figure 1.2). Identified genes regulated by the AhR, 
are those encoding for phase I and II metabolizing enzymes and a number of genes involved 
in the regulation of cell development, proliferation and differentiation 73. Typical ligands of the 
AhR are halogenated hydrocarbons like dioxin and polycyclic aromatic hydrocarbons (PAH's). Also 
numerous dietary plant constituents, like flavonoids, endogenous ligands and pharmaceutical 
agents such as omeprazol and ketoconazole have been identified as AhR ligands7V5. Well known 
targets of the AhR include the cytochrome P450 (CYP) family proteins, which are xenobiotic 
metabolizing monooxygenases. The CYP family consists of many members and in the skin 
CYP1A1, CYP1A2, CYP2A6, CYP2B6 and CYP3A4 are the main cytochrome P450 members, with 
expression observed in the epidermis and the sebaceous glands76. CYP1A1, CYP1A2, CYP1B1 
and CYP2S1 are induced in the skin mainly by exposure to halogenated aromatic hydrocarbons 
and PAHs77'78.
The AhR is also called 'the dioxin receptor', as its most potent ligands are the highly toxic, and 
environmental pollutants, dioxins. Fluman intoxication with dioxin causes a variety of severe 
effects but with regard to the skin, the resulting cloracne is the most prominent symptom. 
Characteristic for this skin disorder is the hyperkeratotic epidermis with squamous metaplasia 
of the epithelial cells within the sebaceous glands79. Even years after dioxin exposure, patients 
still suffer from persistent chloracne, indicating the extremely long half-life of dioxin 80. The 
most intensively studied compound and model ligand for dioxin-mediated AhR activation is 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). TCDD exposure to keratinocytes in vitro results in 
increased expression of genes involved in terminal differentiation 81'83, premature cornification,
17
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hyperkeratinization, increased compactness of the stratum spinosum and granulosum 81, and 
an increased quantity of cornified envelopes 82. In contrast, genes related to proliferation and 
inhibition of senescence of keratinocytes (e.g. p53, p 76(INK4a) and p74(ARF)) are downregulated 
84. Results from in vivo studies corroborated these findings as in utero exposure to TCDD leads to 
induced keratinocyte differentiation 85 and accelerated epidermal barrier formation 83. To explain 
these effects, Sutter et al. recently investigated the presence of XREs in the promoter region 
of all members of the EDC, and analyzed whether these genes are upregulated by TCDD. A 
total of 14 genes of the EDC were up-regulated, including RPTN, HRNR, FLG, FLG2, LCE1C, 
LCE2A, LCE2B, LCE3A, LCE3E, SPRR1A, 5PRR2A, SPRR2B, S100A9, S100A12 and S100A7. Of 
these genes hornerin, FLG, FLG2 and LCE3E had one or two in silico determined XREs in their 
promoter region 83. These studies strongly suggest a role for the AhR signaling in epidermal 
differentiation and skin barrier function. However, AhR downstream signaling is highly ligand- 
dependent86, meaning that the type of ligand that activates the AhR determines the effect of 
AhR activation. Therefore, the effects of AhR signaling described above could be solely attributed 
to the properties of TCDD and not to AhR signaling in general. To circumvent the ligand-specific 
effects on AhR signaling, knockout mice and mice with constitutionally active AhR or its nuclear 
partner ARNT have been generated.
From studies with AhR deficient mice it has become clear that the AhR is critical for the 
development and homeostasis of the immune system in general 87'89, but also for skin-specific 
immune cells (e.g. yS T-cells)90. When focusing on the skin phenotype, AhR knockout mice show 
severe, localized, interfollicular and follicular epidermal hyperplasia, with hyperkeratosis and 
acanthosis, and marked dermal fibrosis87, whereas AhR transgenic mice develop inflammatory 
skin lesions characterized by hyperkeratinization 91. Therefore, the balance of between AhR 
activation and repression seems critical for normal skin development and homeostasis. Deficiency 
or constitutive expression of the AhR nuclear partner ARNT 92-93 also detrimentally affects 
epidermal differentiation and skin barrier function. Therefore, the AhR receptor pathway may 
serve as a candidate for treatment of skin disorders with disturbed epidermal differentiation.
4. Inflam m atory skin diseases -  Atopic Derm atitis
4.1. Clinical features
Atopic dermatitis, also known as 'eczema', is an extremely common inflammatory skin disease 
with an estimated prevalence of 15-20% in children and 1%  in adults 94. The medical, psycho- 
social and economic impact is high. Clinical and histopathological features include a red and scaly 
skin often covered with blisters and crusts, intense itch, loss of skin barrier function, intercellular 
epidermal edema (spongiosis), and occasional keratinocyte apoptosis. Lesional skin is mainly 
found on the flexural surfaces of the joints (Figure 1.3). Not only the affected children suffer but 
often complete family lives are distraught by the sleepless nights and doctor's visits.
The majority of atopic dermatitis patients (80-95%) are considered to have an extrinsic or allergie 
form of atopic dermatitis which is typically characterized by elevated IgE levels 95. However, 
some patients have normal IgE levels and this type is referred to as intrinsic or nonallergic atopic 
dermatitis96. During disease development of the allergie form, three phases can be distinguished. 
The acute phase is characterized by the initiation of allergie inflammation via interleukin (IL)-4,
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IL-5 and IL-13 produced by cutaneous T-cells97. Usually this is referred to as a T helper (Th) 2 
immune response. In this stage, histologically intraepidermal oedema (spongiosis) predominates, 
with fluid accumulation as micro- or macrovesicles. These changes are accompanied by a 
perivascular infiltrate of lymphocytes in the upper dermis and extension of lymphocytes into the 
epidermis. The epidermis is thickened, with developing parakeratosis and the number of T-cells is 
decreased. In chronic lesions, there is a shift from a solely Th2 cytokine milieu to an environment 
with Th2 and Th 1 cytokines like interferon (IFN)-y 9S. Histologically, thickening of the epidermis 
is more pronounced, with mild to absent inflammation and spongiosis. A prominent feature 
of extrinsic atopic dermatitis is the cutaneous infiltration with highly reactive cells of dendritic 
lineage, including Langerhans cells and epidermal dendritic cells (DCs) both of which display the 
high-affinity receptor for the Fc region of IgE on their surface 99.
Figure 1.3 Atopic dermatitis. Typical atopic dermatitis lesions in a child on the flexural site of the knees 
and in the face. Lesions are typically characterized by erythema, blisters and crusts.
4.2. Pathogenesis and genetics
Atopic dermatitis is a multifactorial disease in which both genetic and environmental factors play a 
role in the disease etiology. Stress and recurrent skin infections may influence the disease severity 
i°°,,o1 /\t0pjc dermatitis patients experience frequent cutaneous infections, and Staphylococcus 
aureus is commonly cultured from lesional and nonlesional skin. Recent microbiome analyses 
revealed that the proportion of S. aureus correlates with disease severity, and is greater during 
disease flares than at baseline or post-treatment6, indicating a potential role for this pathogen in 
the disease pathophysiology.
For many years it was believed that atopic dermatitis is caused by an Immunologie disturbance 
causing IgE-mediated sensitization, with the resulting skin inflammation negatively affecting the 
epithelial barrier function. Supporting this hypotheses, several candidate genes involved in the 
development of atopic dermatitis were found on chromosome 5q31-33. All of them encode 
cytokines involved in the regulation of IgE synthesis: IL-4, IL-5, IL-12, IL-13, and granulocyte- 
macrophage colony-stimulating factor (GM-CSF) 102. However, the seminal work of the McLean
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group, completely changed the paradigm. In 2006, they discovered that homozygous loss-of- 
function mutations in the Filaggrin (FLG) gene predispose to ichthyosis vulgaris, a skin disease 
characterized by a dry skin 103. The observation that patients in this study population were also 
affected by atopic dermatitis, led to a second study in which the same authors found that 30% of 
European patients with atopic dermatitis carry a FLG loss-of-function mutation ’04. These results 
were replicated in other cohorts throughout the world 105-107. Very recently, methods have been 
developed to allow the genotyping of FLG copy number variation across large populations 10S. 
This study revealed that each additional filaggrin repeat gained, decreased the odds ratio for 
atopic eczema by 0.88. Thus, FLG copy number variation makes a significant, dose-dependent 
contribution to eczema risk. The authors proposed that even a modest 10-20% increase in 
epidermal filaggrin expression is predicted to be therapeutic for eczema or protective against 
developing eczema 108. Therefore, therapeutic strategies for atopic dermatitis should not only be 
immune suppressive but also aimed at inducing the filaggrin expression in the skin.
The profound effect of having less filaggrin expression on skin barrier function is exemplified 
by murine models of F/g haploinsufficiency which have shown a barrier impairment and enhanced 
percutaneous allergen sensitization 109'110. The barrier integrity phenotype associated with FLG- 
null mutations in human skin is currently emerging, with evidence of a significant reduction of 
natural moisturizing factor in the stratum corneum as well as stratum corneum integrity 
and cohesion impairment 114 Despite the discovery of the FLG risk gene, and the subsequent 
major role for the defective skin barrier in the initiation of inflammation due abnormal exposure 
to external triggers (e.g. allergens), other factors still play a role in the disease etiology since the 
population attributable risk fraction has been estimated between 11-15% in the West-European 
population
In conclusion we can say that atopic dermatitis is a multi-factorial disease, with multiple 
mutations or genetic variations leading to predominantly a disturbed epidermal barrier but also to 
an imbalance in the immune system which together result in a higher susceptibility for developing 
atopic dermatitis (Figure 1.4).
4.3. Therapeutics
Most of the therapies for atopic dermatitis target the immune system (corticosteroids, calcineurin 
inhibitors, UVB irradiation), whereas emollients are used as an adjuvant to improve skin barrier 
function 118.119. Topical application of coal tar for the treatment of skin diseases was already 
described by Flippocrates (5th century BC), and is a cheap, effective and safe therapy 12a121 for 
reducing inflammation and itch. The therapeutic use of coal tar, however, is declining because 
of the -until recently- unknown working mechanism (this work is part of this thesis, covered by 
Chapter 6), obvious cosmetic reasons (smell, color) and safety concerns (presence of polycyclic 
hydrocarbons). Considerable progress has been made in development of targeted therapies 
for psoriasis, and similar drugs for atopic dermatitis are under way. Although they broaden the 
therapeutic options for patients, these 'biologicals' come with considerable cost for society. 
Therefore, a great demand will remain for cheap, yet effective and patiënt friendly therapeutic 
options.
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Figure 1.4 The role of the skin barrier function in the etiology of atopic dermatitis. Schematic 
overview of the epidermis showing the expression of filaggrin (blue dots) within the granular cell layers 
that underlie the dead, terminally differentiated squames of the stratum corneum. An intact skin barrier 
prevents water loss and exposure to environmental factors. In many patients with atopic dermatitis, FLG 
loss-of-function mutations (i) lead to an inherited defect in barrier formation (ii). The defective barrier 
allows entry of foreign substances (iii), which leads to an inflammatory response where Th2 cytokines are 
especially important (iv). These cytokines further repress skin barrier formation (v), thereby completing 
a negative feedback loop. Figure adapted from: Old King Coat - Molecular mechanism underlying an 
ancient treatment for atopic eczema. McLean & Irvine J Clin Invest. 2013; 123(2):551-553
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5. Inflammatory skin diseases -  Psoriasis
5.1. Clinical features
Psoriasis is a common, chronic, and often debilitating skin disease, affecting approximately 2 %  
of the population 122. Almost 90%  of individuals with psoriasis have the most common form 
of the disease, known as psoriasis vulgaris or plaque psoriasis. Affected skin is characterized by 
sharply demarcated, erythematous plaques covered with silvery white scales with a predilection 
for extensor sites of extremities (Figure 1.5). The scalp is also often affected, as are the hands, 
feet and presacrum. Although psoriasis vulgaris can occur in children, it often begins in late 
adolescence or early adulthood and then usually persists throughout life. Histological examination 
of a stable psoriasis plaque shows acanthosis (thickened epidermis), foei with parakeratosis (nuclei 
in the stratum corneum) and a diminished presence or absence of the stratum granulosum. Other 
defining histological features of psoriasis include the presence of neutrophils within small foei 
in the stratum corneum (Munro's microabcesses) and a significant mononuclear infiltrate in the 
epidermis. In the dermis, elongated tortuous capillaries are present, with a perivascular infiltrate 
consisting of primarily lymphocytes and macrophages123.
Figure 1.5 Psoriasis. Lesional psoriatic skin shows sharply demarcated, erythematous plaques covered 
with silvery white scales. Psoriasis plaques are typically observed on the extensor site of the elbows (left) 
and legs but can occur all over the body area (right).
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5.2. Pathogenesis and genetics
The pathophysiology of psoriasis is complex and dynamic, involving skin cells and immune cells. 
It was once thought to be solely a hyperproliferative disease of keratinocytes. However, over the 
past decade, a wide array of studies in mice and patiënt samples followed by genetic studies have 
helped to clarify and confirm many aspects of the disease pathophysiology. It remains, however, 
still under debate whether the initial trigger for inflammation is caused by the keratinocytes 
or the immune cells, as genetic risk factors exclusive for each cellular compartment have been 
discovered. The consensus reached over the years is that the interaction between the keratinocytes 
and immune cells is vital for the instigation and chronicity of the disease.
Psoriatic lesions are highly infiltrated with immune cells, most notably CD3+ T cells and CD11c+ 
dendritic cells (DCs) 124, but also CD8+ T-cells 125-127 and plasmacytoid DCs 128 are implicated in 
the disease pathogenesis. Clinical observations point to an important role of IFN-a as an inducer 
of psoriatic lesions129. This cytokine is mainly produced by plasmacytoid DCs and these cells are 
increased and activated in early psoriatic lesions 12S. IFN-a, together with tumor necrosis factor 
(TNF)-a, interleukin (IL)-1(3 and IL-6 produced by T-cells or keratinocytes, activate myeloid DCs, 
who in turn secrete mediators such as IL-12 and IL-23, leading to the differentiation of Th 1, 
Th 17, and Th22, respectively. Th 1 cells produce cytokines like TNF-a and IFN-y, while Th17 cells 
produce IL-17 and IL-22 ,23. Th22 cells are an important source of IL-22 IFN-y and IL-17 
induce chemokine expression by keratinocytes and the subsequent recruitment of immune cells 
to the skin, whereas IL-22 leads to aberrant keratinocyte proliferation and epidermal hyperplasia 
i32-i34 Moreover, IL-17 and IL-22 cooperatively induce the expression of antimicrobial peptides by 
keratinocytes135. Taken together, a rich interface of effectors of the innate and adaptive immune 
system shapes the psoriatic inflammatory process123.
Many observational studies have supported a role for genetic factors in the development of 
psoriasis. Gunnar Lomholt was the first to study the prevalence and genetics of psoriasis on the 
Faroe Islands in 1963 ,36. One decade later, it was found that the incidence of psoriasis is greater 
among first-degree and second-degree relatives of patients than among the general population
137, and twin studies showed an increased risk of psoriasis among monozygotic twins of two to 
three times compared to dizygotic twins 13S. Psoriasis has been proven to be a polygenic and 
multifactorial disease which has challenged the search for the specific genes responsible for the 
psoriatic phenotype. The genetic contribution is a complex sum of common and rare genetic 
variants, with many individual alleles conferring modest risk. The first identified risk factor for 
psoriasis was discovered by Russel et al. in the early 1970s. Serological typing demonstrated the 
association of human leukocyte antigen (HLA) molecules with psoriasis 139. With the advent of 
genetic linkage studies in the 90's, at least nine chromosomal loei with statistically significant 
linkage to psoriasis were identified. These loei were called psoriasis susceptibility 1 through 9 
(PSORS1 through PSORS9). The first and most influential psoriasis susceptibility locus, PSORS1, 
was found on chromosome 6p21.3 140J41. This locus accounts probably for 35-50% of the 
heritability of the disease 142 and is the strongest and most reproduced psoriasis susceptibility 
locus. PSORS1 contains several genes of potential interest, including HLA-C (HLA-C), coiled-coil 
a-helical rod protein 1 (CCHCR1) and corneodesmosin (CDS/V). The HLA-C*06 allele has been 
associated with psoriasis in many different populations, indicating that it might be the causal 
disease susceptibility allele at the PSORS1 locus ,43'144. However, the penetrance of HLA-C*06 is 
approximately 10%, so it is not sufficiënt to explain all of psoriasis heritability 145.
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Following the completion of the human genome sequence in 2003 and the introduction 
of genome wide association studies, many other PSORS loei have been discovered that have 
potential roles in epidermal pathology as well as immune dysregulation 146. Polymorphisms have 
been found in epidermal specific genes, such as the higher copy number of beta defensins, 
including DEFB4, on chromosome 8p23.1. DEFB4 encodes human beta defensin-2 (hBD-2), which 
is an anti-microbial peptide that is present in increased amounts in psoriatic skin. The recently 
demonstrated, and replicated association of the deletion of LCE3B and LCE3C with psoriasis in 
populations from Spain, Italy, The Netherlands, The USA and China, has indicated a potential 
role for the epidermal barrier function in the onset of psoriasis 57-147-149. Other polymorphisms 
associated with psoriasis were found in genes involved in NFkB activation (REL, TNIP1, TRAF3IP2, 
TNFAIP3, NFKBIA, FBXL19), IL-23 signaling and Th 17 cell adaptive immune responses (IL23R, 
IL12B, IL23A) 15°. For most gene associations, however, functional effects of the polymorphisms 
have yet to be determined.
Myeloid DC Keratinocyte
A M P’s
cytokines
chemokines
Figure 1.6 Drug targets for the treatment of psoriasis. Myeloid DCs produce cytokines that induce 
IFN-y production by Th 1 cells and IL-17 and IL-22 production by Th17 cells and possibly Th22 cells. 
IFN-y, TNF-a, IL-17 and IL-22 cooperate to induce the production of pro-inflammatory mediators like 
chemokines and anti-microbial peptides (AMP’s) by keratinocytes. IL-22 is also involved in promoting 
epidermal hyperplasia. The resulting enhanced immune cell recruitment leads to skin inflammation. Drugs 
can target upstream molecules in this pathway (anti-p40 antibodies and TNF-a inhibitors), whereas drugs 
in the pipeline (antibodies targeting IL-17, IL-17R or IL-22) are directed against downstream molecules. 
Figure adapted from: Johnson-Huang LM, Lowes MA, Krueger JG. Dis Model Mech. 2012 Jul;5(4):423-
33.
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5.3. Therapeutics
Many psoriasis patients have a mild form and can be treated with topical agents, like 
corticosteroids or vitamin D analogues 1S1. However, patients with moderate-to-severe psoriasis 
(about one third) require additional therapies, including UV light therapy or systemic medications 
like cydosporine. The use of classical therapies like coal tar and dithranol ointment is declining 
in modern dermatological practice. Drug-associated toxicity and therapy resistance requires the 
development of improved therapies that target the underlying pathological mechanisms more 
specifically. The discovery of the many players within the psoriatic cytokine milieu has led to the 
development of targeted therapies to block cytokine receptors or to scavenge soluble cytokines 
using antibodies (both known as 'biologicals'). Different biologicals are currently available which 
successfully targets various immune effector pathways,52 (Figure 1.6). However, these biologicals 
are extremely expensive and pose a significant economical burden on the public health care. 
Effective but affordable therapies for psoriasis are therefore still urgently needed.
6. In vitro skin models
6.1. Human keratinocyte culture
For decades, the monolayer culture of human keratinocytes has been the main technique to 
study skin biology and pathophysiology in vitro. Primary human keratinocytes are usually isolated 
from convenient sources as juvenile foreskin, adult breast or abdominal skin removed by surgery. 
By enzymatic digestion, the epidermis is separated from the dermis and a single cell suspension 
of keratinocytes is obtained. Using a mouse fibroblast feeder layer, these keratinocytes can be 
expanded and cryo-preserved until later use. This method was first described by Rheinwald and 
Green in 1975 and all protocols currently used, are adapted from this original w ork153. They were 
also the first to describe that these monolayer cultures can differentiate and form multilayered 
structures,54.
Keratinocyte differentiation in vitro can be initiated by various methods. The most commonly 
used technique is the increased Ca2+ concentration in the culture medium which triggers 
epidermal differentiation since many processes during epidermal differentiation are dependent on 
the presence of Ca2+ (e.g. TGase activity). The depletion of growth factors in the culture medium 
also initiates differentiation 1SS. Most often these methods are employed in combination with a 
fully confluent culture. The contact inhibition of keratinocytes when they reach 100% confluence 
triggers epidermal differentiation and keeping keratinocytes confluent for several days, has 
been used to study keratinocyte differentiation 156. Addition of disease-associated cytokines and 
subsequent therapeutic modalities to keratinocyte monolayers has resulted in the development of 
an in vitro psoriasis model by our group 155 and a high throughput screening model to study drugs 
which may affect epidermal differentiation 157. Due to the simplicity and high reproducibility of 
keratinocyte monolayers it is still a widely used and appreciated in vitro model system. However, 
these keratinocyte monolayer cultures do not represent many features of a stratified epithelium, 
and a functional stratum corneum is lacking. The keratinocytes are forced to adapt to artificial 
circumstances, such as a flat surface and submerged culture, which might alter gene expression 
and cell function 158. To study cell-cell interactions, the regulation of keratinocyte proliferation 
and differentiation, and also the re-epithelialization process after wounding, models are required
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that resemble the basic architecture of the skin. Therefore, 3D skin models (also referred to as 
organotypic skin models or human skin equivalents) have been developed and serve nowadays 
as a gold Standard for in vitro dermatological research on keratinocyte differentiation and skin 
barrier function.
6.2. Human skin equivalents
In 1981, the development of skin equivalents from human adult epidermal cells and dermal 
substrates cultured at the air-liquid interface was first described '59. Prior to this finding, mouse 
and rat keratinocytes were grown on collagen gels '6ai61 and cultured at the air-liquid interface. 
From these studies it was concluded that not only the exposure to air but also the dermal 
substrate and presence of a basement membrane appeared vital for obtaining a multilayered 
stratified epithelium 152. Hereafter, culture protocols were optimized and refined, and todaythere 
are many different types of human skin equivalents based on the type of dermal substrate. Even 
in the absence of a dermis, a fully developed stratified epidermis can now be grown on a simple 
plastic support.
The first used dermal substrates to culture cells consisted of collagen 163J64 and soon after, 
these collagen gels were populated with dermal fibroblasts to obtain a 'living skin equivalent' 
K55.166 5jnce a basement membrane was lacking in these collagen gels, corneal epithelial cells 
were cultured on the collagen cells until a basement membrane equivalent, containing laminin 
and collagen IV was deposited 167. Thereafter, the corneal cells were removed and keratinocytes 
were seeded. Although the fibroblast-populated collagen gels are still widely used, attempts 
were made in the late 1970's to generate skin equivalents using ex vivo dermis. The use of 
inverted dead pig skin was first described by Freeman et al. for the outgrowth of keratinocytes 
from skin explants 16S. This study set the stage for Regnièr and Prunièras to develop a protocol 
for generating human de-epidermised dermis while preserving basement membrane proteins,69. 
This de-epidermised dermis (DED) was then used by Ponec et al. to culture keratinocytes which 
attached to the existing basement membrane. After culture at the air-liquid interface a stratified 
epithelium was obtained ’70. W e still use the model developed by Ponec et al. to generate high 
quality human skin equivalents which closely resemble in vivo epidermis (Figure 1.7).
The composition of the culture medium is crucial for proper keratinocyte differentiation and 
stratification in vitro. Supplementation of epidermal growth factor and keratinocyte growth 
factor 171, the presence of serum during the early stages of development 172 and addition of 
lipids during the terminal differentiation phase 173 have improved the quality of skin equivalents. 
In skin equivalents generated from DED, introduction of fibroblasts using a centrifugal seeding 
method improved epidermal morphogenesis 174. Also in collagen gels, the presence of fibroblasts 
normalized the expression pattern of markers for epidermal differentiation and activation 175. 
The growth factors produced by fibroblasts mediate keratinocyte proliferation, and the life 
span of skin equivalents with fibroblasts can now be doubled up to 6-7 weeks. Especially skin 
equivalents produced by the self-assembly approach are long-lived and require less growth 
factors supplemented in the culture medium. For this, fibroblasts are cultured for several weeks 
to produce their own extracellular matrix and keratinocytes are subsequently seeded onto this 
newly-formed matrix 175'177. These skin equivalents show superior barrier properties as compared 
to collagen-gel based skin equivalents 17S, however, the three-week long culture period to 
obtain such a fibroblast-derived dermis is a major drawback for industrial or pharmaceutical use. 
Commercialized models are therefore mainly composed of only keratinocytes. Keratinocytes are
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1
grown on inert filters (EpiDerm™, SkinEthic™) or collagen sheets (Episkin™) and are currently 
used by the toxicological and pharmaceutical industry as a replacement for the traditional skin 
corrosion and irritation (Draize) test in experimental animals. Efforts are also made to develop 
models to replace the in vivo skin sensitization test179'180. However, these models have not been 
validated or approved by the regulatory bodies.
More sophisticated, multi-cellular skin models have been generated over the last decades. 
Pigmented skin equivalents have been developed by the incorporation of melanocytes to study 
the effects of UV radiation 1S1'182, congenital pigmentation disorders183 and whitening potential of 
candidate genes184. In addition, Langerhans cells were successful introduced into this pigmented 
skin model185. Endothelialized models to study angiogenesis186'187 have been described as well as 
immunocompetent skin equivalents in which macrophages are integrated 188‘189. Recent advances 
have been made to study skin innervation and the interaction between neurons and keratinocytes
190. Neural-derived peptides were found to control keratinocyte growth and innervated skin 
equivalents generated from atopic dermatitis keratinocytes showed increased neurite growth 
and epidermal thickness, indicative of an interaction between both cell-types. These models are 
closing the gap between the in vitro and in vivo skin morphology. Despite the clear contribution 
of these models to the current knowledge of skin biology, these labor intensive and rather 
expensive models are difficult to commercialize and will remain mainly be utilized in basic Science.
Punch
biopsy
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3D skin m odels - human skin equivalents
Figure 1.7 Schematic overview of skin equivalent development. After skin biopsy, the epidermis 
is separated from the dermis to isolate keratinocytes or fibroblasts, respectively. The keratinocytes are 
expanded on mouse fibroblast feeder cells and frozen in liquid nitrogen until further use. To generate a 
human skin equivalent, the keratinocytes can be grown onto a cellular matrix (fibroblast-collagen matrix), 
acellular matrix (de-epidermised dermis (DED) or collagen) or inert plastic filter. For several days, the 
keratinocytes are grown in submerged culture after which the culture medium level is lowered for culture 
at the air-liquid interface. Two weeks later, a multilayered stratified epithelium is formed similar to normal 
epidermis in vivo.
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7. Applications of human skin equivalents
7.1. Wound healing
Because our skin serves as a barrier to protect our body from the environment, the loss of skin 
through burns and wounds can result in potential life threatening infections. Therefore, the 
application of cultured autologous keratinocytes to cover large areas of wounded skin is the most 
obvious therapeutic application of cultured human skin equivalents. Soon after Rheinwald and 
Green reported the in vitro expansion of human adult keratinocytes in 1975, efforts were made 
to generate protocols to culture autologous keratinocytes from patients with excessive wounds, 
and patients were treated with these cultured epidermal sheets ,91'192. Unfortunately, after all 
these years, full or split skin grafts remain the gold Standard in the treatment of cutaneous 
wounds. However, in patients with more than 50% of burned skin area, donor sites are limited 
and in patients with chronic wounds the take rates of skin grafts are rather low. Therefore, 
finding new treatment modalities to accelerate wound healing, if possible without excessive 
scarring, remains a major quest for many researchers and industrial companies since they will 
have significant implications for patient's quality of life and the public health-care budget. 
Bioengineered skin products are now commercially available to treat wounded skin (e.g. Apligraf, 
Integra, or Alloderm) and promising results have been obtained using full-thickness autologous 
skin equivalents in patients with lower leg ulcers ’93, however long culture periodsand complicated 
logistics will keep the latter from becoming an 'off-the-shelf' solution. Continuous efforts will be 
made to further improve bioengineered matrices. Model systems are required to test such newly 
developed matrices and therefore we have developed an in vitro skin wound model in which 
reepithelialization on dermal matrices can be tested (Chapter 4 of this thesis).
7.2. Modeling skin diseases
Mimicking a disease-specific phenotype in human skin equivalents is a challenging task. As many 
skin diseases have a multifactorial or polygenic cause it is difficult to mimic all features of the 
disease in the in vitro environment. For psoriasis and atopic dermatitis several models have been 
developed by our group and others. The study by Barker et al. was the first to describe an in vitro 
skin equivalent model for psoriasis. Keratinocytes and fibroblasts from healthy volunteers and 
psoriatic patients were used to generate full-thickness skin equivalents. Although the morphology 
of the skin equivalents was quite poor, some striking differences were found between the 
psoriatic and normal skin equivalents. Pro-inflammatory cytokine production and chemokine 
receptor expression was strongly induced, and more proliferative keratinocytes were found in 
the psoriatic skin equivalent ’94. Based on this model, others have also used keratinocytes and 
fibroblasts from psoriasis patients in combination with cells from healthy volunteers to generate 
full-thickness skin equivalents. Herein, the presence of lesional keratinocytes was found to be most 
important for the induction of a psoriatic phenotype as characterized by epidermal thickening, 
increased involucrin expression and less filaggrin and loricrin expression 195. Comparable results 
were obtained when culturing psoriatic skin explants on DED 196. The use of patient-derived 
keratinocytes to generate an in vitro psoriasis model seems attractive, however, the amount of 
keratinocytes from patiënt biopsies is limited and hampers large scale production. Therefore, our 
lab has sought alternatives to generate an in vitro psoriasis model based on using keratinocytes
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from healthy volunteers who underwent plastic surgery. After the addition of psoriasis-associated 
cytokines, TNF-a, IL-1a, IL-6 and IL-22, to normal skin equivalents, the healthy keratinocytes 
behaved like psoriasis keratinocytes at the molecular level. Cytokine stimulation resulted in an 
increased expression of many psoriatic markers like keratin 16, hBD-2 and SKALP and this induction 
could be inhibited by anti-inflammatory drugs 197. Since psoriasis result from the interaction 
between keratinocytes and immune cells we further refined this model by the incorporation of 
T-cells in normal skin equivalents. This study is part of this thesis and is described in Chapter 5.
To develop atopic dermatitis models various approaches have been described. The first model 
resembling an eczematous phenotype was based on the incorporation of memory effector 
T-cells (CD45RO+ T-cells) into a collagen gel-based skin equivalent, generated from foreskin 
fibroblasts and immortalized keratinocytes (HaCaT cells) '98. The addition of memory effector 
T cells induced apoptosis, reduced expression of E-cadherin and resulted in barrier dysfunction. 
Induced expression of pro-inflammatory cytokines, chemokines and adhesion molecules was 
observed. Of note, none of these markers were specific for atopic dermatitis but related to 
inflammatory conditions in general. Therefore, our group aimed to develop a more specific 
model for atopic dermatitis, principally similar to the psoriasis model developed by Tjabringa 
et al. 197. Skin equivalents were generated from normal keratinocytes and disease-associated 
cytokines, IL-4 and IL-13 were used to stimulate normal skin equivalents. IL-4 and IL-13 induced 
spongiosis and apoptosis, both histological hallmarks for atopic dermatitis. In addition, altered 
gene expression specific for atopic dermatitis was observed 199. This model together with skin 
equivalents generated from keratinocytes from genetically predisposed atopic dermatitis patients 
enabled the study described in Chapter 6 of this thesis, in which we identified the molecular 
mechanism of coal tar therapy in atopic dermatitis.
7.3. Genetic approaches in 3D skin cultures
To study gene function in vitro, several types of strategies can be used to increase, decrease or 
completely ablate its expression. These approaches may yield valuable information on specific 
gene function or the products of gene translation (RNA, protein). Introducing foreign gene-coding 
DNA into host cells may lead to translation of this DNA and ultimately protein translation which 
results in gene overexpression. Although seemingly straightforward, the main problem with this 
approach lies in the fact that mammalian cells, and especially primary cells, do not take the large 
and electrically charged DNA molecules. Therefore, methods to deliver the DNA to the host cell 
have been developed over the years. In principle, there are two types of gene delivery systems: 
non-viral and viral systems. The non-viral systems are based on the use of carrier molecules. At 
first, molecules like DEAE-dextran were used to coat the DNA to form a non-charged molecule. 
Thereafter, the DNA could pass the cell membrane 20°. This process is referred to as 'transfection'. 
Nowadays, lipid-based methods are predominantly used in which the DNA is encapsulated in 
artificial liposomes or micelles that can fuse with the cell membrane leading to endocytosis and 
release of the DNA into the host cell 201-202. Physically transfecting cells with foreign DNA can 
be accomplished by electroporation where electric pulses produce holes in the cell membrane 
to facilitate the entrance of DNA 203. In addition, DNA-coated gold particles can be shot into 
host cells using the 'gene gun'. Although primarily used in plant research, this method has been 
used to successfully transfect keratinocytes 204. The above mentioned techniques all lead to 
transient transfection and for primary cells the transfection efficiency is rather disappointing and 
often insufficiënt to obtain reliable results. The transient nature of these techniques make them
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unsuitable for application in human skin equivalents since the culture period of skin equivalents 
is too long to sustain transfection. Therefore, a (lenti)viral gene delivery system is more suitable 
as herein high infection rates are achieved leading to stable integration of nucleic acid into a host 
cell's DNA, a process called 'transduction' 205. Several viral vectors are available for transduction 
of mammalian cells 206, however, lentiviruses are most suitable for use in human skin equivalents. 
They infect both dividing and non-dividing cells and stably integrate their nucleic acid into the 
host genome leading to sustained expression throughout the life span of the keratinocyte 205. 
DNA constructs delivered in the cell may be placed under the control of a strong general 
promoter to study overexpression in the entire tissue, or may be directed by a tissue-specific 
promoter to achieve time and position-specific expression of the transgene. W e have done so 
for epidermis-specific genes under the control of the involucrin promoter (unpublished data). In 
addition to overexpression of genes, it may be desirable to study a decrease or total ablation of 
gene expression in vitro.
The introduction of RNA interference (RNAi) technologies has enabled the investigation of 
the function of certain genes in keratinocyte biology. Especially when combined with human skin 
equivalents the function of specific genes or cellular pathways in skin morphogenesis and barrier 
function can be determined. RNAi is a mechanism that induces posttranscriptional gene silencing 
via sequence specific mRNA degradation 207. This conserved mechanism functions as an anti- 
viral system to silence viral genes 208’209 and involves a multistep process (Figure 1.8). The double 
stranded DNA is cleaved into small interfering RNA (siRNA) by Dicer, a RNAse II family member. 
This initiates the formation of the RNA-induced silencing complex (RISC). Within this complex the 
siRNA is used as a template for recognizing complementary messenger RNA (mRNA). The mRNA 
strand is then cleaved by the Argonaute protein leading to translational repression 21°.
The RNAi mechanism has been used extensively over the last decade providing research tools for 
the in vitro knockdown of many genes and serves as a good alternative for knock out animals. 
Three main types of RNAi can be used in experimental research: synthetic RNAi delivery systems, 
plasmid transfection and viral infection systems. The first is not recommended for use in skin 
equivalents since this is a transient knockdown and the effects will be lost during the culture 
period of the skin equivalent. Repetitive transduction will be costly and inefficient due to the 
multilayered and rather impermeable structure of the human skin equivalent. The viral delivery 
system offers asolution bythe lentiviral delivery of short hairpin RNA (shRNA) into the keratinocytes 
prior to development of the skin equivalent. The shRNA is recognized by Dicer in the keratinocyte 
to produce siRNA molecules for sequence specific gene silencing. The continuous production of 
siRNAs in the cell will result in a stable gene knockdown throughout the culture period of the 
skin equivalent. The use of RNAi strategies in human skin equivalents has resulted in many new 
insights into processes involved in keratinocyte proliferation2" '212, differentiation 93’2U2,4and skin 
barrier function 2'5-216.
A few publications (including our study described in Chapter 3) have applied genetic techniques 
like overexpression or RNAi in 3D reconstructed skin models to study biological processes or to 
model a disease. As mentioned earlier in this chapter, FLG loss-of-function mutations are the 
main cause for developing atopic dermatitis. Knockdown of FLG in skin equivalents demonstrated 
the importance of this protein for the barrier function of the skin. Increased fluorescent dye 
penetration 216 and paracellular permeability barrier abnormalities215 were observed upon FLG 
knockdown. These studies provide an explanation for the increased trans-epidermal water loss in 
skin of patients with FLG mutations. Knockdown of the TGase 1 gene (TGM1) in skin equivalents
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resulted in a more detailed understanding of the molecular pathways in patients with lamellar 
ichthyosis and also identified potential therapeutic targets217. We also employed such strategy to 
investigate the role of a candidate gene, CST6, in the etiology of cornification disorders (Chapter 
3 of this thesis). Keratinocytes from Netherton syndrome patients have been used to develop 
an in vitro disease model in which gene therapy was investigated 218. Netherton syndrome is a 
debilitating congenital skin disorder caused by mutations in the 5PINK5 gene leading to defective 
inhibition of serine protease activity, and therefore premature degradation of corneodesmosomes 
and a defective skin barrier. Genetically corrected keratinocytes showed restored inhibition of 
protease activity resulting in improved epidermal architecture of skin equivalents generated 
thereof.
Figure 1.8 Lentiviral shRNA-mediated knockdown approach. The single stranded (ss) viral RNA 
is transcribed in the host cell to a complementary double stranded (ds) DNA strand, which is stably 
integrated into the host genome. After transcription, the short hairpin (sh) RNA is processed via Dicer, 
and the Argonaute protein in the RNA-induced silencing complex (RISC) degrades the complementary 
target mRNA resulting in post-transcriptional gene silencing.
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8. Thesis aims and outline
General aims of the thesis
To study skin development, pathophysiological pathways or new therapeutics for skin diseases, 
models are required that faithfully mimic the skin structure and its function or display specific 
disease characteristics. For obvious reasons the availability of human skin from healthy 
volunteers or patients is limited and there is considerable societal pressure to reduce the use 
of experimental animals. In addition, the use of genetically modified animals (e.g. knockout or 
transgenic mice) is time-consuming and costly. 3D skin models that use human cells derived from 
healthy volunteers or from genetically defined patients could overcome many of these problems.
The first aim of my thesis was to develop in vitro 3D skin models in which epidermal 
development, wound healing and skin inflammation can be studied at the microscopic and 
molecular level. This would require introduction of other cell types (e.g. inflammatory cells) or 
vectors for genetic modification in existing conventional 3D skin models. Using in vitro skin 
models that are amenable to genetic modification or addition of inflammatory cells we aimed to 
create 'diseased' tissue in vitro to study gene function and the mode of action of drugs.
The second aim of my thesis was to actually apply these models and to demonstrate 
their power to solve scientific questions. Although Chapters 2 to 5 primarily describe model 
development, they also provide a number of applications. In Chapters 6 and 7 scientific questions 
regarding gene function and drug action are investigated using 3D skin models.
Outline of the thesis
To generate 3D skin models, large quantities of primary human keratinocytes are required. 
Flowever, the availability of donor skin to isolate keratinocytes is limited as well as the life span 
of keratinocytes derived thereof. At our Dermatology laboratory, a large biobank of primary 
adult keratinocytes from healthy volunteers, psoriasis patients and atopic dermatitis patients has 
been generated over the last decade. The supply of these keratinocytes is limited and thereby 
hampering their use for human skin equivalent development. Therefore, we employed the use 
of a Rho-kinase inhibitor, Y-27632, to prolong the life span human adult primary keratinocytes 
(Chapter 2) as this was previously shown for foreskin keratinocytes. Keratinocytes were cultured 
in the presence or absence of Y-27632 and serially passaged until senescence occurred. We 
then generated 3D skin models from these early and late passage keratinocytes to test their 
ability to generate a fully stratified epithelium. Application of gene knock-down or overexpression 
techniques in 3D skin models is an elegant way to functionally analyze individual gene function 
in an organ-like environment. We previously observed that the proliferative capacity of adult 
keratinocytes after lentiviral transduction is insufficiënt to generate a stratified epithelium, and 
we therefore assessed whether gene transduction in adult keratinocytes and subsequent 3D skin 
development would benefit from Y-27632 treatment.
This lentiviral transduction strategy was further employed to investigate the role of the 
cysteine protease inhibitor, cystatin M/E (CST6), in the process of epidermal differentiation and 
cornification (Chapter 3). Cystatin M/E deficient mice display a hyperplastic, hyperkeratotic 
epidermis and die shortly after birth of dehydration, due to a disturbed skin barrier function. Based 
on this phenotype we considered CST6 as a candidate gene for human disorders of cornification
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with unknown etiology. We first screened a large number of patients with autosomal recessive 
congenital ichthyosis but could not find any mutations in the CST6 gene. We therefore used 
lentiviral delivery of shRNA targeting CST6 to elucidate the effect of CST6 deficiency on epidermal 
development and skin structure. This enabled us to explain the lack of C5T6 mutations in the 
human population.
As our skin protects us from environmental challenges, fast and proper wound heaiing is vital 
to prevent possible life threatening infections or severe skin inflammation. The main feature 
of wound heaiing is the re-epithelialization process in which keratinocytes migrate from the 
wound edges underneath the scab to provide a new protective barrier. Often dermal matrices 
are used to substitute the dermis in large wound areas. It is vital to assess which type of matrix 
is suitable to ensure proper re-epithelialization. We therefore aimed to develop an in vitro, low 
throughput, 3D wound heaiing model, in which the re-epithelialization process can be studied 
on various dermal matrices (Chapter 4). Such in vitro model would reduce and refine animal 
experimentation in pre-clinical screening of newly developed dermal matrices for wound heaiing 
purposes. Therefore, we aimed to validate the results obtained from our in vitro 3D wound 
heaiing model by transplantation of the same dermal matrices onto wounded mice skin.
During daily life we are continuously exposed to potentially harmful stimuli for which our skin 
serves as a protective barrier. In case of skin barrier defect, inflammation can occur and sometimes 
this inflammation continues and becomes chronic in nature. Psoriasis and atopic dermatitis are 
chronic inflammatory skin diseases and much research is performed worldwide to provide a better 
understanding of the disease pathogenesis and to develop new therapeutics. The interaction 
between immune cells and keratinocytes has been proven vital in the initiation and chronicity of 
these inflammatory skin diseases. W e therefore intended to generate an in vitro model faithfully 
recapitulating major disease characteristics in which keratinocytes and T-cells reside in a 3D 
microenvironment to closely resemble in vivo skin inflammation (Chapter 5). Such model could 
provide an excellent platform for scientists to study pathogenesis or aid in the screening of newly 
developed drugs. We analyzed and targeted the cross talk between keratinocytes and immune 
cells in our model, thereby providing evidence for its suitability in skin inflammation research.
Inflammatory 3D skin models based on the addition of disease-associated cytokines have 
been previously developed by our lab. For atopic dermatitis the Th2 cytokines IL-4 and IL-13 are 
key players in the development and morphological phenotype of the disease. Addition of these 
cytokines to normal 3D skin models induces an atopic dermatitis phenotype in the epidermis. 
Using this model and keratinocytes from atopic dermatitis patients, we sought to elucidate the 
molecular mechanism of the oldest known therapy for atopic dermatitis, namely coal tar. We 
hypothesized that the aryl hydrocarbon receptor has a key role in the therapeutic effect of coal tar 
based on the presence of known ligands for this receptor in coal tar (Chapter 6). Using genetic, 
cell biological and morphological approaches we studied and revealed the molecular mechanisms 
of coal tar effects on atopic dermatitis skin.
Besides the development of skin disease models based on genetic manipulation of keratinocytes 
(Chapter 3), physicalalterations(Chapter4), orthe addition of disease-related mediators tohealthy 
skin keratinocytes (Chapter 5 and 6), another strategy is to use patient-derived keratinocytes to 
study the effect of inherent factors such as genetic mutations on skin development. In the final 
experimental chapter of this thesis we used keratinocytes from patients with the ectrodactyly,
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ectodermal dysplasia, and cleft lip/palate (EEC) syndrome, in which p63 mutations are causative 
for the disease, to identify new p63 target genes and to study the effect of p63 mutations on 
epidermal development (Chapter 7). Using the in vitro generated EEC 3D skin model we aimed to 
study the potential of a newly developed drug to restore the function of the mutated p63 protein, 
thereby rescuing the epidermal phenotype in these patient-derived p63 mutated keratinocytes.
Finally, the results presented in this thesis are summarized and future perspectives are discussed 
and outlined (Chapter 8).
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Chapter 2
Abstract
The use of tissue engineered human skin equivalents (HSEs) for fundamental research and 
industrial application requires expansion of keratinocytes from a limited number of skin biopsies 
donated by adult healthy volunteers or patients. A pharmacological inhibitor of Rho-associated 
protein kinases, Y-27632, was recently reported to immortalize neonatal human foreskin 
keratinocytes. Here, we investigated the potential use of Y-27632 to expand human adult 
keratinocytes and evaluated its effects on HSE development and in vitro gene delivery assays. 
Y-27632 was found to significantly increase the life span of human adult keratinocytes (up to 
5-8 passages). Epidermal morphology of HSEs generated from high passage, Y-27632-treated 
keratinocytes resembled native epidermis and was improved by supplementing Y-27632 during 
the submerged phase of HSE development. In addition, Y-27632-treated keratinocytes responded 
normally to infiammatory stimuli, and could be used to generate HSEs with a psoriatic phenotype, 
upon stimulation with relevant cytokines. Furthermore, Y-27632 significantly enhanced both 
lentiviral transduction efficiency of primary adult keratinocytes and epidermal morphology of 
HSEs generated thereof. Our study indicates that Y-27632 is a potentially powerful tooi for a 
variety of applications of adult human keratinocytes.
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Introduction
There is a growing demand for tissue engineered in vitro skin models for industrial applications 
and in fundamental research. In vitro pharmacotoxicological testing and industrial screening 
of drugs are nowadays accepted as an alternative to experimental animal testing and in vitro 
skin models are increasingly used to study skin biology and pathophysiology of skin diseases. 
Although the development of organotypic cultures, furtherdesignated as human skin equivalents 
(HSEs), for reconstructive purposes has been disappointing over the last decades, there are several 
indications that they may find their way to the clinic. Their potential use ranges from application 
in chronic ulcers \ to treatment of patients with keratinization disorders or blistering diseases 
using epidermal grafts of keratinocytes derived from genetically corrected induced pluripotent 
stem cells2.
Submerged keratinocyte cultures have been extensively used as in vitro skin models, however, 
over the last decade, HSEs have emerged as a more biologically and physiologically relevant 
model as they more closely mimic native epidermis. To meet the increasing need for HSEs, large 
quantities of primary human keratinocytes are required. Recently, increased cloning efficiency 
of neonatal human foreskin keratinocytes 3 and even efficient immortalization due to increased 
telomerase expression and stabilization of the telomere lengths4 has been described. Both studies 
used a selective inhibitor of the Rho-associated coiled-coil forming protein serine/threonine kinase 
(ROCK), Y-27632.
The Rho/ROCK pathway is essential in a variety of cellular functions in keratinocytes 
including, actin cytoskeletal organization s, keratinocyte adhesion 6 and motility 7' 8. Related to 
skin morphogenesis, it was recently described that RhoE, a member of the Rho GTPase family, is 
required for epidermal morphogenesis by regulating epidermal stratification 9. RhoA, however, 
was found to be dispensable for skin development, as knockout mice lack a skin phenotype
8. In contrast, downstream effectors of RhoA, ROCK I and II, have been reported to regulate 
keratinocyte differentiation 10-".
Hitherto, studies describing ROCK inhibition by Y-27632 use HaCaT cell lines or neonatal 
foreskin keratinocytes. However, in HSE development, primary human adult keratinocytes are 
preferably used since they generate HSEs that more closely resemble native epidermis in structure 
and function u. For application of HSEs in reconstructive surgery or gene therapy, expansion of 
primary keratinocytes isolated from a few biopsies is required to generate sufficiënt amounts 
of cells. However, the life span of primary adult keratinocytes is relatively short and senescence 
is usually observed after a few passages. In the light of the emerging applications of HSEs, we 
anticipate a strong need for human adult keratinocytes and have therefore evaluated the potential 
of Y-27632 to prolong the life span of these cells. In addition, we thoroughly investigated the 
effects of Y-27632 on HSE development. Finally, we studied the potential of Y-27632 to facilitate 
gene delivery studies using lentiviral-transduced adult keratinocytes to generate HSEs.
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Materials and Methods
Cell culture
Cells from the mouse fibroblast cell line 3T3 were cultured in Dulbecco's modified Eagle's medium 
(Life Technologies, Inc., Grand island, NY) supplemented with penicillin/streptomycin (50 IU/ 
mL; ICN Biomedicals, Zoetermeer, The Netherlands) and 10% calf serum with iron (Hyclone, 
Logan, UT). Keratinocytes were isolated from human abdominal skin derived from donors who 
underwent surgery for abdominal wall correction as previously described 12. The study was 
conducted according to the Declaration of Helsinki principles. Keratinocytes were stored in 
liquid nitrogen or were used directly. Keratinocytes were cultured in Greens medium (2:1 [v/v] 
DMEM:Ham's F12 (both from Life Technologies, Inc.) supplemented with 10% fetal bovine 
serum (Hyclone Laboratories, Inc., Logan, UT), l-glutamine (4 mmol/mL; Life Technologies, Inc.), 
penicillin/streptomycin (50 lU/mL; Life Technologies, Inc.), adenine (24.3 pg/mL; Calbiochem, 
San Diego, CA), insulin (5 pg/mL; Sigma, St. Louis, MO), hydrocortisone (0.4 pg/mL; Merck, 
Darmstadt, Germany), triiodothyronine (1.36 ng/mL, Sigma) and cholera toxin (10~10 mol/mL, 
Sigma) in the presence of irradiated 3T3-J2 feeder cells. After three days, medium was replaced 
by Greens medium containing epidermal growth factor (EGF, 10 ng/mL; Sigma). Cells were grown 
in the presence or absence of 10 pM Y-27632 (Sigma) as indicated and were refreshed every two 
to three days. Upon 90-100% confluency, cells were subcultured by removal of feeder cells by 
EDTA (Sigma) and subsequent trypsinization with trypsin-EDTA (0.05%; Sigma) after which they 
were passaged 1:10 on irradiated 3T3-J2 feeder cells.
Estimation of population doubling rate
At each passage the number of cells harvested was determined and population doubling was 
calculated as: PD= 3.32(log[number of cells harvested/number of cells seeded])4.
Analysis of cloning efficiency
To assess the effect of Y-27632 on cloning efficiency of freshly isolated adult keratinocytes versus 
liquid nitrogen stored adult keratinocytes, cells were seeded at different seeding densities on 
3T3-J2 feeders cells and cultured as described above. Cells were grown in presence or absence 
of 10 (jM Y-27632 and after three days, 3T3-J2 feeder cells were removed by EDTA treatment 
and keratinocyte colonies were fixed using 3.7% paraformaldehyde for 20 minutes at room 
temperature. Cells were washed two times with PBS (Braun) and stained with freshly prepared 
1 %  Rhodanile Blue (Sigma) in PBS for 15 minutes. Afterwards the cells were washed extensively 
with tap water and photographs were taken. Quantification analysis was performed using Image 
J software.
Generation of human skin equivalents
De-epidermized dermis was generated as reported previously 12 and 8-mm tissue samples were 
obtained using a biopsy punch. De-epidermized dermis was placed in a 24-wells ThinCert (Greiner 
Bio-One) and seeded with 105 keratinocytes. Liquid nitrogen stored primary adult keratinocytes 
(passage 1) or Y-27632-treated keratinocytes (passage 6 or 13) were used for experiments as 
indicated. After culturing the HSEs submerged for three days in medium containing 5 %  serum, 
consisting of two parts Dulbecco's modified Eagle's medium and one part Ham's F12 medium 
(both from Life Technologies, Inc.) supplemented with 5 %  calf serum (Hyclone), 4 mmol/mL 
L-glutamine and 50 lU/mL penicillin or streptomycin (both from Life Technologies, Inc.), 24.3 pg/
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mL adenine (Calbiochem), 1 pmol/mL hydrocortisone (Merck KGaA), and 50 pg/mL ascorbic acid, 
0.2 pmol/mL insulin, 1.36 ng/mL triiodothyronine, and 10-10 mmol/mL cholera toxin (all from 
Sigma), the HSEs were cultured at the air-liquid interface for ten days in medium without serum, 
consisting of two parts Dulbecco's modified Eagle's medium and one part Ham's F12 medium 
(both from Life Technologies, Inc.) supplemented with 4 mmol/mL L-glutamine and 50 lU/mL 
penicillin or streptomycin (both from Life Technologies, Inc.), 24.3 pg/mL adenine (Calbiochem), 
1 mg/mL L-serine and 2 pg/mL L-carnitine (both from Sigma), bovine serum albumin lipid mix 
(25 pmol/mL palmitic acid, 7 pmol/mL arachidonic acid, 15 pmol/mL linoleic acid, and 0.4 pg/ 
mL vitamin E; all from Sigma), 1 pmol/mL hydrocortisone (Merck KGaA), and 50 pg/mL ascorbic 
acid, 0.1 pmol/mL insulin, 1.36 ng/mL triiodothyronine, 10~10 mmol/mL cholera toxin, 5 ng/mL 
keratinocyte growth factor, and 2 ng/mL epidermal growth factor (all from Sigma). Y-27632 was 
supplemented in the culture medium at indicated culture periods and concentrations.
Cytokine stimulation
Liquid nitrogen-stored primary adult keratinocytes or Y-27632-treated adult keratinocytes (passage 
6) were cultured to confluency in keratinocyte growth medium (KGM), consisting of KBM (0.15 
mM Ca2+ BioWhittaker, Verviers, Belgium) supplemented with ethanolamine (0.1 mM; Sigma), 
phosphoethanolamine (0.1 mM, Sigma), bovine pituitary extract (0.4% vol/vol; BioWhittaker) 
epidermal growth factor (10 ng/mL; Sigma), insulin (5 pg/mL; Sigma), hydrocortisone (0.5 pg/ 
mL; Collaborative Research, Lexington, MA), penicillin (100 U/mL; Life Technologies, Inc), and 
streptomycin (100 pg/mL; Life Technologies, Inc.), with different concentrations of Y-27632. Cells 
were switched to KGM depleted of growth factors (bovine pituitary extract, epidermal growth 
factor, hydrocortisone, and insulin) for 48 hours. Differentiating cell cultures were stimulated 
with pro-inflammatory cytokines IL-1a (30 ng/mL), TNF-a (30 ng/mL) and interferon-y (500 U/mL) 
(all from Preprotech, London, UK), or left untreated. After 48 hours the cells were harvested for 
mRNA isolation using TRIzol reagent (Life Technologies, Inc.).
Psoriatic skin equivalents were generated by stimulating HSEs during the last three days of 
the air-liquid interface culture with a mixture of IL-1a (10 ng/mL) and TNF-a (5 ng/mL) and IL-6 (5 
ng/mL) (all from Preprotech), as described previously 12.
Lentiviral vector production
For generation of recombinant lentiviral particles, we used the third-generation self-inactivating 
transfer vector pRLL-cPPT-PGK-GFP-PRE-SIN (kind gift from Dr F. van de Loo, Department of 
Rheumatology, Radboudumc. See Geurts et al. '3 for details on plasmids and cells used for virus 
production). Packaging of VSV-G pseudotyped viruses was performed by transient transfection of 
293T cells. 293T cells were seeded in a T225 flask at 1 x105 cells/cm2 in DMEM (Life Technologies, 
Inc.) supplemented with 10% bovine cals serum (BCS, Hyclone), 100 pg/mL penicillin (Life 
Technologies, Inc.), 100 pg/mL streptomycin (Life Technologies, Inc.), 1 mM sodium pyruvate 
(Sigma) and 0.01 mM water-soluble cholesterol (Sigma). At least one hour prior transfection, 
the medium was replaced with 24 mL DMEM supplemented with 10% BCS, 1 mM sodium 
pyruvate and 0.01 mM water-soluble cholesterol. For each flask the following DNA mixture was 
prepared containing 56.7 pg transfer vector, 42.3 pg packaging vector pMDL-g/p-RRE, 20.0 pg 
expression vector pHIT-G and 14.2 pg expression vector pRSV-REV in a final volume of 100 pl 
water. Subsequently 1.5 mL 0.5 M CaCI2 (Sigma) was added and 1.5 mL 2xHBSS (Hepes-buffered 
saline solution, Sigma) was added gently under constant mixing. The formed precipitates 
were immediately added to the cells. 16 hours after transfection the medium was refreshed
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with DMEM supplemented with 100 pg/mL penicillin, 100 pg streptomycin and 1 mM sodium 
pyruvate. 48 hours post transfection the virus-containing supernatant was filtered through a 0.45 
pm Stericup (Millipore) to remove cell debris. Recombinant lentiviral particles were concentrated 
to 1.5 mL and dialyzed against sterile PBS using an Amicon filter (MWCO 100 kDa, Millipore). 
Viral stocks are aliquoted and stored at -80 °C. Viral titers were determined using an enzyme- 
linked immunosorbent assay (ELISA) kit (Abbott) targeting the viral envelope protein p249ag and 
expressed as ng p24/pl.
Lentiviral transduction of adult keratinocytes
Primaryadult keratinocytes from three different donors were grown to 4 0 %  confluency in a6-wells 
plate using KGM medium (Lonza) supplemented or not with 10 pM Y-27632. Subsequently, each 
well was incubated with 2 pg of eGFP-lentivirus for 4 hours after which the cells were washed 
twice with sterile PBS. After 24 hours of recovery in KGM supplemented or not with 10 pM 
Y-27632, cells were harvested with trypsin-EDTA and washed twice using PBS. The percentage of 
eGFP positive keratinocyte was analyzed by flow cytometry (EPICS Elite flow cytometer, Coulter, 
Luton, UK).
To generate eGFP-transduced HSEs, 1.5x105 harvested keratinocytes were seeded onto DED 
in 24-wellsThinCerts (Greiner Bio-One) and HSEs were generated as described above with 10 pM 
Y-27632 supplemented during the submerged phase of the HSE culture as indicated.
Quantitative real-time PCR
For the skin equivalents, epidermis was separated by dispase (Roche Diagnostics, Mannheim, 
Germany) treatment for 2 hours at 4°C, and total RNA was isolated from the epidermis using 
TRIzol reagent (Life Technologies, Inc.) and subsequent RNeasy mini kit (Qiagen Benelux B.V.) 
according to manufacturers specifications. cDNA was generated and used for quantitative real- 
time PCR (qPCR), which was performed with the MyiQ Single-Colour Real-Time Detection System 
for quantification with Sybr Green and melting curve analysis (Bio-Rad Laboratories, Inc) as 
previously described14. Primers for KRT10, KRT14, IVL, LOR, Ki-67, FLG, TGM1, LCE3E, DEFB4, 
TNF, IL8, IL1B and the housekeeping gene human acidic ribosomal phosphoprotein P0 (RPLP0) 
were obtained from Biolegio (Malden, The Netherlands). Relative mRNA expression levels of all 
examined genes were measured using the method described by Livak et a l,5. See Table 2.1 for 
primer sequences.
Morphological and immunohistochemical analysis
HSEs were fixed in buffered 4 %  formalin for 4 hours, processed for routine histology and 
embedded in paraffin. 6-pm sections were stained with hematoxylin and eosin (H&E) (Sigma) or 
processed for immunohistochemical staining using an indirect immunoperoxidase technique with 
avidin-biotin complex enhancement (Vectastain Laboratories, Burlingame, CA, USA). To study 
epidermal proliferation, an antibody directed against Ki-67 (1:50; MIB-1; Dako, Denmark) was 
used whereas epidermal differentiation was studied using antibodies directed against cytokeratin
10 (1:100; Sanbio, Uden, The Netherlands), cytokeratin 14 (1:50, Novocastra, UK), involucrin 
(1:50; Mon150; Sanbio), loricrin (1:500; BAbCO, Richmond, CA, USA), filaggrin (1:200; 
Novocastra), transglutaminase 1 (1:200, Santa Cruz) and late cornified envelope 2 (LCE2; 1:1000, 
See Bergboer et al. 16). The stress or psoriatic marker, hBD-2, was stained using goat anti-hBD-2 
polyclonal serum (1:100; Abcam, Cambridge, UK) and SKALP/elafin was stained using polyclonal 
antibodies as described previously 17. Detection by 3-amino-9-ethylcarbazole (Calbiochem) was
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followed by nuclei counterstaining with Mayer's hematoxylin solution (Sigma), and sections were 
mounted using glycerol gelatin (Sigma).
Statistics
Statistical significance was determined using paired two-tailed Student's t test.
Table 2.1: Primer sequences of all genes examined by real-time quantitative PCR
Gene Description of 
gene
Forward primer Reverse primer E*
KRT10 Keratin 10, (K10) tggttcaatgaaaagagcaagga gggattgtttcaaggccagtt 1.93
KRT14 Keratin 14, (K14) ggcctgctgagatcaaagactac cactgtggctgtgagaatcttgtt 1.93
KI67 Ki-67 (Ki-67) aaaccaacaaagaggaacacaaatt gtctggagcgcagggatattc 2.21
IVL Involucrin (IVL) acttatttcgggtccgctaggt gagacatgtagagggacagagtcaag 1.93
LOR Loricrin (LOR) aggttaagacatgaaggatttgcaa ggcaccgatgggcttagag 2.08
FLG Filaggrin (FLG) acttcactgagtttcttctgatggtatt tccagacttgagggtctttttctg 1.89
LCE3E Later cornified envelope 3E (LCE3E) ctgatgctgagacaagcgatctt gatcccccacaggaaaacct
2.20
TGM1 Transglutaminase 1 (TGM1) cccccgcaatgagatctaca
atcctcatggtccacgtacaca 1.99
DEFB4 Human beta defensin-2 (hBD-2) gatgcctcttccaggtgttttt
ggatgacatatggctccactctt 1.99
IL8 Interleukin 8, CXCL8, (IL-8) cttggcagccttcctgattt
ttctttagcactccttggcaaaa 2.11
TNF Tumor necrosis factor alpha, (TNF) tcttctcgaaccccgagtga
cctctgatggcaccaccag 2.00
IL1B Interleukin 1 beta (IL1B) aatctgtacctgtcctgcgtgtt
tgggtaatttttgggatctacactct 2.19
RPLO Ribosomal phospho- protein PO, (RPLO) caccattgaaatcctgagtgatgt tgaccagcccaaaggagaag
2.02
Parentheses refers to the name used in text 
* E is efficiency as fold increase in fluorescence per PCR cycle
Results
Y-27632 increases the life span of primary adult keratinocytes
As described previously for freshly isolated neonatal foreskin keratinocytes4, we cultured liquid 
nitrogen-stored primary adult keratinocytes obtained from 3mm skin biopsies and neonatal 
foreskin keratinocytes with or without Y-27632. The population doubling rate was calculated 
at each passage. Based on previous work and dose optimization studies, a 10 pM concentration 
of Y-26732 was used. As shown in Figure 2.1a, senescence was observed between days 30 and 
60 of culture in all five adult keratinocyte donors cultured without Y-27632, this in contrast 
to neonatal foreskin keratinocytes which remained proliferative throughout the culture period, 
which indicates the profound differences between foreskin and adult keratinocytes. All adult
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keratinocytes cultured in presence of Y-27632 showed a markedly increased life span and three 
out of five keratinocyte donors remained proliferative for 80 days or longer. Morphologically, 
high passage keratinocytes cultured with Y-27632 resembled primary keratinocytes as they were 
small and homogenous in size and formed a honeycomb pattern of cohesive poiygonal cells. 
Adult keratinocytes cultured in absence of Y-27632 became large and heterogeneous in size with 
bloated cytoplasm, which are signs of senescence (Figure 2.1b). Since immortalization of foreskin 
keratinocytes by Y-27632 due to induced telomerase expression was reported 4, we analyzed 
telomerase mRNA expression in high passage, Y-27632-treated adult and foreskin keratinocytes, 
however, we were unable to detect telomerase expression in all samples (data not shown). We 
also studied the effect of Y-27632 on the proliferation rate of freshly isolated adult keratinocytes 
as compared to liquid nitrogen-stored, primary adult keratinocytes and found no differences 
between both keratinocyte batches (Figure 2.1c and Supplemental Figure 2.1), suggesting that 
keratinocyte culture of previously isolated and liquid nitrogen stored adult keratinocytes can 
benefit from Y-27632 treatment.
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Figure 2.1 Effect of Y-27632 on life span and cloning efficiency of primary human adult 
keratinocytes. (a) Growth rate of human keratinocytes from one neonatal foreskin (HFK) donor or 
five adult (HAK1 -5) donors (abdominal wall skin) cultured in the presence or absence of 10 pM Y-27632. 
The arrows indicate cells lines that continued to divide after 100 days in culture. The growth rate is 
measured as population doubling per day. (b) Images of primary adult keratinocytes (left), passage 
4 adult keratinocytes cultured without Y-27632 (middle) and passage 13 adult keratinocytes cultured 
with Y-27632 (right). Scale bar = 100 pm (c) Fold increase in cloning efficiency of freshly isolated 
keratinocytes and liquid nitrogen-stored primary keratinocytes cultured with Y-27632 as compared to 
culture without Y-27632. Error bars represent SD (N=3).
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Normal human skin equivalents can be generated from Y-27632-treated 
keratinocytes
To evaluate the effect of Y-27632 on HSE development, we used our 3D skin model consisting of 
de-epidermised dermis as a matrix, and supplemented the culture medium with 10 |jM Y-27632. 
Y-27632-treated keratinocytes (passage 6) were used to generate skin equivalents and we 
compared them to liquid nitrogen-stored, primary adult keratinocytes (passage 1), with Y-27632 
supplemented during different phases of the skin equivalent development. Passage 6 adult 
keratinocytes generated high quality HSEs, with a multilayered epidermis, presence of stratum 
granulosum and a basket weave stratum corneum (Supplemental Figure 2.2). Normal expression 
patterns of major epidermal differentiation proteins were observed and HSEs were negative for 
the stress/psoriatic marker human beta defensin-2 (hBD-2) (Figure 2.2). (See Supplemental Figure 
2.3a for epidermal differentiation analysis in control HSEs).
Y-27632 Y-27632
control submerged phase entire culture period
...
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Ki-67
Figure 2.2 Epidermal differentiation 
patterns in human skin equivalents 
(HSEs) generated from passage 6, 
Y-27632-treated keratinocytes. HSEs 
were cultured without Y-27632 (left panel), 
with 10 pM Y-27632 supplemented during 
the submerged phase (middle panel) or 
during the entire culture period (right 
panel). HSEs show normal expression 
patterns for all analyzed epidermal markers: 
Ki-67 (proliferative cells), keratin 14 (basal 
keratinocytes), keratin 10 (suprabasal 
keratinocytes) and involucrin and 
transglutaminase 1, loricrin, filaggrin and 
late cornified envelope 2 (LCE2) (terminal 
differentiation). HSEs are negative for 
the stress/psoriatic marker, human beta 
defensin-2 (hBD-2). Scale bar =100 pm.
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Even at passage 12, Y-27632-treated adult keratinocytes still generated high quality HSEs 
comparable to native epidermis (Supplemental Figure 2.3b). Furthermore, epidermal morphology 
appeared more regular when Y-27632 was supplemented during the submerged phase of the 
culture period (Supplemental Figure 2.2c and d), this in contrast to HSEs cultured with Y-27632 
during the entire culture period in which epidermal morphology was negatively affected and deep 
epidermal ridges were observed (Supplemental Figure 2.2e and f). Therefore, it was decided to 
use Y-27632 only during the submerged phase of the HSE development for further experiments.
Since we had observed that timing of Y-27632 exposure clearly affected HSE morphology, 
we also addressed possible adverse effects of high concentrations of the ROCK inhibitor on 
epidermal morphology. At 30 and 100 pM of Y-27632, deep epidermal ridges were observed 
and at 100 pM epidermal protrusions were seen in the stratum corneum (Figure 2.3a). These 
morphological changes were, however, not associated with significant alterations in epidermal 
differentiation gene expression (Figure 2.3b) or protein expression (Supplemental Figure 2.4), or 
caused by induction of a keratinocyte inflammatory response as all HSEs lacked hBD-2 expression 
(Supplemental Figure 4). Protein expression of involucrin, however, was slightly extended towards 
the stratum spinosum in HSEs cultured with 30 and 100 pM of Y-27632, which may be indicative 
of an activated epithelium.
b
Figure 2.3 Y-27632 concentration dependant changes in epidermal morphology. (a) Deep rete 
ridges are observed in human skin equivalents (HSEs) generated in the presence of 30 or 100 pM Y-27632 
and epidermal protrusions are observed at 100 pM. Scale bar = 100 pm. (b) Relative mRNA expression 
levels of various epidermal differentiation genes in HSEs generated with 10, 30 or 100 pM Y-27632. The 
relative amount of mRNA in Y-27632 stimulated HSEs is normalized to the mean of unstimulated HSEs 
Error bars represent SD (N=2).
In vitro psoriasis skin models can be generated from Y-27632-treated 
keratinocytes
As human primary keratinocytes are extensively used in vitro to study their function in the 
innate immune system, we cultured adult keratinocytes (passage 1) submerged with various 
concentrations of Y-27632 and used pro-inflammatory cytokines IL-1 a, TNF-a and IFN-y to mimic 
an inflammatory milieu in vitro. As depicted in Figure 2.4a, unstimulated (control) keratinocytes 
showed lower expression levels of DEFB4, while IL1B mRNA expression levels were slightly
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elevated at 10 and 100 pM Y-27632. More importantly, keratinocyte activation was unaffected by 
Y-27632 as DEFB4, TNF, IL8 and IL1B mRNA expression levels were still significantly induced after 
cytokine stimuli. High passage Y-27632-treated keratinocytes also showed significant induction 
of hBD-2 when cultured with 10 |jM Y-27632 (Figure 2.4b). To verify this in our 3D skin model, 
we generated HSEs from Y-27632-treated keratinocytes and added 10 pM Y-27632 during 
the submerged phase of HSE development. Thereafter, HSEs were stimulated with psoriasis- 
associated cytokines, IL-6, IL-1a and TNF-a during the last three days of air-exposed culture. 
Protein expression of the psoriatic markers hBD-2 and SKALP/elafin was strongly induced in 
cytokine-stimulated HSEs (Figure 2.4c), indicating that psoriatic skin equivalents can be generated 
from Y-27632 treated keratinocytes.
In the experiments just described we used keratinocytes from healthy donors to generate a 
psoriasis-like phenotype in vitro. W e also successively used Y-27632 to prolong the life span of 
keratinocytes derived from patients with skin diseases such as psoriasis or atopic dermatitis (data 
not shown), which could be subsequently used for HSE development.
Figure 2.4 Normal keratinocyte response to inflammatory stimuli after exposure to Y-27632.
Primary adult keratinocytes (a) and passage 6 Y-27632-treated keratinocytes (b) were cultured submerged 
with 10 or 100 pM Y27632 and stimulated with pro-inflammatory (Th1) cytokines IL-1 ot (10 ng/ml), 
TNF-a (50 ng/ml) and IFN-y (500 U/ml). Relative mRNA expression levels of DEFB4, TNF, IL8 and IL1B 
were compared to unstimulated (control) keratinocytes. Significant induction (P<0.01) of all analyzed 
genes was observed after cytokine stimulation. The already low basal hBD-2 levels further decreased by 
10 (P<0.05) and 100 pM (P<0.01) of Y-27632, while basal IL1A levels significantly increased (P<0.05) 
at 10 and 100 pM of Y-27632. Error bars represent SD (N=3-5). (c) Immunohistochemical staining of 
psoriatic markers, hBD-2 and SKALP/elafin shows strong induction of both markers in HSEs generated 
from Y-27632-treated keratinocytes with 10 pM Y27632 supplemented during the submerged phase of 
HSE development, upon stimulation with psoriasis-associated cytokines IL-6 (5 ng/ml), TNF-a (5 ng/ml) 
and IL-1a (10 ng/ml). Scale bar = 100 pm.
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Y-27632 facilitates gene delivery studies in human adult keratinocytes
The application of gene knock-down or overexpression techniques in HSEs is an elegant way to 
functionally analyze individual genes in an organ-like environment. W e have observed that the 
proliferative capacity of high passage adult keratinocytes after lentiviral transduction is insufficiënt 
to generate HSEs thereafter (data not shown). Therefore, we assessed whether adult keratinocyte 
culture and subsequent HSE development can benefit from Y-27632 treatment in gene delivery 
assays. We used eGFP lentivirus as a model system for gene transduction and generated HSEs of 
eGFP-transduced keratinocytes which were cultured in the presence or absence of Y-27632, and 
compared gene transduction efficiency and HSE morphology. eGFP-transduced HSEs generated 
in the absence of Y-27632, showed a poorly formed epidermis consisting of only few cell layers, 
no stratum granulosum and parakeratosis present in the stratum corneum. HSEs generated from 
Y-27632-treated keratinocytes with Y-27632 present during the submerged phase of the HSE 
development, generated significantly improved skin equivalents with a multilayered epidermis, 
presence of stratum granulosum and no parakeratosis in the stratum corneum (Figure 2.5a). 
Expression of epidermal differentiation markers in Y-27632 treated, eGFP-transduced HSEs 
appeared similar to native skin as shown by the normal expression pattern of major epidermal 
differentiation proteins: keratin 10, involucrin, loricrin and LCE2 (Figure 2.5b). Importantly, 
Y-27632-treated keratinocytes showed a significantly higher percentage of eGFP-transduced cells 
after recovery (Figure 2.5c), and this was also prominent in the Y-27632-treated HSEs with the 
majority of keratinocytes expressing eGFP (Figure 2.5d).
conlrol Y-27632
Figure 2.5 Lentiviral transduction of human adult keratinocytes. (a) HSEs generated from 
transduced keratinocytes that express eGFP driven by a GSK promoter cultured in presence of Y-27632 
show superior epidermal morphology to transduced HSEs generated in absence of Y-27632 (control). 
(b) Epidermal differentiation markers keratin 10, LCE2, involucrin, and loricrin are normally expressed 
in Y-27632-treated, eGFP-transduced HSEs. (c) Fiow cytometric analysis shows a significantly higher 
percentage of eGFP-positive cells in Y-27632-treated keratinocytes. Error bars represent SD (N=3). 
* P<0.05. (d) HSEs generated from Y-27632-treated keratinocytes show eGFP expression in the majority 
keratinocytes while in untreated lentiviral-transduced HSEs only few eGFP positive cells are detected. 
Scale bar = 100 pm.
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Discussion
HSE development has been extensively optimized over the last decade to generate HSEs highly 
comparable to native skin. HSEs can nowadays be generated using a variety of dermal matrices 
such as animal-derived collagen matrices populated or not with human fibroblasts 1S, human 
de-epidermised dermis 12 or human fibroblast-derived dermal equivalents 19. Large scale HSE 
development is therefore only restricted by the limited availably of human adult keratinocytes. 
Here, we demonstrate an adequate solution for this problem, as Y-27632 prolongs the life span 
of human adult keratinocytes and improves HSE quality.
Increased cloning efficiency by Y-27632 has been described for several freshly isolated 
epithelial cells 20, including, human neonatal foreskin keratinocytes 3' 4, human and murine 
prostate epithelial cells 3' 21, human vaginal and cervical epithelial cells 4 and also for human 
embryonic stem cells 22. Here, we describe increased cloning efficiency and a prolonged life 
span of human adult keratinocytes which have been stored in liquid nitrogen prior to Y-27632 
treatment. Our findings may therefore have wide spread applications for other institutes to 
expand their established cell banks.
The immortalization of human foreskin and cervical keratinocytes due to increased 
telomerase expression and stabilized telomere lengths was described by Chapman et a l4. We, 
however, were not able to detect such phenomena in our adult keratinocytes. This is probably 
due to the very high passage number (from passage 34 onwards) in which they reported these 
characteristics while we were only able to culture our human adult keratinocytes till passage 15. 
The differences in life span between the Y-27632-treated keratinocytes used in our study and 
those used by Chapman et al. may result from differences in cell source (neonatal foreskin vs. 
adult keratinocytes). Moreover, liquid nitrogen stored keratinocytes might have a shorter life span 
than freshly isolated keratinocytes, although during the first passages we observed no differences 
in proliferation rate between freshly isolated or liquid nitrogen stored keratinocytes.
It has been reported that high passage Y-27632-treated epithelial cells display normal cell 
cycle progression, karyotype and DNA damage response 4'2Q. Also Y-27632-treated epithelial cells 
are not capable of inducing tumors after subcutaneous injection in mice 20. These data suggest 
that Y-27632 treatment of epithelial cells does not result in permanent DNA damage or induction 
of tumor-like characteristics. Our study shows that, at least for the biomarkers used here, the 
Y-27632-treated adult keratinocytes do not behave differently from control cells.
Chapman et al. generated organotypic cultures from Y-27632-treated foreskin keratinocytes 
without the addition of Y-27632 during the entire culture period. The morphology of these 
organotypic cultures, however, did not completely resemble native epidermis, as a recognizable 
stratum granulosum was absent and involucrin expression extended into the stratum spinosum. 
The latter is abnormal and only observed in activated epidermis (e.g. psoriasis or skin injury). Also, 
from our previous studies we know that foreskin-derived HSEs show an activated phenotype 
as witnessed by parakeratosis and expression of the psoriasis marker SKALP/elafin '2. Here, we 
demonstrate that HSEs generated from high passage, Y-27632-treated, adult keratinocytes 
faithfully mimic native epidermis, both in epidermal morphology and protein expression. We 
performedelaborate protein expression analysis and all investigated major epidermal differentiation 
proteins showed similar expression patterns to that of native skin. We can, however, not exclude 
that other genes or biological processes may be affected by Y-237632 treatment. The beneficial 
effect of Y-27632 on HSE morphology when used during the first three days (submerged phase) 
of HSE culture might be due increased keratinocyte survival and/or proliferation by Y-27632,
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resulting in a well formed multilayered epidermis later on. Even when Y-27632 was added during 
the terminal differentiation phase, we were able to generate HSEs with multilayered epidermis 
and stratum granulosum which corresponds to the finding that RhoA is dispensable for epidermal 
morphogenesis 8. The previously reported effects of ROCK I and II depletion on keratinocyte 
differentiation were obtained from submerged keratinocyte cultures 6 and/or HaCaT cell lines
10. Such models are, however, considered less biologically relevant than in vitro generated HSEs. 
Also, the normal terminal differentiation observed in our Y-27632-treated HSEs may be indicative 
of compensatory mechanisms only present in an organ-like environment to overcome ROCK 
depletion as a necessity in epidermal morphogenesis. The observed changes in HSE epidermal 
morphology when using Y-27632 throughout the HSE culture period or at high concentrations of 
Y-27632, might be due to the roles of the Rho/ROCK pathway in actin-cytoskeletal architecture 5 
or cell migration 7'8. In addition, Y-27632 has also been described to inhibit other kinases such as 
citron kinase, protein kinase C and myosin light chain kinase23, Although the potency of Y-27632 
for ROCK is >100 times higher than for these kinases, additional effects on other kinases when 
using Y-27632 at high concentrations cannot be completely excluded.
Primary keratinocytes are widely used to model skin inflammation in vitro as they play pivotal 
roles in inflammatory skin diseases as psoriasis and atopic dermatitis (reviewed by Guttman- 
Yassky et al. 24). We have previously described induction of a psoriatic ,2' 25 and atopic dermatitis 
26 phenotype in submerged keratinocytes cultures and HSE models. For these models, large 
quantities of human adult keratinocytes are required and here we demonstrated that Y-27632- 
treated keratinocytes can be used for such purposes as keratinocyte activation remains unaffected 
by Y-27632.
In vitro skin irritation and corrosion testing of new chemical compounds or drugs using 
HSEs is now recognized as a validated method to substitute experimental animal use 2A28 For 
this purpose, also, large quantities of human primary keratinocytes are needed. Companies 
developing HSEs at a large scale for commercial use, may therefore benefit from the effects of 
Y-27632 on adult keratinocytes herein reported.
Over the last decade, small interfering RNA (siRNA) and transgenic techniques have made 
it possible to investigate gene function and signaling pathways in vitro. Only few studies have 
described in vitro gene therapy in HSEs using various methods for gene delivery 29-31. Low 
transduction efficiency and poor epidermal morphology of transduced HSEs appears to be a 
common hurdle for which Y-27632 might provide a solution. Here, we have demonstrated 
increased lentiviral transduction efficiency in Y-27632-treated keratinocytes and, importantly, 
epidermal morphology of transduced HSEs was markedly improved by Y-27632. As Y-27632 
has been described to suppress dissociation-induced apoptosis in murine prostate cells 21 and to 
increase thaw-survival rates of stem cells after cryopreservation 22, keratinocytes might overcome 
transduction-induced stress when cultured with Y-27632, and Y-27632 might prevent cell death 
after dissociation of transduced keratinocytes to generate HSEs.
W e have demonstrated that Y-27632 is a powerful tooi for large scale human adult 
keratinocyte culture and HSE development, as high passage adult keratinocytes generated HSEs 
comparable to native epidermis. Furthermore, Y-27632 enhances lentiviral transduction efficiency 
and improves epidermal morphology of transduced HSEs, thereby facilitating gene delivery studies 
in primary keratinocytes and providing biologically relevant applications.
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Supplemental Figure 2.1 Effects of 
Y-27632 on doning efficiency, (a)
Liquid nitrogen-stored keratinocytes 
compared to (b) freshly isolated 
keratinocytes. Keratinocytes were 
cultured in the presence or absence 
of 10 pM Y-27632 and images were 
taken after Rhodanile blue staining.
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Supplemental Figure 2.2 Epidermal 
morphology of human skin 
equivalents (HSEs) generated from 
Y-27632-treated keratinocytes.
Primary adult keratinocytes (control) 
and passage 6, Y-27632-treated 
keratinocytes cultured on de- 
epidermised dermis without Y-27632 
(a and b), with 10 pM Y-27632 
supplemented during the submerged 
phase (c and d) or during the entire 
culture period (e and f) of HSE 
development show a fully differentiated 
epidermis with a stratum granulosum 
and cornified layer with superior 
morphology in HSEs generated with 
Y-27632 supplemented during the 
submerged phase. Scale bar = 100 pm.
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Supplemental Figure 2.3 Epidermal differentiation patterns in human skin equivalents (HSEs).
(a) HSEs generated from primary adult keratinocytes with 10 pM Y-27632 supplemented during HSE 
development. (b) HSEs generated from high passage, Y-27632-treated adult keratinocytes with 10 
pM Y-27632 supplement only during the submerged phase of HSE development. HSEs show normal 
expression patterns for all analyzed epidermal markers: Ki-67 (proliferative cells), keratin 14 (basal 
keratinocytes), keratin 10 (suprabasal keratinocytes) and involucrin and transglutaminase 1 (terminal 
differentiation). HSEs are negative for the stress/psoriatic marker, human beta defensin-2 (hBD-2). Scale 
bar = 100 pm.
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Supplemental Figure 2.4 Epidermal differentiation patterns in human skin equivalents (HSEs) 
generated in the presence of 10, 30 or 100 pM Y-27632. HSEs show normal expression patterns 
for epidermal markers: Ki-67 (proliferative cells), keratin 14 (basal keratinocytes), keratin 10 (suprabasal 
keratinocytes) and transglutaminase 1 (terminal differentiation). Involucrin expression (terminal 
differentiation) is slightly extended towards the stratum spinosum at 30 and 100 pM Y-27632. HSEs are 
negative for the stress/psoriatic marker, human beta defensin-2 (hBD-2). Scale bar = 100 pm.
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Abstract
The protease inhibitor cystatin M/E regulates a biochemical pathway involved in stratum corneum 
homeostasis, and its deficiency in mice causes ichthyosis and neonatal lethality. Cystatin M/E 
deficiency has not been described in humans so tar, and we did not detect disease-causing 
mutations in the cystatin M/E (CST6) gene in a large number of patients with autosomal recessive 
congenital ichthyosis (ARCI), who were negative for mutations in known ichthyosis-associated 
genes. To investigate the phenotype of cystatin M/E deficiency in human epidermis, we used 
lentiviral delivery of short hairpin RNAs that target cystatin M/E in a 3D reconstructed skin model. 
Knockdown of cystatin M/E expression did not lead to the expected ichthyosis-like phenotype, 
but prevented the development of a multilayered epidermis. The phenotypic discrepancy between 
mouse and human may be explained by the differences in specificity of cystatin M/E towards 
one of the target proteases (legumain), differences between the mouse and human cathepsin L 
orthologues or the presence of cathepsin V, a paralogous gene of cathepsin L that is absent in 
mice.
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Materials and Methods 
DNA samples
The study was conducted according to Declaration of Helsinki principles and approved by the 
medical ethical committee (Commissie Mensgebonden Onderzoek Arnhem-Nijmegen), the 
ethical committee of the Medical Faculty of the University of Cologne, and the institutional review 
board of the University Hospital of Münster. In advance, approval and individual written informed 
consent were obtained.
Mutation anaiysis
Mutation anaiysis of all three CST6 exons including exon/intron boundaries was performed 
in genomic DNA by direct sequencing of amplified DNA. Primers sequences and sequencing 
reactions are performed as described previously6’9.
Keratinocyte isolation
Cells from the mouse fibroblast cell line 3T3 were cultured in Dulbecco's modified Eagle's medium 
(Life Technologies, Grand Island, NY) supplemented with 50 lU/mL penicillin/streptomycin (ICN 
Biomedicals, Zoetermeer, The Netherlands) and 10% calf serum with iron (Hyclone, Logan, UT). 
Keratinocytes were obtained from human abdominal skin derived from donors who underwent 
surgery for abdominal wall correction. After isolation by trypsin treatment for 16 to 20 hours at 
4°C, keratinocytes were cultured in the presence of irradiated (3295 cGy for 4.10 minutes) cells 
from the 3T3 cell line. 3T3 cells were seeded at a concentration of 3x104 cells per cm2 in Greens 
medium, which consisted of two parts Dulbecco's modified Eagle's medium (Life Technologies) 
and one part of Ham's F12 medium (Life Technologies) supplemented with 10% fetal bovine 
serum (Hyclone), 4 mmol/L l-glutamine (Life Technologies), 50 lU/mL penicillin/streptomycin (Life 
Technologies), 24.3 pg/mL adenine (Calbiochem, San Diego, CA), 5 pg/mL insulin (Sigma, St. 
Louis, MO), 0.4 pg/mL hydrocortisone (Merck, Darmstadt, Germany), 1.36 ng/mL triiodothyronine 
(Sigma) and 10-10 mol/L cholera toxin (Sigma). The next day keratinocytes were added at a 
concentration of 5x104 cells per cm2. After three days, medium was replaced by Greens medium 
containing 10 ng/mL epidermal growth factor (EGF, Sigma). The cells were then refreshed every 
two to three days, and upon confluency, cells were trypsinized and stored in liquid nitrogen.
Lentiviral constructs
The generation of recombinant lentiviral particles were based on the third-generation self- 
inactivating transfer vector pRLL-cPPT-PGK-mcs-PRE-SIN in which the PGK promoterwas replaced 
by the RNA polymerase III U6 promoter (referred as pSIN-U6) to allow expression of short hairpin 
RNAs (shRNAs) (a kind gift from Dr. Fons van de Loo, Department of Rheumatology, Radboudumc, 
The Netherlands). A total of four different hairpins directed against the CST6 gene were selected 
based on experiments with synthetic siRNAs that were transfected in keratinocytes (data not 
shown) and using the Block-lt RNAi designer from Invitrogen (https://rnaidesigner.invitrogen. 
com/rnaiexpress/). Sequences for scrambled control hairpins were obtained from literature 10. 
Supplemental Table 3.1 shows location and sequence of the shRNA targets. Primers were designed 
containing the complete shRNA sequence followed by a polymerase III termination sequence. 40 
pM of both primers were incubated in annealing buffer (10 mM Tris pH 8.0, 20 mM NaCI) at 
95°C for 10 minutes and cooled down to room temperature overnight. The annealed primers, 
containing Hpal and Nsil compatible ends, were ligated into the Hpal/Nsil digested pSin-U6 vector
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with T4 DNA ligase (Invitrogen, Carlsbad, CA) and transformed into TOPIO cells (Invitrogen). 
Recombinant clones were selected on LB plates containing ampicillin (Invitrogen). Insertion of 
hairpins into pSin-U6 was confirmed by sequencing. Sequencing reactions were performed by 
the sequence facility of the Radboud University Nijmegen Medical Centre, based on the Sanger 
method using the BigDye Terminator version 3 chemics (Applied Biosystems, Foster City, CA).
Lentiviral vector production
VSV-G pseudotyped lentiviruses were produced after transient transfection of 293T cells. 
Cells were seeded in a T225 flask at 1x105 cells/cm2 in DMEM (Invitrogen) supplemented with 
10% bovine calf serum (Hyclone), 100 pg/mL penicillin (Invitrogen), 100 pg/mL streptomycin 
(Invitrogen), 1 mM sodium pyruvate (Sigma) and 0.01 mM water-soluble cholesterol (Sigma). 
Prior to transfection, the media was replaced with 24 mL DMEM supplemented with 10% BCS, 
1 mM sodium pyruvate and 0.01 mM water-soluble cholesterol. Per flask the following DNA 
mixture was prepared containing 56.7 pg transfer vector, 42.3 pg packaging vector pMDL-g/p- 
RRE, 20 pg expression vector pHIT-G and 14.2 pg expression vector pRSV-REV in a final volume 
of 100 pl water. The DNA was added to 1.5 mL 0.5 M CaCI2 (Sigma) and subsequently 1.5 mL 
2xHBSS (Hepes-buffered saline solution. Sigma) was added drop wise under constant stirring. 
The formed precipitates were added to the cells immediately afterwards. Sixteen hours post 
transfection the media was refreshed with DMEM supplemented with 100 pg/mL penicillin, 100 
pg streptomycin and 1 mM sodium pyruvate. 48 hours post transfection the virus-containing 
supernatant was collected and cell debris was removed by filtration through a 0.45 pm Stericup 
(Millipore, Billerica, MA). Lentiviral particles were dialysed against PBS and concentrated to 1.5 mL 
using an Amicon filter (M WCO 100 kDa, Millipore). Viral stocks are aliquoted and stored at -80°C. 
Viral titers were determined using an enzyme-linked immunosorbent assay (ELISA) kit (Abbott, 
Chicago, IL) targeting the viral envelope protein p24ga9 and expressed as ng p24/pl.
Lentiviral transduction of adult keratinocytes
Keratinocytes from two different donors were grown to 40%  confluency in a 6-wells plate 
using KGM medium (Lonza, Verviers, Belgium) supplemented with 10 pM Y-27632 (Sigma), as 
described previously " ,  Subsequently, each well was incubated with 0.5 or 2 pg of scrambled, 
shRNA-CSTGA and shRNA-CS76-3 lentivirus for 4 hours after which the cells were washed twice 
with sterile PBS. After 24 hours of recovery in KGM supplemented with 10 pM Y-27632, cells 
were harvested for skin equivalent generation or grown to confluency after which they were let 
to differentiate for 48 hours in growth factor depleted KGM, supplemented with 5 %  serum.
Generation of human skin equivalents
Lentiviral transduced human skin equivalents were generated as described previously11. Briefly, 
8-mm tissue samples of de-epidermized dermis were placed in a 24-wells ThinCerts (Greiner Bio- 
One) and seeded with 1.5x105 lentiviral transduced keratinocytes. The human skin equivalents 
were cultured submerged for three days in medium containing 5 %  serum, consisting of two 
parts Dulbecco's modified Eagle's medium and one part Flam's F12 medium (both from Life 
Technologies) supplemented with 5 %  calf serum (Hyclone), 4 mmol/L L-glutamine and 50 IU/ 
mL penicillin or streptomycin (both from Life Technologies), 24.3 pg/mL adenine (Calbiochem), 
1 pmol/L hydrocortisone (Merck), and 50 pg/mL ascorbic acid, 0.2 pmol/L insulin, 1.36 ng/mL 
triiodothyronine, 10~10 mmol/L cholera toxin and 10 pM Y-27632 (all from Sigma). Thereafter, the 
human skin equivalents were cultured at the air-liquid interface for ten days in medium without
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serum, consisting of two parts Dulbecco's modified Eagle's medium and one part Ham's F12 
medium (both from Life Technologies) supplemented with 4 mmol/L L-glutamine and 50 lU/mL 
penicillin or streptomycin (both from Life Technologies), 24.3 pg/mL adenine (Calbiochem), 1 mg/ 
mL L-serine and 2 pg/mL L-carnitine (both from Sigma), bovine serum albumin lipid mix (25 pmol/L 
palmitic acid, 7 pmol/L arachidonic acid, 15 pmol/L linoleic acid, and 0.4 pg/mL vitamin E; all from 
Sigma), 1 pmol/L hydrocortisone (Merck), and 50 pg/mL ascorbic acid, 0.1 pmol/L insulin, 1.36 
ng/mL triiodothyronine, 10~10 mmol/L cholera toxin, 5 ng/mL keratinocyte growth factor and 2 
ng/mL epidermal growth factor (all from Sigma).
Morphological and immunohistochemical analysis
Human skin equivalents were fixed in buffered 4 %  formalin for 4 hours, and processed for 
routine histology. Skin equivalents were embedded in paraffin, and 6-pm sections were stained 
with hematoxylin and eosin (H&E) (Sigma) or processed for immunohistochemical staining using 
an indirect immunoperoxidase technique with avidin-biotin complex enhancement (Vectastain 
Laboratories, Burlingame, CA). To study cystatin M/E knockdown, a polyclonal goat anti-cystatin 
M/E antibody (AF1286, R&D) was used. Detection by 3-amino-9-ethylcarbazole (Calbiochem) was 
followed by nuclei counterstaining with Mayer's hematoxylin solution (Sigma), and sections were 
mounted using glycerol gelatin (Sigma).
mRNA isolation and real-time qPCR
Lentiviral transduced keratinocytes were harvested after 48 hours and total RNA was purified 
from these cells as previously described ,2. A DNase I treatment was performed according to the 
manufacturer's protocol (Invitrogen, Carlsbad, CA). First strand cDNA was synthesized using an 
input of 1 pg of DNase 1 treated RNA with the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) 
according to the manufacturer's recommendation. Real-time quantitative PCR was performed 
with the MyiQ Single-Colour Real-Time Detection System for quantification with SYBR Green and 
melting curve analysis (Bio-Rad) as previously described ,3. Primer validation, qPCR reactions, and 
determination of relative mRNA expression were performed as previously described 12. Expression 
of the target genes (CST6, ITGB1, IVL, Ki-67, KRT14, STAT1 and OAS2) was normalized to that of 
human ribosomal phosphoprotein PO (RPLPO). Relative quantity of gene expression was measured 
with the delta-delta Cycle threshold (AACt) method 14. Primers for qPCR (Biolegio, Nijmegen, the 
Netherlands) were only accepted if their efficiency was 100±10 % . Corrections were made for 
primer efficiency. Primer sequences and efficiency are shown in Supplemental Table 3.2.
Cystatin M/E ELI SA
Lentiviral transduced keratinocytes were harvested after 48 hours and protein was extracted by 
repeated freeze/thawing of the cells in extraction buffer (50 mM Tris-HCI pH 7.5, 150 mM NaCI,
0 .5%  Triton-X-100, and a protease inhibitor cocktail) followed by centrifugation for 10 min at 
15000 x g. The supernatants that harbor the soluble proteins were measured for the presence of 
cystatin M/E by ELISA as described previously 15.
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Results
Mutation analysis
An overview of all sequenced patients that were considered as candidates for CST6 mutations 
are listed in Table 3.1.
Table 3.1: Patients screened for CST6 mutations
Diagnosis Nijmegen Munster Cologne Total
Ichtyosis (ARCI) 5* 13* 88** 106
Keratosis Pilaris 1 - - 1
IFAB syndrome 2 1 - 3
IFAB syndrome with 
corneal lesions
1 - - 1
* Negative for mutations in TGM1
** Negative for mutations in TGM1, ALOX12B, ALOXE3, NIPAL4 and CYP4F22
Validation of lentiviral shRNA constructs for cystatin M/E knockdown
Primary human keratinocytes were infected with lentiviruses that were engineered to produce 
shRNAs that suppress the expression cystatin M/E. shRNA-CS76 (nos. 1-4) and Controls (no virus 
and scrambled sequence) were first examined in submerged keratinocyte cultures. qPCR analysis 
revealed a strong reduction (80-90%) at the mRNA level for all designed shRNAs (2 pg of virus/ 
well), when compared to the scrambled "mock" control (Figure 3.2a).
Potential off-target effects including interferon activation due to gene knockdown by 
siRNA delivery must be checked ,6' ’7, especially since keratinocytes are sensitive to interferon 
stimulation18. Therefore, two genes that indicate an interferon response (STAT 1 and OAS2) were 
analyzed by qPCR (Figure 3.2b). The scrambled control showed a small increase (2-fold) for STAT1 
and OAS2 expression levels. Three shRNA-C576 constructs (nos. 1-3) showed no differences in 
mRNA expression levels when compared to the mock control. shRNA-C5T6-4, however, showed 
a 2-fold increase in OAS2 mRNA expression when compared to the mock control, and a 4-fold 
increase when compared to the cultured cells that were not infected with virus.
In addition, we checked if infection with lentiviral shRNA-CSTC constructs and subsequent 
knockdown of cystatin M/E showed off-target effects or exert influence on the expression level 
of other genes that are known to be expressed in human epidermis (Figure 3.2c). All shRNA- 
CST6 constructs showed comparable levels (~2-fold induction) of gene expression for cathepsin 
L (physiologic target protease for cystatin M/E), the antigen identified by monoclonal antibody 
Ki-67 (proliferation marker), and (31 -integrin and keratin 14 (both expressed in the basal layer 
of the epidermis). Only involucrin (expressed in the suprabasal layers) showed a slight increased 
expression (approximately 3-fold) for all used shRNA-CS76 lentiviral constructs, and was hence 
not considered to be an off-target effect but a genuine result of CST6 knockdown. After we 
validated cystatin M/E knockdown at the protein level (Figure 3.2d), we used the shRNA- 
C5T6-1 and shRNA-CSre-3 lentiviral constructs for knockdown studies of cystatin M/E in a 3D 
reconstructed skin model.
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(a) C S T 6 (c)
J
(b)
Figure 3.2 Validation of lentiviral expressed shRNAs to knockdown cystatin M/E. (a) Lentiviral 
(2 |jg/well) infection of monolayers with cultured primary human keratinocytes revealed that all four 
designed shRNAs significantly reduce the CST6 mRNA expression. (b) STAT1 and OAS2 both showed 
slightly increased mRNA levels (not significant), as the control (no virus) was compared to the lentiviral 
infected keratinocytes. The mock control and shRNA-CSfö nos. 1 -3 showed comparable levels of these 
interferon response genes. (c) Genes that are normally expressed in the basal layer (ITOB1, KRT14), all 
epidermal layers (CTSL) or are known as proliferation specific (MKI67), were not drastically affected 
by knockdown of the CST6 gene. Only the expression of the IVL gene (suprabasal layer) was slightly 
increased. (d) Cystatin M/E protein knockdown was confirmed by ELISA on cell extracts of lentiviral 
infected keratinocytes.
Cystatin M/E knockdown impairs epidermis formation in a human skin 
equivalent
The effect of cystatin M/E knockdown on the development and morphology of human skin 
equivalents was evaluated by histological analysis. A fully differentiated epidermis with a stratum 
granulosum and cornified layer is formed in the control and mock constructs (Figure 3.3a, b), 
whereas cystatin M/E knockdown with shRNA-CS76-1 and shRNA-CST6-3 completely disturbed 
the development of a multilayered epidermis (Figure 3.3c, d). From these skin equivalents no 
mRNA and protein could be extracted for respectively qPCR analyses and protease activity assays. 
Using lower concentrations of both viral constructs led to insufficiënt knockdown of cystatin 
M/E protein levels resulting in a normal epidermal development (shRNA-CST6-1) ora moderately 
disturbed (shRNA-CSTC-S) morphology of the human skin equivalents (Figure 3.3e, f).
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(a) control
(b) mock (scrambled)
H I K
(c) 2 |jg shRNA-CST6-1
■ .-.r'
(d) 2 )jg shRNA-CST6-3
(e) 0.5 |jg shRNA-CST6-1
(f) 0.5 pg shRNA-CST6-3
Figure 3.3 Cystatin M/E 
knockdown by lentiviral 
delivery of shRNA impairs 
epidermis formation in a 
human skin equivalent. 
Hematoxylin & Eosin staining 
showed the morphology of 
the human skin equivalents 
(left column). The control 
and mock (scrambled shRNA) 
showed a normal developed 
skin equivalent (a, b), whereas 
the formation of a multilayered 
epidermis is prevented by 
cystatin M/E knockdown (c, d) 
The use of lower shRNA-C5T6 
virus concentrations showed 
incomplete cystatin M/E 
knockdown (e, f). Scale bar = 
100 pm.
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Discussion
In vitro biochemical approaches as weil as the use of in vivo mouse models have revealed that 
cystatin M/E is a key molecule in a biochemical pathway that Controls skin barrier formation by 
regulation of both crosslinking and desquamation of the stratum corneum( Figure 3.1). As cystatin 
M/E deficiency in mice causes ichthyosis, follicular hyperkeratosis and corneal abnormalities we 
first assumed that if CST6 deficiency in humans exist the clinical symptoms might resemble the 
phenotype of the cystatin M/E deficient mice. W e were, however, unable to find CST6 mutations 
in a large number of patients with unexplained ichthyoses. Even in a patiënt with a phenotype 
that included ichthyosis and corneal abnormalities we did not find CST6 mutations. In order to 
predict the epidermal phenotype of CST6 deficiency in humans, we here examined the phenotype 
of cystatin M/E deficiency in human epidermis using in vitro 3D reconstructed skin equivalents. 
Surprisingly, we did not observe an expected ichthyosis-like phenotype, but rather an atrophic 
epidermis, which, we speculate, might lead to embryonic lethality in humans.
Recently, the use of synthetic siRNA or lentiviral-delivered transgenes has been described in 
reconstructed skin models19' 20. In pilot experiments with synthetic siRNAs directed against the 
CST6 gene we have previously succeeded in gene-specific (>90%) knockdown of cystatin M/E at 
the protein level in a submerged culture system (unpublished data). Although delivery of synthetic 
siRNA has been used successfully in a 3D reconstructed skin model for several target genes 2a
21, we found that this approach was not suitable for the CST6 gene (data not shown). Therefore 
we decided to use lentiviral vectors for gene knockdown (by delivery of shRNA). We succeeded 
to design four shRNA-CSTO constructs that resulted in a satisfying knockdown of cystatin M/E 
expression at the mRNA level as well as at the protein level in submerged keratinocyte cultures. 
These lentiviral constructs did not induce significant changes in expression levels of genes that 
are known to be expressed in human epidermis. However, we detected a modest induction of IVL 
expression as a result of cystatin M/E deficiency. It is known that interferon-y can stimulate human 
involucrin gene expression22, though we found no dramatic interferon responses compared to the 
mock control as measured by STAT1 and OAS2 mRNA expression levels. From this we conclude 
that the induction of IVL expression is a specific consequence of CST6 knockdown, rather than 
an off-target effect23' 24.
Deficiency of cystatin M/E in 3D skin constructs resulted in an unexpected disturbance of 
epidermal development, which made it impossible to study the involvement of cystatin M/E in 
the pathway of epidermal differentiation and stratum corneum formation and maintenance. We 
were unable to extract epidermal proteins to study protease- and transglutaminase activity, nor 
could we measure consequences of cystatin M/E deficiency on the expression levels of genes 
involved in epidermal differentiation and cornification.
The phenotypic discrepancy between mouse and human may be explained by several factors. 
First, human legumain is strongly inhibited by human cystatin M/E, whereas mouse cystatin M/E is 
unable to inhibit legumain due to an aspartate residue (D64) in the proposed legumain inhibitory 
site instead of the important asparagine (N64) 17. Therefore we do not exclude that legumain 
has a function in human skin (e.g. processing of cathepsins) that is controlled directly by cystatin 
M/E, which might be essential for normal epidermal development. Furthermore, no orthologue 
of cathepsin V in mice has been discovered yet and differences exist between the mouse and 
human cathepsin L orthologues. In fact, human cathepsin V is phylogenetically more closely 
related to murine cathepsin L than to human cathepsin L 25. Phenotypical differences between 
man and mice exist. For example, it was shown that cystatin A, a cysteine protease inhibitor like
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cystatin M/E found in the upper layers of the skin, has a role in cell-cell adhesion, and loss-of- 
function mutations in CSTA underlie exfoliative ichthyosis26. However, no specific phenotype was 
observed in mice that lack the Csta gene 27.
The results of cystatin M/E knockdown in our reconstructed skin model showed an impaired 
epidermal morphogenesis rather than ichthyosis-like features. The lack of a well-formed 
suprabasal compartment precluded further analysis of the cystatin M/E regulated processes as we 
did before using our mouse models, e.g. in situ activities of transglutaminases and proteases7. 
From this study we conclude that cystatin M/E is indispensable for human skin development, and 
deficiency of this molecule may be incompatible with normal foetal development.
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Supplemental Tables
Supplemental Table 3.1: Primers used for construction of hairpins
shRNA Orientation Position* Sequence**
CST6
shRNAl
Forward
Reverse
nt242 TGGCAACAGCATCTACTACTTCCCGAAGGAAGTAGTAGAT-
GCTGTTGC III I IIATGCATAAAAAAGCAACAGCATCTAC- 
TACTTCCTTCGGGAAGTAGTAGATGCTGTTGCCA
C5T6
shRNA2
Forward
Reverse
nt460 TG CAG AACT CCT CT CAGCT CCTAC G AATAG G AG CTG AG A-
GGAGTTCTGTTTTTTATGCATAAAAAACAGAACTCCTCT-
CAGCTCCTATTCGTAGGAGCTGAGAGGAGTTCTGCA
CST6
shRNA3
Forward
Reverse
nt263 T G G AG  ACACGCAC AT CAT CAAGGC G AAC CTTG ATG ATGT- 
GCGTGTCTCI I FffIATGCATAAAAAAGAGACACGCACAT- 
C ATC AAG GTTCG C CTTG ATG ATGTGC GTGTCTC C A
CST6
shRNA4
Forward
Reverse
nt147 TGGGAGCGCATGGTCGGAGAACTCGAAAGTTCTCCGAC-
CATGCGCTCCÏÏT I I IATGCATAAAAAGGAGCGCATGGTCG- 
GAGAACTTTCGAGTTCTCCGACCATGCGCTCCCA
Scrambled
(control)
Forward
Reverse
TGCCTAAGGTTAAGTCGCCCTCGCTCTAGAGGGCGACT-
TAACCTTAGGTTTTTTATGCATAAAAAACCTAAGGTTAAGTC-
GCCCTCGCTAGAGCGAGGGCGACTTAACCTTAGGCA
* Corresponds to the 5'-end of the shRNA 
** CST6 target sequence is in bold and underlined
Supplemental Table 3.2: Primers used for quantitative real-time PCR
Gene
symbol
Description
gene/protein
Forward
primer
Reverse
primer
E*
CST6 cystatin M/E tccgagacacgcacatcatc ccatctccatcgtcaggaagtac 1.96
CTSL cathepsin L gttgctattgatgcaggtcatga actgctacagtctggctcaaaataaa 1.90
ITGB1 (31 -integrin agttgcagtttgtggatcactgat aaagtgaaacccggcatctg 2.20
IVL involucrin a cttatttcg g gt ccg ctag gt gagacatgtagagggacagagtcaag 1.93
MKI67 Ki-67 aaaccaacaaagaggaacacaaatt gtctggagcgcagggatattc 2.20
KRT14 keratin 14 ggcctgctgagatcaaagactac cactgtggctgtgagaatcttgtt 1.93
OAS2 2'-5'-oligoadenyl- 
ate synthetase 2
caacctggataatgagttacct gctctaggaagcatttgttg 2.03
RPLO ribosomal protein 
PO, hARP
caccattgaaatcctgagtgatgt tgaccagcccaaaggagaag 2.00
STAT1 signal transducer 
and activator of 
transcription 1
ccatgcctttggaaagtatt cacagaaatcaactcagtcttg 2.08
* E is efficiency as fold increase in fluorescence per PCR cycle
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Abstract
Re-epithelialization of skin wounds is essential to restore barrier function and prevent infection. 
This process requires coordination of keratinocyte proliferation, migration and differentiation, 
which may be impeded by various extrinsic and host-dependent factors. Deep, full thickness 
wounds, e.g. burns, are often grafted with dermal matrices before transplantation of split skin 
grafts. These dermal matrices need to be integrated in the host skin and serve as a substrate for 
neo-epidermis formation. Systematic preclinical analysis of keratinocyte migration on established 
and experimental matrices has been hampered by the lack of suitable in vitro model systems. 
Here we developed an in vitro full thickness wound healing model in tissue engineered human 
skin that allowed analysis of the re-epithelialization process across different grafted dermal 
substitutes. W e observed strong differences between porous and non-porous matrices, the latter 
being superior for re-epithelialization. This finding was corroborated in rodent wound healing 
models. The model was optimized using lentivirus transduced keratinocytes expressing eGFP and 
by the addition of human blood which accelerated keratinocyte migration underneath the clot. 
Our model shows great potential for preclinical evaluation of tissue engineered dermal substitutes 
in a medium throughput format, thereby obviating the use of large numbers of experimental 
anima Is.
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Introduction
Regeneration of the skin epithelium is crudal for the repair of the protective barrier after skin 
injury. Impairment of this barrier, as in large mechanical traumas, burn wounds or chronic 
wounds, leads to microbial infections and continuous inflammation which in turn causes 
poor anatomical and functional outcome Therefore, surgical intervention is often necessary 
to restore skin function. Autologous skin transplantation is the gold Standard for hard to heal 
full thickness wounds. In case of large skin defects, insufficiënt amounts of autologous skin 
may be available and harvesting of skin causes scarring at the donor site. Therefore, allografts 
frequently serve as temporary wound closing agents, providing pain relief and preventing fluid 
loss and microbial contamination. Rejection of the allograft is a major drawback and ultimately 
a final permanent transplantation with autologous skin may be required 2. Tissue engineered 
skin substitutes are promising therapies to overcome the problem of donor shortage and 
provide ready to use products for the often immunocompromised patients. Substitutes have 
been developed that replace both layers of the skin or that replace only the epidermis or the 
dermis3. Permanent substitutes containing epidermal components commonly rely on autologous 
keratinocytes but show poor attachment and high costs4, although stem cell technology might 
overcome these problems in the future 5. Most research on skin substitutes has been performed 
on the replacement of dermal components. Dermal substitutes typically contain diverse allogenic, 
xenogenic or synthetic extracellular matrix components6. After transplantation of a dermal matrix 
the transplant should become stably integrated resulting in granulation tissue followed by the 
addition of keratinocytes on top of the neo-dermis. Once applied, the keratinocytes need to 
attach, migrate, proliferate and differentiate in order to restore the barrier function of the skin 4. 
Cultured autologous keratinocyte sheets or transplantation of meshed split-skin autografts can 
be a source of keratinocytes. Fibroblasts are the most prominent cells that generate the neo- 
dermis. The interaction, however, between the transplanted dermal matrix and keratinocytes is 
of major importance for the re-establishment of the epidermal barrier.
Tissue engineered human skin equivalents (HSEs) have contributed significantly to the 
understanding of biological processes and skin diseases 7‘12. Wound heaiing has been studied 
before in HSE in which wounds were created by burning, freezing or punching the epithelium u
14. Most of these wound heaiing models study keratinocyte migration on a single dermal matrix 
whereas in the clinical situation keratinocytes need to migrate from the intact epithelium over a 
provisional endogenous matrix or a grafted dermal subsititute. Although keratinocyte migration 
has been studied in detail in submerged 2D systems, the lack of suitable model systems has 
precluded in depth studies of keratinocyte migration and re-epithelialization in 3D systems. 
In a clinical situation, transplantation of split skin mesh grafts is usually performed on dermal 
substitutes applied to wound beds. The model presented here mimics the situation within one 
single mesh, where keratinocytes are migrating from a wound edge over a dermal matrix. Based 
on previously published HSE models 8-10> 11' 15 we now present a model that allows us to evaluate 
different experimental dermal matrices.
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Materials and Methods
Generation of human skin equivalents
De-epidermized dermis was generated as reported previously 10 and 8-mm tissue samples were 
obtained using a biopsy punch. De-epidermized dermis was placed in a 24 wells ThinCert (Greiner 
Bio-One) and seeded with 105 keratinocytes to generatea HSE as described previously. Tissues and 
cells from human subjects were obtained following approval by the Medical Ethics Committee 
(CMO regio Arnhem-Nijmegen), adhering to the declaration of Helsinki principles.
Insertion of dermal matrices in wounded HSE
HSEs cultured for 8 days at the air-liquid interface were removed from the 24-well ThinCerts and 
placed in a sterile Petri dish. Using a 2 or 3 mm biopsy punch a full thickness wound was created 
(see Figure 4.1a). The donut shaped HSE was subsequently placed in a 12-well ThinCert. Dermal 
matrices (2 or 3 mm) were pre-conditioned for 24 hours in medium without serum and growth 
factors before insertion into the space created in the recipient HSE. W e used two non-porous 
matrices: de-epidermized human dermis (DED) was prepared as described before, and Glyaderm 
was a kind gift of Dr. N. Richters (Euro Skin Bank, Beverwijk, the Netherlands). Glyaderm has 
been treated with NaOH to remove cellular components and is approved for use in humans. Both 
matrices are derived from human cadaver skin. Furthermore, we used two porous matrices: the 
collagen/glycosaminoglycan part (without the silicone membrane) of the commercially available 
matrix Integra (Integra life sciences), and a collagen/elastin scaffold described before 16' 17 (a 
kind gift of Dr. M. Ulrich, Association of Dutch Burn Centres, Beverwijk, the Netherlands). After 
insertion of the matrices, the HSEs were cultured submerged for 3 days followed by culture at 
the air-liquid interface. During the wound healing process, growth factors are depleted from 
the culture medium. In another set of experiments the inserted dermal matrix was covered with 
approximately 50 |iL of freshly drawn human blood from healthy volunteers. The blood was 
allowed to clot and the HSE was further cultured at the air-liquid interface, and analyzed as 
described below.
Morphological and immunohistochemical analysis
HSEs, mouse and rat tissues were fixed in buffered 4 %  formalin for 4 hours, and processed for 
routine histology and immunohistochemistry as described previously 19.
Lentiviral transfer vector generation and lentivirus production
The coding sequence of E-2 crimson was amplified from pCMV-E2-Crimson (Clontech) 
and cloned into pCR2.1 vector using the TOPO TA cloning kit (Life Technologies) (primer 
sequences: forward primer 5'-ACCGGTGCCACCATGGATAGCACTG-3' and reverse primer 
5'-GTCGACCTACTGGAACAGGTGGTGGCG-3'. Using restriction enzymes Sal-I and Age-I the 
coding sequence is removed from the pCR2.1 vector and cloned into pRLL-cPPT-PGK-mcs-PRE- 
SIN (kind gift from Dr. F. van de Loo, Department of Rheumatology, Radboudumc, Nijmegen). 
Generation of recombinant lentiviral particles and infection of keratinocytes was performed as 
described previously20.
Rat and mouse transplantations
Female Wistar Unilever rats and C57BL76J mice, 8 weeks old, were kept on a 12 h: 12 h light-dark 
cycle and fed with Standard laboratory chow and water ad libitum. Analgesics (Temgesic) were
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administered prior to and four times after the transplantation with twelve hours intervals. After 
sufficiënt induction of anesthesia (Isoflurane) the animals were shaved and four 8mm diameter 
full thickness wounds were created on the back of the rats and two wounds per mice. The 
wounds were left untreated or transplanted with Glyaderm or the collagen matrices. Differences 
in thickness between the dermal substitutes and the rodent skin were accommodated by 
transplanting the matrices partially underneath the skin to facilitate unobstructed keratinocyte 
migration over the matrices. Transplanted matrices were 12 mm in diameter while the wounds 
were 8mm giving a 2 mm overlap under the circumference of the wounds. All wounds were 
covered with Mepitac (Molnlycke Healthcare) and subsequently the animal was wrapped with 
elastic bandages (Petflex). Rats (n=4) and mice (n=8) were sacrificed at day 8 or 14, respectively, 
after transplantation and wounds were evaluated using histology. All animal studies were 
conducted at the Central Animal Facility of the Radboudumc (Nijmegen, the Netherlands). The 
Institutional Animal Welfare Committee (DEC) approved the experimental protocols used in the 
animal studies.
Statistics
Data anaiysis was performed by Fisher exact test. P-values < 0.05 were considered to be significant.
Results
Development of a human skin equivalent model for re-epithelialization
Human skin equivalents (HSEs) were generated using de-epidermized human dermis (DED) as a 
matrix. After 7 days of culture at the air-liquid interface, a full thickness wound was made in the 
centre of the construct, using a biopsy punch (Figure 4.1a). A new acellular DED was transplanted 
in the created wound and keratinocyte migration from the preexisting HSE over the transplanted 
DED was followed in time using histological anaiysis. After two days, a small migrating tongue 
of collectively migrating keratinocytes was detected starting from the differentiated pre-existing 
epithelium across the transplanted DED (Figure 4.1b). Generally, after 6 to 7 days a transplant 
of 3 mm in diameter was completely covered by migrated keratinocytes (Figure 4.1c, d). In time, 
stratification of the migrated cells started at the edges towards the middle of the wounds (Figure 
4.1e). Generation of a de novo stratified epithelium across the entire transplant was completed 
in 9 to 10 days. This was confirmed by immunohistochemical demonstration of epidermal 
differentiation markers filaggrin (Figure 4.2a), cathepsin V (Figure 4.2b), loricrin (Figure 4.2c) 
and keratin 10 (Figure 4.2d). These experiments showed that excisional wounding of a HSE and 
subsequent replacement with the same dermal matrix was technically feasible.
Studies on migration of keratinocytes in 3D models largely depend on histological anaiysis 
making it impossible to follow migration in real-time. To circumvent this problem we used 
keratinocytes genetically tagged with eGFP (Supplemental Figure 4.1) to enable longitudinal 
anaiysis of the migration process. W e used lentiviruses to infect keratinocytes with high efficiency 
(80-90%) prior to generation of the HSEs and followed the fluorescent keratinocytes while 
migrating over the inserted matrix. Even with a low-cost conventional fluorescence microscope 
the migration of the epidermal sheet was easily visualized. Supplemental Figure 4.1a shows a 
bright fluorescent stratified epithelium and a darker inner ring of the acellular inserted matrix 
at day 0. The same construct at day 3 is shown in Supplemental Figure 4.1b and a thin layer 
of migrated keratinocytes is visible, indicated by the dashed line. Image anaiysis showed that
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the eGFP-transduced keratinocytes covered approximately 50% of the wounded area at day 3. 
After fluorescence microscopy, the samples were fixed and analysed using conventional histology 
which confirmed the coverage of the DED by the eGFP-transduced cells (Supplemental Figure 
4.1c).
Figure 4.1 Keratinocyte migration 
across the inserted new dermal 
matrix, (a) Schematic drawing of 
the generation of wounds in HSEs. 
(b, c and d) Histological analysis of 
keratinocyte migration at day 2,4 and 
6 after wounding, respectively. (e) 
Histological analysis of keratinocyte 
migration and re-epithelialization 
from the wound edge towards 
the migrating tongue. The boxed 
region indicates the area of higher 
magnification. Histological staining 
by H&E. Scale bar = 100 pm in (a-d) 
and 25 pm in (e).
Figure4.2 Epidermal differentiation 
patterns of re-epithelialized neo- 
epidermis. IMormal expression pattern 
of (a) filaggrin, (b) cathepsin V, (c) 
loricrin and (d) keratin 10, in neo- 
epidermis on top of an inserted DED. 
Scale bar = 100 pm.
Evaluation of experimental dermal matrices in the HSE wound model
As a next step we used our model system to investigate the re-epithelialization process on 
dermal substitutes other than DED. In addition to DED, we used a second non-porous matrix, 
the commercially available Glyaderm, which is similar to DED but essentially devoid of cellular 
remnants and basement membrane components (Supplemental Figure 4.2) 21' 22. Two porous 
matrices were evaluated; a collagen/glycosaminoglycan matrix and a collagen/elastin matrix.
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Figure 4.3a and b shows that the two non-porous matrices support keratinocyte attachment and 
migration in our model, where keratinocytes failed to migrate from the pre-existing DED across 
the two porous matrices (Figure 4.3c and d).
The generated de novo stratified epithelium across the Glyaderm transplant resembles native 
skin comfirmed by immunohistochemical analysis of epidermal differentiation markers filaggrin 
(Figure 4.4a), cathepsin V (Figure 4.4b), loricrin (Figure 4.4c and keratin 10 (Figure 4.4d). DED 
and Glyaderm both allowed re-epithelialization, despite their differences in basement membrane 
components. W e therefore investigated whether basement membrane proteins were deposited 
by the keratinocytes that migrated over the Glyaderm matrix, thereby providing their own 
anchoring substrate. In contrast to the surrounding DED or a transplanted DED (Figure 4.4e), 
we did not detect heparan sulphate (Figure 4.4f) or collagen IV deposition (not shown) on the 
Glyaderm matrix. This indicates that keratinocyte migration is not dependent on anchoring to 
pre-existing basement membrane components and that deposition of the complete array of 
basement membrane components is dispensable for re-epithelialization in vitro.
a b c d
Figure 4.3 Insertion of different dermal matrices into the created wounds. (a) Keratinocyte 
migration across a control DED insert. (b, c and d) Keratinocyte migration across Glyderm, collagen matrix 
containing elastin and collagen containing glycosaminoglycan. No migration and re-epithelialization is 
observed in the two HSEs containing an inserted porous collagen matrix. All images taken at day 6-8 after 
wounding. Scale bar = 100 pm.
Figure 4.4 Epidermal differentiation of 
re-epithelialized neo-epidermis formed 
on Glyaderm inserts. Normal expression 
pattern of (a) filaggrin, (b) cathepsin V, 
(c) loricrin and (d) keratin 10, in neo- 
epidermis on top of an inserted Glyaderm.
(e) Fleparan sulfate staining is detected at 
the dermal-epidermal border throughout 
the wounded skin construct inserted with 
a DED (f) Staining for heparan sulfate is 
lacking at the Glyaderm-epidermal border 
where there is staining underneath the 
epithelium based on the surrounding DED. 
Scale bar = 100 pm.
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In vivo validation of the HSE skin wound model
Ideally, the HSE wound model should predict the in vivo behaviour of experimental dermal 
substitutes, at least as far as re-epithelialization is concerned. W e therefore evaluated grafting 
of porous (collagen/elastin or collagen/glycosaminoglycan) and a non-porous (Glyaderm) matrix 
into full thickness surgical wounds on the back of rats or mice. At day 8 after transplantation 
there was no macroscopic difference in wound size between wounds transplanted with porous 
or non-porous matrices (P=  0.75) in rats. In wounds transplanted with Glyaderm the complete 
transplant was present in all the wounds, and in 5 out of 6 wounds, keratinocyte migration is 
observed from the wound edge across the transplanted Glyaderm similar to the in vitro migration 
(Figure 4.5a and b). All the porous collagen/elastin matrices were only partially integrated in the 
wound bed (Figure 4.5c, d and e) and most of the collagen fibers end up in the wound scab 
(Figure 4.5f). The small integrated part of the matrix is highly vascularised and surrounded by a 
new extracellular granulating, fibrous matrix. Migrated keratinocytes utilize this newly produced 
matrix to migrate over and to re-epithelialize the site of injury, whereas migration directly over 
the transplanted porous collagen matrix was not observed. In a similar way, transplantation of 
the porous collagen/glycosaminoglycan matrix into full thickness wounds in mice did not result in 
complete integration of the matrix, or migration of keratinocytes across the remaining collagen 
matrix (see Supplemental Tables 4.1 and 4.2 for statistics). Taken together these in vivo data 
confirm those obtained in vitro, indicating the predictive value of the HSE wound model system.
Beneficial effects of blood to keratinocyte migration and differentiation
An essential step in normal wound healing is the blood coagulation cascade. The formed blood 
clot is important for hemostasis and serves as a provisional matrix for invading cells. Next to 
these events, the blood clot is a rich source of growth factors, cytokines and other inflammatory 
mediators. To our knowledge no models exist that include blood clots to study in vitro wound 
healing. Therefore, we further improved our model system described above, and investigated 
if keratinocytes are capable of migrating underneath an in vitro formed blood scab and if the 
addition of blood has beneficial effects on keratinocyte migration. HSEs were wounded and 
transplanted with a DED as previous, and immediately after insertion of the new matrix we 
applied freshly drawn human blood on top of the wound and allowed the blood to coagulate. 
W e made the observation that keratinocytes readily migrated underneath the scab and rapidly 
formed a new epithelium (Figure 4.6). Wounded HSE covered with blood completely formed a 
new stratified epithelium in 5 days while air exposed cultures formed a neo-epidermis only after
9 days. These results indicate that the presence of blood in wounded skin is highly beneficial to 
keratinocyte migration and differentiation.
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Figure 4.5 Histological analysis of rat wounds transplanted with Glyaderm and a collagen matrix.
(a) Integration and re-epithelialization of Glyaderm (glya) in wounds at day 8 after transplantation by 
H&E staining and (b) Elastic von Gieson staining. (c) Wound at day 8 of a collagen matrix transplantation.
(d) The same wound stained by elastic von Gieson shows that only a small part of the collagen matrix is 
integrated into the wound bed. (e) Magnification of square depicted in (d), thick collagen fibers indicated 
by the arrows. (f) Elastic von Gieson staining on the scab coming from the wound shown in (c) and (d) 
confirms the presence of thick collagen fibers derived from the transplanted collagen matrix outside 
the wound bed. Epi = epithelium, glya = glyaderm, md = mouse dermis, m = musde, gra = granulation 
tissue, * = scab. Scale bar = 100 pm (a-d and f) and 25 pm in (e).
Figure 4.6 Addition of blood to the wounded skin equivalents, (a) Histological analysis of a neo- 
epidermis formed underneath the blood scab at day 5 after insertion of an empty DED. The dotted lines 
indicate the inserted DED. The magnification inlay (b) shows the wound edge with stratum corneum (sc) 
and adjacent blood dot (scab) with neo-epidermis (neo) formed underneath. Scale bar = 100 pm in (a) 
and 25 pm in (b).
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Discussion
Keratinocyte migration is often studied in monolayer cultures using scratch assays on plastic. 
Although these assays are convenient to study the effect of soluble factors on cell behavior, they 
do not take into account many other factors such as cell-matrix interactions, tissue geometry 
and air exposure. It is known that skin cells grown in 3D cultures closely resemble native skin, 
and model systems to study clinically relevant situations (diseases, wound healing and genetic 
diseases) have recently been developed ia 12' 23. Here we describe a model that generates 
reproducible full thickness wounds and enables grafting of different dermal matrices into these 
full thickness wounds. Keratinocytes migrate from the wound edges as epithelial tongues and 
cover the wounds in three days which resembles the in vitro keratinocyte migration speed 
found previously 14-24. The restored neo-epidermis shows similar morphology and expression of 
differentiation markers as the surrounding pre-existing HSE and normal skin. Using genetically 
tagged keratinocytes expressing eGFP migration of keratinocytes is easily visualized in real time 
using low cost conventional fluorescence microscopy. Our model might pave the way for state- 
of-the-art high resolution microscopic anaiysis of keratinocyte migration at single cell level. In 
addition, the application of lentiviruses for the introduction or knock down of genes creates 
opportunities to study proteins involved in keratinocyte migration and differentiation in HSE.
One of the advantages of our model is that it examines migratory processes at the transition 
between different matrices thereby mimicking keratinocyte migration from the pre-existing 
epidermis into the wound bed. This creates a situation resembling a meshed split thickness skin 
graft transplanted onto a wound bed. Keratinocytes have to migrate from the transplanted 
split skin across the wound bed to fill up the meshes and restore a complete epidermis. The 
experiments using Glyaderm as an inserted dermal matrix show that keratinocytes are capable of 
migration across two different dermal matrices. During this process no deposition of basement 
membrane components is observed and even after complete re-epithelialization, expression 
of basement membrane components is lacking. Although this indicates that keratinocytes are 
capable of migrating without basement membrane formation in vitro, a solid interaction between 
keratinocyte and basement membrane is necessary for normal skin function. The absence of 
a fully developed basement membrane might be a consequence of the lack of co-cultured 
fibroblasts, which exert strong effects on epidermal morphogenesis 25.
Next to Glyaderm, we used porous collagen scaffolds as transplanted dermal matrices in 
our model. In contrast to Glyaderm and DED, both porous collagen-based synthetic dressings 
did not facilitate keratinocyte migration and were unable to support a neo-epidermis. In vivo 
experiments demonstrated that Glyaderm allowed epithelial migration but we did not observe 
direct migration of keratinocytes over the transplanted experimental collagen matrices. We 
speculate that the lack of migration and re-epithelialization across these collagen matrices is due 
to the relatively large porosity of the matrices compared to DED and Glyaderm. The intended 
use of dermal substitutes is to function as a replacing dermal matrix that allows fast resorption, 
enhanced granulation and neo-angiogenesis26’27. After integration by the host, a thin split skin 
graft is placed on the granulated tissue to finalize the transplantation process. Our data suggest 
that the model presented here can be used to evaluate the re-epithelialization speed of candidate 
dermal matrices.
The situation that we are trying to model here comes most close to the clinical situation 
within one mesh of a split skin mesh graft placed on a dermal substitute. The difference (and 
drawback) of our model is that in the clinical situation the keratinocytes will ideally migrate over
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a vascularized dermal matrix, which is not the case here. Our model system, however, allows the 
introduction of growth factors, ECM molecules and cells in the experimental dermal matrix to be 
evaluated in vitro.
Although we successfully validated our in vitro findings in vivo, rodent models for wound 
healing are clearly not ideal as they tend to heal by contraction rather than by re-epithelialization. 
W e used fairly large wounds to reduce the relative effect of contraction, and in addition we 
observed, to our surprise, that wounds with a transplanted dermal equivalent contracted less 
than the untransplanted wounds. This allowed us to compare the different dermal matrices 
without significant interference by early wound contraction. We are, however, currently trying 
to implement silicone splints in our rodent models to minimize contraction in future validation 
experiments.
When skin is injured one of the first steps taken is the formation of a provisional barrier by 
the deposition of a platelet plug and a fibrin matrix. The platelet plug functions as a physical 
barrier as well as a reservoir for growth factors and cytokines2S. In vitro platelet lysates have been 
shown to directly affect keratinocyte migration 29. These studies were performed in monolayer 
cultures and use only platelet lysates. Aiming at a more in vivo like situation we applied human 
full blood to our migration model and followed keratinocyte migration in time. In agreement with 
the monolayer results we observed an increased keratinocyte migration and re-epithelialization 
and the migration of keratinocytes underneath the blood scab resembles the morphology and 
speed of normal wound healing 30. It is unknown by which mechanism the blood, or individual 
factors in blood accelerates the observed wound healing in vitro. But it is likely that the formed 
blood scab provides a protective layer and a moist surrounding for the migrating keratinocytes 
thereby preventing dehydration. In addition, the blood-derived growth factors may stimulate 
re-epithelialization. Although the addition of blood stimulates re-epithelialization on top of 
inserted DEDs, we did not observe and improvement in the poor migration across an inserted 
porous collagen matrix (data not shown). This highlights the importance of a proper matrix for 
re-epithelialization by keratinocytes in full thickness skin wounds. The addition of a blood clot 
to the model constitutes a further improvement and moves the model even closer to the in vivo 
situation. Addition of fibroblasts and endothelial cells may be used to study the granulation 
process for a particular matrix.
Improved skin models will strongly contribute to fundamental knowledge of skin biology and 
skin diseases and will lead to reduction of the use of experimental animals used for scientific 
research. We believe that the full potential of skin models has not yet been reached. The 
application of genetic techniques such as lentiviral delivery of genes or siRNA will enable an ever 
larger array of tools in the near future. Sophisticated in vitro wound models closely resembling 
the in vivo situation, such as the model reported herein, will ultimately, contribute to facilitate and 
accelerate application of artificial matrices for wound healing in humans.
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Supplemental Tables
Supplemental Table 4.1: Integration of transplanted dermal matrices in mice
Day 14 Day 21
Integrated Non-integrated Integrated Non-integrated
porous matrix 
(Integra)
5 out of 6 1 out of 6 5 out of 6 1 out of 6
non-porous matrix 
(Glyaderm)
0 out of 6 6 out of 6 1 out of 6 5 out of 6
P=0.008* P=0.033*
‘ Fisher exact test
Supplemental Table 4.2: Integration of transplanted dermal matrices in rats
Day 14 Day 21
Integrated Non-integrated Integrated Non-integrated
porous matrix 
(Integra)
5 out of 5 0 out of 5 5 out of 5 0 out of 5
non-porous matrix 
(Glyaderm)
0 out of 6 6 out of 6 0 out of 6 6 out of 6
P=0.002* P=0.002*
*Fisher exact test
95

5
Crosstalk between 
keratinocytes and T-cells in a 
3D microenvironment: a model 
to study inflammatory skin 
diseases
Ellen van den Bogaard1'2*, Geuranne Tjabringa1*, Irma Joosten2, Esther van 
Rijssen2, Mieke Vonk-Bergers1, Henk Tijssen2, Mirthe Erkens1, Joost Schalkwijk1'? 
and Hans Koenen2*
* These authors contributed equally 
$ These authors share senior authorship
' Department of Dermatology, 2 Department of Laboratory Medicine, Laboratory 
of Medical Immunology, Nijmegen Centre for Molecular Life Sciences, Nijmegen 
Institute for Infection, Inflammation and Immunity, Radboud university medical center, 
Nijmegen, The Netherlands.
J  Invest Dermatol, 2013 Oct 10; epub ahead of print
Chapter 5
Abstract
The interaction between keratinocytes and immune cells plays a major role in the development 
of infiammatory skin diseases like psoriasis and atopic dermatitis. Pharmacological intervention 
to inhibit T-cell derived pro-inflammatory mediators is an effective therapy in the treatment of 
psoriasis. Here, we present a model to study the interaction between keratinocytes and T-cells 
in a 3D microenvironment, based on human skin equivalents populated with CD4+ T-cells. T-cell 
migration into the dermis initiated keratinocyte activation within two days, with hallmarks of a 
psoriasiform inflammation after four days. Expression of epidermal psoriasis marker genes was 
upregulated, and pro-inflammatory cytokines and chemokines were highly expressed. Disturbed 
epidermal differentiation was shown by downregulated filaggrin expression and involucrin 
expression in the spinous layer. These effects were mediated via soluble factors produced by the 
T-cells. The psoriasiform inflammation was also observed using Th 1 and Th 17 polarized CD4+ 
T-cells. We validated our model by treatment with anti-inflammatory drugs, which reduced the 
expression of pro-inflammatory cytokines and chemokines and suppressed the psoriasiform 
inflammation. W e propose that our T-cell driven infiammatory skin equivalent model has potential 
to study the pathogenesis of infiammatory skin diseases and may serve as a preclinical screening 
tooi for anti-inflammatory drugs.
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Introduction
Inflammatory skin diseases like psoriasis and atopic dermatitis are highly prevalent and pose a 
significant burden on patients. Our understanding of these diseases is greatly advanced, but many 
aspects of their etiology and pathogenesis are still unknown. Recent genetic studies now lead 
to an emerging consensus that psoriasis and atopic dermatitis result from gene polymorphisms 
related to immune and skin barrier function 1_3. The translation of genetic characteristics to 
(immuno)biological function in these diseases is clearly a challenge as suitable models will require 
the presence of both keratinocytes and immune cells to study the crucial interaction between 
these cellular components.
At present, crosstalk between keratinocytes and lymphocytes is studied in submerged co- 
cultures 4‘6, but these models are limited by the lack of a 3D microenvironment such as found in 
the skin. The generation of a 3D human inflammatory skin model comprising both keratinocytes 
and lymphocytes, has many requirements such as the correct geometry and spatial distribution of 
the cells, a matrix that allows lymphocyte trafficking, and a culture medium that allows adequate 
growth and survival of all cell types involved. In the absence of clinical parameters (erythema, itch), 
the readout relies on the quantification of molecular markers of disease. In psoriasis, the changes 
in the keratinocyte transcriptome are well documented with many molecular markers described, 
including Ki67, cytokeratin 16 (KRT16), elafin (PB), psoriasin (S100A7), MRP8 (S100A8) and 
p-defensin-2 (DEFB4) 7'8. (For gene and protein nomenclature of molecular markers used in this 
study, see Supplemental Table 5.1). Also pro-inflammatory cytokines and chemokines such as IL-
6, IL-8, CXCL10 and CCL2 are highly upregulated in psoriatic keratinocytes9. Disturbed terminal 
differentiation in psoriatic plaques is witnessed by low levels of filaggrin, upregulated involucrin 
expression 10 and induction of the LCE3 family members, e.g. LCE3A " .F o r  atopic dermatitis, only 
few studies describe molecular epidermal markers that discriminate between atopic dermatitis 
and psoriasis, such as NELL2, TARC and CA2 12J3. Atopic dermatitis has been associated with 
Th2 cytokines, which are well documented for their effects on epidermal differentiation. Th2- 
mediated inflammation reduces expression of epidermal differentiation genes, filaggrin, involucrin 
and loricrin ,4-'6 and induces eosinophil chemoattractants (e.g CCL26)17.
Recently, in vitro cultured skin equivalents were successfully introduced in humanized mouse 
models and injection of psoriatic immune cells induced inflammation in these skin equivalents 
18''9, recapitulating features of psoriasis. However, the low-throughput, high costs and ethical 
considerations of animal experimentation limits the use of these models for drug development. 
Inflammatory skin equivalents using disease-associated cytokines have been successfully 
developed by our group 20-21, but these models lack the presence of immune cells. Attempts to 
generate in vitro human skin equivalents with immune cells resulted in human skin equivalents 
populated with Langerhans cells or dermal dendritic cells to study skin sensitization 22.
In our current work, we report on the successful population of 3D skin equivalents with 
activated CD4+ T-cells and Th 1 and Th 17 polarized T-cells. These T-cell subsets and their cytokines 
are strongly associated with psoriasis pathoiogy. We studied the crosstalk between the T-cells 
and keratinocytes at the mRNA and protein level upon direct and indirect contact between 
both cellular compartments. The keratinocyte transcriptome was indicative of a psoriasiform 
inflammation, and anti-inflammatory drugs reduced the inflammatory phenotype. This T-cell 
driven inflammatory skin equivalent model may aid to study pathogenesis of inflammatory skin 
diseases and may serve as a preclinical screening tooi for anti-inflammatory drugs.
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Materials and Methods
Generation of inflammatory human skin equivalents
Human skin equivalents were generated using de-cellularized de-epidermised dermis as described 
previously and seeded with 105 human primary keratinocytes 21. After seven days of culture 
at the air-liquid interface, activated T-cells obtained from donors allogeneic to the skin, were 
introduced in the skin equivalents (Figure 5.1a). T-cell viability in the skin equivalents was assessed 
by morphology and TUNEL staining. To study the effect of cyclosporin A (400 ng/mL; Novartis 
Pharmaceuticals Corporation, Arnhem, The Netherlands), and all-trans retinoic acid (10*6 M; 
Sigma-Aldrich, Zwijndrecht, The Netherlands) the drugs were administered two days after T-cell 
migration. Infliximab was administered at 10 pg/mL at the time of T-cell introduction.
T-cell isolation and stimulation
CD4+ T-cells were purified from peripheral blood mononuclear cells obtained healthy blood 
donors by negative selection as described previously23 and depleted from CD25h'9hTreg by CD25 
magnetic-activated cell sorting beads (MACS) (Miltenyi-Biotec, Bergisch-Gladbach, Germany). 
Sorted naïve CD4+ T-cell populations were typically more than 98%  pure. To activate the T-cells 
they were subsequently stimulated with anti-CD3/CD28-beads (Life Technologies, Inc.) at a 
T-cell:bead ratio of 5:1 for 5 hours. Thereafter, the activated cells were washed and taken in skin 
equivalent medium and added to the skin equivalent.
T cell polarization
For Th1, Th2, Th17 polarization of T-cells, isolated naïve CD4+ T-cells were activated with anti- 
CD3/CD28 beads (T-cell:bead ratio of 5:1) and cultured for five days under Th1, Th2 and Th 17 
polarizing conditions. The following human recombinant cytokines and anti-human monoclonal 
antibodies (mAb) were used to polarize naïve T-cells, for Th 1 polarization: IFN-y (Endogen, 200 
U/mL), IL-12 (Life Technologies, 50 ng/mL) and anti-IL-4 (R&D Biosciences, 5 pg/mL), for Th2 
polarization: IL-4 (R&D Biosciences, 250 U/mL) and anti-IFN-y (R&D Biosciences, 5 pg/mL), for 
Th 17 polarization: IL-1a (Invitrogen, 50 ng/mL), IL-6 (R&D Biosciences, 20ng/mL) and anti-IL-4 
plus anti-IFN-y. T-cell culture conditions were conducted as reported previously23.
Transcriptional analysis
Epidermis was separated from the skin equivalents by dispase (Roche Diagnostics, Almere, The 
Netherlands) treatment for 2 hours at 4°C. mRNA isolation, subsequent complementary DNA 
generation and quantitative PCR was performed as previously described42. Using the comparative 
AACt-method and RPLP0 as reference gene, relative mRNA expression levels were calculated 43. 
Transcriptional analysis of polarized T-cells was performed using TaqMan qPCR analysis according 
to manufacturer's instructions using HPRTas a reference gene.
Histology and immunohistochemistry
Formalin fixed human skin equivalents were processed for routine histology. Sections were stained 
with hematoxilin-eosin (H&E) or processed for immunohistochemical staining using an indirect 
immunoperoxidase technique with avidin biotin complex enhancement (Vector Laboratories, 
Peterborough, UK). Antibodies used are depicted in Supplemental Table 5.2).
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Flow cytometry and antibodies
T-cells were analyzed by 5-color flow cytometry as described previously 23, using antibodies 
depicted in Supplemental Table 5.2.
Cytokine analysis by ELISA and Luminex
Human cytokines were determined in culture supernatants using the Bio-Plex systems (Bio-Rad, 
Veenendaal, The Netherlands) and ELISA (IL-22, R&D systems, Abingdon, UK) according to the 
manufacturer's instructions.
Statistics
Data are given as mean ± SEM of N=3-5 biological replicates. Statistical analysis of qPCR data was 
performed on AACt values using commercially available software (PASW Statistics 18). One-way 
analysis of variance, followed by Bonferroni post hoc testing, and two-sided paired t-tests were 
performed. P< 0.05 was considered statistically significant.
Results
Migration of T-cells in the dermis of human skin equivalents
To introducé T-cells into the skin equivalents, fully developed skin equivalents were lifted from the 
transwell system and CD4+ T-cells stimulated with anti-CD3/CD28 mAb-coated beads (further 
referred to as T-cells) were placed between the transwell membrane and dermal side of the skin 
equivalents (Figure 5.1a). The activation status of the T cells was confirmed by flow cytometry 
(Supplemental Figure 5.1a). We started off by adding 2* 106 CD4+ T-cells and observed T-cell 
migration in time, with T-cells present in the dermis from day two onwards (Figure 5.1b). However, 
as the epidermal morphology was negatively affected at these high cell numbers (Figure 5.1c), we 
tested a concentration series and observed that with numbers as low as 0.25*106, T-cells could 
still be demonstrated in the dermis, while epidermal morphology was preserved (Figure 5.1 d). 
Activated T cells just before addition to the skin equivalents, were able to produce IFN-y, TNF-a, 
IL-17 and IL-22 (Figure 5.1e), but not IL-4 and IL-5 (data not shown). Non-activated CD4+T-cells 
were unable to migrate and populate the dermis (Supplemental Figure 5.1b). After two and four 
days of migration we analyzed the gene expression levels of the T-cells in the dermis of the skin 
equivalents and observed that the expression of pro-inflammatory cytokines was highest at two 
days of migration, and IFNG expression was relatively most abundant as compared to IL17, IL22 
and TNF (Supplemental Figure 5.1c).
Activated CD4+ T-cells induce an activated, inflammatory phenotype in 
epidermal cells
After administration of 0.25*106 T-cells to the skin equivalents (day 0), molecular markers of 
epidermal inflammation were determined at days 2 and 4 by qPCR analysis. We found a time- 
dependent induction of the psoriasis-associated genes DEFB4, PI3 and LCE3A, while KRT16 and 
S100A7 reached a plateau at day two (Figure 5.2a, b). Molecular markers of atopic dermatitis, 
CAI and NELL2 were not induced (data not shown). Pro-inflammatory cytokine and chemokine 
production by the keratinocytes reached a maximum at day 2 (Figure 5.2c). Immunostaining 
of the inflammatory skin equivalents confirmed the mRNA expression data, showing induced 
expression of psoriasis-associated proteins hBD-2, KRT16 and elafin (Figure 5.2d). Since psoriatic
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Figure 5.1 Activated CD4+ T-cells migrate into skin equivalents, (a) The skin equivalents are lifted 
from the transwell support and T-cells are placed underneath the dermis. (b) CD4 immunostaining 
of migrating T-cells. Images are representative of N=2 individual experiments. Scale bar = 100 pm.
(c) Epidermal morphology of skin equivalents with 2* 10& T-cells at day 4 after T-cell administration. 
Representative image of N=3 individual experiments. Scale bar = 50 pm (d) Epidermal morphology of 
skin equivalents with 0.25*106 T-cells. Arrows indicate T-cells in the dermis. Representative image of 
N=3 individual experiments. Scale bar = 50 pm. (e) Cytokine levels produced by the T-cells just before 
addition to the skin equivalents, and after stimulation with anti-CD3/CD28-beads (N=5 T-cell donors; 
mean ± SEM).
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Figure 5.2 Epidermal response to T-cells 
represents a psoriasiform phenotype.
Keratinocyte mRNA expression levels 
of (a) DEFB4 and (b) other psoriasis- 
associated genes in the epidermis after
2 and 4 days (2d, 4d) of 0.25*106 
T-cell migration. (c) mRNA expression 
levels of pro-inflammatory cytokines 
and chemokines by keratinocytes after 
T-cell migration. (d) Immunostaining 
of psoriasis-associated proteins hBD-
2, KRT16 and Elafin after 2 and 4 days 
of T-cell migration. Scale bar = 100 pm. 
(e) Epidermal differentiation proteins 
filaggrin and involucrin demonstrated by 
immunostaining. Scale bar = 100 pm. (f) 
Ki67 mRNA levels of control and T-cell 
populated skin equivalents. (For all mRNA 
data: N=5 T-cell donors in 2 independent 
experiments, N= 2 keratinocyte donors; 
mean ± SEM; *P<0.05, **P<0.01 relative 
to control skin equivalents)
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skin is characterized by increased proliferation and disturbed differentiation, we analyzed these 
parameters in our model. The terminal differentiation process was clearly disturbed, as seen by 
reduced filaggrin expression and increased involucrin expression in the stratum spinosum (Figure 
5.2e). Flowever, Ki67 expression at the mRNA (Figure 5.2f) and protein level (data not shown) was 
unaffected and no signs of acanthosis or hyperkeratosis were observed.
Direct contact is not absolutely required for crosstalk between keratinocytes 
and T-cells
To address the question whether the infiammatory phenotype is caused by direct contact 
between T-cells and the skin equivalent or whether soluble factors produced by these cells suffice, 
we exposed skin equivalents to 0.25*106 T-cells placed in the lower chamber of a transwell 
system (indirect) or allowed T-cells to migrate into the dermis of the skin equivalents (direct). Only 
upon direct, but not indirect contact, we observed epidermal inflammation as exemplified by the 
induced expression of psoriasis-associated marker genes DEFB4 (Figure 5.3a), LCE3A, PI3, KRT16 
and others (Figure 5.3b) and the expression of pro-inflammatory cytokines IL6, IL8 and IL23 
(Figure 5.3c). Of interest, upon indirect contact with the T-cells, CCL2 and CXCL10 expression 
was highly upregulated in keratinocytes (Figure 5.3d). This would indicate that the T-cells, 
through soluble factors, can activate keratinocytes to produce chemokines. We then wondered 
whether the relatively low cell numbers, and the associated concentration gradiënt of the pro- 
inflammatory mediators produced by the T-cells, might have been a limiting factor with regard 
to the lack of disease-marker expression. Therefore, we increased the number of T-cells to 2*106 
in the lower chamber. Although the epidermal morphology was still not affected, epidermal 
inflammation was instigated with upregulation of all investigated psoriasis-associated markers 
(Figure 5.3e and f) and pro-inflammatory cytokine expression (Figure 5.3g). Since soluble factors 
produced by the T-cells appear the main factor responsible for the infiammatory phenotype in our 
model, we measured the cytokine levels in the culture medium after four days of co-culture with 
skin equivalents. Indeed, higher levels of IFN-y, IL-6, IL-22, IL-17 and TNF-a were associated with 
higher T-cell numbers (Figure 5.3h). Th2-cytokines IL-4 and IL-5 were undetectable at either T-cell 
concentration, which could well clarify the lack of an atopic dermatitis phenotype in our model.
Th1 and Th17 polarized CD4+T-cells elicit psoriasis-like epidermal inflammation
Our skin equivalents populated with T-cells express many molecular markers associated with 
psoriasis. As it is commonly accepted that psoriasis is a Th1/Th17 mediated disease, we used in 
vitro polarized Th 1 and Th 17 cells to populate the skin equivalents. To this end, we cultured naïve 
CD4+ T-cells under Th 1 or Th17 polarizing conditions during five days using well established 
cytokine and blocking antibody cocktails23. Following T-cell polarization, the activation status, 
which is vital for migration, as well as cytokine expression of the polarized cells was analyzed. 
All cultured T-cells proven activated based on CD69 expression (Supplemental Figure 5.2a). As 
compared to activated T-cells cultured for 5 days in the absence of polarizing cytokines/antibodies 
(referred to as non-polarized T-cells), Th 1 polarized cells showed clear induction of IFNG with a loss 
of /Wand IL17A (Figure 5.4a). In the Th17 polarized cells, IL17A/F and IL22 was induced, while 
IL4 expression was repressed. The IL17A expression in Th17 polarized cells was confirmed at the 
protein level (Figure 5.4b). We also attempted to include polarized Th2 cells. Although these cells 
showed downregulated expression of IFNG, IL17A/Far\d IL22 (Figure 5.4a), no expression of the 
Th2-cytokine IL4 was induced. Four days after T-cell administration, the skin equivalents exposed 
to non-polarized, Th1, Th17 or Th2 polarized cells were analyzed for signs of inflammation at
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the mRNA and protein level. Th1 and Th17 polarized T-cells, but not non-polarized orTh2 cells 
(Supplemental Figure 5.2c), significantly induced DEFB4 and LCE3A (Figure 5.4c) and CXCL10 
chemokine (Figure 5.4d) expression. Also a trend for upregulated PI3 and KRT16was observed, 
however this was not statistically significant (Supplemental Figure 5.2b). Induction of DEFB4 and 
KRT16 was confirmed at the protein level by immunostaining (Figure 5.4e). Reduced filaggrin 
expression and spinous cell expression of involucrin indicated disturbed epidermal differentiation 
in the Th 1 and Th 17 polarized inflammatory skin equivalents (Supplemental 5.2d).
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Figure 5.3 Cross talk between T-cells and keratinocytes upon indirect contact. Activated 0.25*10' 
T-cells were allowed to migrate into the skin equivalents (direct contact) or placed in the lower chamber 
of the transwell system (indirect contact) for 4 days. Keratinocyte mRNA expression levels of (a) DEFB4,
(b) other psoriasis-associated genes, (c) pro-inflammatory cytokines, and (d) chemokines CCL2 and 
CXCL10 upon indirect and direct contact. Keratinocyte mRNA levels of (e, f) psoriasis-associated genes, 
and (g) pro-inflammatory cytokine expression when 2* 106 T-cells are used in the indirect model as com­
pared to 0.25*106 T-cells. (h) Pro-inflammatory cytokine levels measured in the culture medium of the 
indirect model after 4 days of co-culture with 2x106 T-cells by Luminex. (For all figures, N=3 T-cell donors; 
mean ± SEM; *P<0.05, **P<0.01; ***P<0.001)
Anti-inflammatory drugs counteract the epidermal inflammatory phenotype
To further validate ourT-cell-based inflammatory 3D skin model, we studied the effect of targeting 
either the epidermal compartment by all-trans retinoic acid (ATRA) or the T-cell compartment by 
cyclosporin-A (CsA). Based on the initial experiments where disease-markers were found to be 
induced after two days of T-cell migration, we allowed T-cells (as used in Figure 5.2) to migrate for
2 days. Subsequently, the culture medium was supplemented with ATRA or CsA and the culture 
was continued for another 2 days. Psoriasis-associated genes DEFB4, PI3 and S100A8were found 
to be downregulated upon treatment with either ATRA or CsA (Figure 5.5a). We also observed 
the same trend for LCE3A and to a lesser extent KRT16, but this decrease was not statistically 
significant (Supplemental Figure 5.2e). Protein expression analysis of hBD-2 and elafin confirmed 
the effect of ATRA or CsA on the inflamed skin equivalents, showing reduced expression of both 
proteins upon treatment. The expression of filaggrin was partially restored upon CsA treatment
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(Figure 5.5b). To determine the treatment effects on the pro-inflammatory mediators present 
in our model, we measured cytokine levels in the conditioned medium from the inflammatory 
skin equivalents. IL-17 and IL-22 levels were reduced upon treatment with ATRA and CsA, while 
IFN-y was only affected by CsA treatment (Figure 5.5c). Again, Th2-cytokines IL-4 and IL-5 were 
undetectable in all experimental conditions (data not shown). CXLC10 and CCL2 chemokine 
expression by the keratinocytes was only reduced upon CsA treatment (Figure 5.5d). In addition, 
we used the anti-psoriatic drug, Infliximab (TNF-a antibody) to target the TNF-a produced by 
either the T-cells or keratinocytes in our model, and found significantly reduced expression levels 
of TNF, DEFB4 and CXCL8 and a similar trend to S100A8, CXCL10 and CCL2 (Supplemental 
Figure 5.2f).
Figure 5.4 Th1 and Th17 polarized CD4+ T-cells induce inflammation. Naïve CD4+T-cells were 
polarized for 5 days using cytokines and blocking antibodies or left untreated (non-pol). After 5 days the 
T-cells were stimulated for 6 hours using anti-CD3/anti-CD28 mAb coated beads in a T-cell:bead ratio of 
5:1 toensureT-cell activation. (a) mRNA expression profilesof theThl, Th17 and Th2 polarized T-cells just 
before addition to the skin equivalents (N=3 T-cell donors; mean ± SEM; *P<0.05, **P<0.01, relative to 
non-polarized T-cells). (b) IL-17A secreted in the culture medium by the different T-cell subsets just before 
addition to the skin equivalents (N=3 T-cell donors; mean ± SEM) (c) Keratinocyte mRNA expression 
levels of DEFB4 and LCE3A after 4 days of T-cell migration by Th 1, Th2 and Th17 cells (N=3 T-cell donors; 
mean ± SEM; *P<0.05, ** P<0.01, relative to non-polarized T-cells). (d) CXCL10chemokine expression 
by keratinocytes in response to polarized T-cells (N=3 T-cell donors; mean ± SEM; * P<0.05, ** P<0.01, 
relative to non-polarized T-cells). (e) Immunostaining of hBD-2 and KRT16 protein in skin equivalents 
populated with Th1 and Th 17 polarized T-cells (representative image of N=3 T-cell donors). Scale bar = 
50 (jm.
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Figure 5.5 Anti-inflammatory drugs target crosstalk and reduce the inflammatory phenotype.
CD4+CD25- T-cells were activated by anti-CD/CD28 bead stimulation for 5 hours and allowed to 
migrate into the skin equivalents for 2 days to initiate inflammation, thereafter the culture medium 
was supplemented with cydosporine A (CsA) or all-trans retinoic acid (ATRA) for another 2 days. (a) 
Keratinocyte mRNA expression levels of the psoriasis-associated genes DEFB4, PI3 and S100A8 in 
untreated (T-cell), ATRA and CsA treated inflammatory skin equivalents (N=3 T-cell donors; mean ± 
SEM; *P<0.05. ** P<0.01, *** P<0.001). (b) Immunostaining of hBD-2 and elafin and filaggrin protein 
before (T-cell) and after ATRA or CsA treatment. Scale bar = 100 pm. (c) Cytokine levels of IL-17A, IL-22, 
IFN-y, and IL-6 in the culture medium of the skin equivalents (N=3 T-cell donors; mean ± SEM; '”P<0.05, 
**P<0.01, ***P<0.001) (d) Keratinocyte mRNA levels of CXCLWand CCL2 (N=3 T-cell donors; mean ± 
SEM; *P<0.05, ‘ *P<0.01, ***P<0.001).
Discussion
Recent studies combining transcriptomics data from psoriasis and healthy skin resulted in a 
consensus molecular profile giving us more insight in the disease pathogenesis7'8. These molecular 
markers of disease are highly valuable for validating in vitro disease models as presented here.
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Many of the top 50 of upregulated genes in psoriatic lesions were also upregulated in our model 
such as DEFB4, PI3, IL8, S100A7 and more. Also, the protein expression wassimilarto psoriatic skin 
with increased levels of the aforementioned molecular markers and induced keratin 16 protein 
expression, which is typical for hyperproliferative disorders such as psoriasis 24. The key feature 
of hyperproliferative skin disorders such as psoriasis is a thickened epidermis with high numbers 
of Ki67 positive cells in the basal and suprabasal layers. We did not observe this feature in our 
model. IL-22 has been shown to be critical for epidermal hyperproliferation in mouse models 
25'26, submerged keratinocytes cultures 27, and skin equivalents stimulated with IL-22 showed 
acanthosis28'29. The concentration of IL-22 used to stimulate the skin equivalents was, however, 
40 fold higher than we measured in our model, in addition, the previously reported acanthosis 
was a result from epidermal hyperplasia and not from increased proliferation 28. Apparently, the 
crucial mediator(s) that cause keratinocyte proliferation are lacking in our model, and peripheral 
blood derived-CD4+T-cells and the soluble mediators the produce (e.g IFN-y, TNF-a, IL-22, or 
IL-17) are probably not the main instigators of epidermal hyperproliferation. Alternatively, an 
excess of growth-inhibitory molecules may be present (e.g. TGF-p). In addition, Ki67 expression 
levels of our skin equivalent model when compared to normal skin in vivo, indicate that the 
skin equivalents still have a high proliferation rate after a culture period of fourteen days (data 
not shown). Perhaps, this could explain why we were not able to induce proliferation since the 
proliferation rate was already high. It could be expected that upon a longer culture period of 
our normal skin equivalents (e.g. three to four weeks), the proliferation rate will lower, and then 
the T-cells may be capable of inducing keratinocyte hyperproliferation. Obviously, several other 
potentially relevant cell types such as fibroblasts, dendritic cells, endothelial cells and mast cells 
are absent here, some of which may be pivotal in promoting keratinocyte proliferation.
The main goal of our study was to develop a model for the crosstalk between T-cells and 
keratinocytes in a 3D microenvironment. This type of crosstalk is an essential feature in disease 
pathogenesis, as immune cells produce mediators to activate keratinocytes, who in turn 
modulate the expression of skin homing markers on T-cells 30'31 and produce chemokines to 
attract immune cells 32-33, thereby completing the vicious circle of chronic inflammation. Here, we 
have demonstrated such crosstalk by the induction of keratinocyte-derived chemokines (Figure 
5.3d) in response to soluble factors produced by peripheral blood-derived CD4+ T-cells. In our 
indirect model using low number of T-cells, this chemokine production appeared to be the initial 
step in epidermal activation as pro-inflammatory cytokine levels and epidermal disease markers 
(e.g. DEFB4, KRT16) were undetectable. Comparing the levels of soluble factors produced by the 
T-cells in our skin equivalent model to the concentrations used in previous studies21, indicates 
that the T-cells produce a wider variety of cytokines but at lower concentrations (data not shown). 
This suggests that our T-cell driven inflammatory skin model is probably more physiologically 
relevant than using an overload of cytokines to stimulate skin equivalents.
Using polarized T-cells we aimed to generate inflammatory skin equivalents with a disease 
phenotype specific for the subset of helper T-cells introduced in the skin equivalents. For Th 1 
and Th 17 polarized cells this was successful as shown by the induction of molecular markers 
for psoriasis, even though we did not observe hyperproliferation or acanthosis. The epidermal 
inflammation observed by addition of activated T-cells was similar to that of Th 1 or Th17-skewed 
T-cells which indicates that our T-cell populated skin equivalent model represents a psoriasiform 
inflammation. Despite activation, the 5 days cultured, non-polarized or Th2 skewed T-cells did not 
induce any signs of epidermal inflammation and we did not detect any of these cells in the dermis 
of our skin equivalents (data not shown). Also the keratinocytes did not respond to these cells as
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shown by the lack of chemokine production (Figure 5.4d), which appeared to be the initial step 
in the inflammatory process in our model, as discussed above. The lack of chemokine production 
could be an explanation for the absence of T-cells in the dermis of the skin equivalents, and also 
demonstrates the importance of crosstalk between the cellular compartments.
The inflammatory phenotype of our skin equivalents rather resembled psoriasis than atopic 
dermatitis. Molecular markers of atopic dermatitis (CA2 and NELL2) 12 and morphological 
features such as spongiosis and/or apoptosis34 were absent, likely due to lack of IL-4 and IL-5 
production by the T-cells. To generate a more atopic dermatitis-like phenotype, we cultured naïve 
CD4+ T-cells under Th2 polarizing conditions and added these to our skin equivalents. The Th2 
polarization protocol led to downregulation of Th 1 and Th 17 associated genes, but the cells 
failed to demonstrate IL-4 upregulation (Figure 5.4a). Thus, so far, to study atopic dermatitis 
pathogenesis and therapeutic intervention in vitro, we are still limited to cytokine-stimulated skin 
equivalents16.
The use of patient-derived keratinocytes and T-cells or skin resident T-cells would be a valuable 
application of our model. Flumanized mouse models based on the initial studies using the SCID 
mouse xenograft model35 have been crucial for our current knowledge of psoriasis pathogenesis. 
Many pathophysiological pathways and therapeutic strategies have been elucidated by 
xenografting human skin and immune cells from healthy volunteers or psoriasis patients onto 
immunodeficient mice or mice deficient in type I and type II interferon receptors36'38. It would be 
very interesting to study if our model has the potential to partially replace these models by using 
patient-derived keratinocytes versus healthy immune cells and vice versa. Since the in vivo models 
all show hyperproliferation and acanthosis, this might tackle the problem in our model where 
these features are absent.
In lesional psoriatic skin, CD4+ T-cells (as we studied in our model) are mainly localized to the 
dermis while CD8+ T-cells are present in the epidermis. The role of CD8+ T-cell in the epidermis and 
in psoriasis pathogenesis is of current interest39'40. Therefore, we are in the process of introducing 
CD8+ T-cells to our model system. Entrance of these cells in the epidermal compartment would 
be biologically relevant and would enable studying the role of these cells in the pathogenesis of 
psoriasis. In addition, the implementation of other types of immune cells in our model like natural 
killer cells and dendritic cells would also be of interest since these cell types play an important role 
in the development of psoriasis41. Initial experiments incorporating both T-cells and dendritic cells 
in our skin equivalents show promising results and this is feed for future studies.
In summary, the here presented T-cell driven in vitro model of skin inflammation faithfully 
mimics many characteristics of epidermal psoriasiform inflammation. In this model, clinically 
used drugs that target the crosstalk between keratinocytes and T-cells successfully reduced the 
inflammatory phenotype, thereby supporting the notion that our model may serve as a highly 
suitable platform for drug screening purposes in a pre-clinical setting.
Acknowledgements
We would like to thank Bram van Cranenbroek, Esther Fasse and Ellen Borg for technical 
assistance. Funding for this work was provided by the N4i (grant number R0001128) and Dutch 
Program of Tissue Engineering (grant number bgt. 6739).
108
3D inflammatory skin model
References
1. Bergboer JG, Zeeuwen PL & Schalkwijk J. 2012. Genetics of psoriasis: evidence for epistatic interaction 
between skin barrier abnormalities and immune deviation. J Invest Dermatol. 132:2320-2321.
2. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. 2006. Common loss-of-function variants of the 
epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 
38:441-446.
3. Roberson ED & Bowcock AM. 2010. Psoriasis genetics: breaking the barrier. Trends Genet. 26:415- 
423.
4. Martin G, Guerard S, Fortin MM, et al. 2012. Pathological crosstalk in vitro between T lymphocytes 
and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact. Lab Invest. 92:1058- 
1070.
5. Muhr P, Renne J, Schaefer V, Werfel T & Wittmann M. 2010. Primary human keratinocytes efficiently 
induce IL-1-dependent IL-17 in CCR6+ T cells. Exp Dermatol. 19:1105-1107.
6. Renne J, Schafer V, Werfel T & Wittmann M. 2010. lnterleukin-1 from epithelial cells fosters T cell-de- 
pendentskin inflammation. Br J Dermatol. 162:1198-1205.
7. Suarez-Farinas M, Li K, Fuentes-Duculan J, et al. 2012. Expanding the psoriasis disease profile: in- 
terrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol. 
132:2552-2564.
8. Tian S, Krueger JG, Li K, et al. 2012. Meta-analysis derived (MAD) transcriptome of psoriasis defines 
the "core" pathogenesis of disease. PLoS One. 7:e44274.
9. Nickoloff BJ, Xin H, Nestle FO & Qin JZ. 2007. The cytokine and chemokine network in psoriasis. Clin 
Dermatol. 25:568-573.
10. Bernard, BA Asselineau D, Schaffar-Deshayes L & Darmon MY. 1988. Abnormal sequence of expres­
sion of differentiation markers in psoriatic epidermis: inversion of two steps in the differentiation 
program? J Invest Dermatol. 90:801-805.
11. Bergboer JG, Tjabringa GS, Kamsteeg M, et al. 2011. Psoriasis risk genes of the late cornified en- 
velope-3 group are distinctly expressed compared with genes of other LCE groups. Am J Pathol. 
178:1470-1477.
12. Kamsteeg M, Jansen PA, van Vlijmen-Willems IM, et al. 2010. Molecular diagnostics of psoriasis, atop­
ic dermatitis, allergie contact dermatitis and irritant contact dermatitis. B rJ Dermatol. 162:568-578.
13. Nomura I, Gao B, Boguniewicz M, et al. 2003. Distinct patterns of gene expression in the skin lesions 
of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol. 112:1195-1202.
14. Flowell MD, Kim BE, Gao P et al. 2009. Cytokine modulation of atopic dermatitis filaggrin skin expres­
sion. J Allergy Clin Immunol. 124:R7-R12.
15. Kim BE, Leung DY, Boguniewicz M & Flowell, MD. 2008. Loricrin and involucrin expression is 
down-regulated byTh2 cytokines through STAT-6. Clin Immunol. 126:332-337.
16. van den Bogaard EH, Bergboer JG, Vonk-Bergers M, et al. 2013. Coal tar induces AFIR-dependent skin 
barrier repair in atopic dermatitis. J Clin Invest. 123:917-927.
17. Bao L, Shi VY & Chan LS. 2012. IL-4 regulates chemokine CCL26 in keratinocytes through the Jak 1, 
2/Stat6 signal transduction pathway: Implication for atopic dermatitis. Mol Immunol. 50:91-97.
18. Carretero M, Guerrero-Aspizua S & Del Rey M. 2013. Bioengineered skin humanized model of psori­
asis. Methods Mol Biol. 961:305-323.
19. Guerrero-Aspizua S, Garcia M, Murillas R, et al. 2010. Development of a bioengineered skin-human- 
ized mouse model for psoriasis: dissecting epidermal-lymphocyte interacting pathways. Am J Pathol. 
177:3112-3124.
20. Kamsteeg M, Bergers M, de Boer R, et al. 2011. Type 2 helper T-cell cytokines induce morphologic and 
molecular characteristics of atopic dermatitis in human skin equivalent. Am J Pathol. 178:2091-2099.
21. Tjabringa GS, Bergers M, van Rens D, et al. 2008. Development and validation of human psoriatic skin 
equivalents. Am J Pathol. 173:815-823.
109
Chapter 5
22. Rees B, Spiekstra SW, Carfi M, et al. 2011. Inter-laboratory study of the in vitro dendritic cell migration 
assay for Identification of contact allergens. Toxicol In Vitro. 25:2124-2134.
23. Koenen HJ, Smeets RL, Vink PM, et al. 2008. Human CD25highFoxp3pos regulatory T cells differenti- 
ate into IL-17-producing cells. Blood.112:2340-2352.
24. Leigh IM, Navsaria H, Purkis PE, et al. 1995. Keratins (K16 and K17) as markers of keratinocyte hyper- 
proliferation in psoriasis in vivo and in vitro. B rJ Dermatol. 133:501-511.
25. Wang C, Wu L, Bulek K, et al. 2013 The psoriasis-associated D10N variant of the adaptor Act1 with 
impaired regulation by the molecular chaperone hsp90. Natlmmunol. 14:72-81.
26. Zheng Y, Danilenko DM, Valdez P, et al. 2007. lnterleukin-22, a T(H)17 cytokine, mediates IL-23-in- 
duced dermal inflammation and acanthosis. Nature. 445:648-651.
27. Mitra A, Raychaudhuri SK & Raychaudhuri SP. 2012. IL-22 induced cell proliferation is regulated by 
PI3K/Akt/mTOR signaling cascade. Cytokine. 60:38-42.
28. Boniface K, Bernard FX, Garcia M, et al. 2005. IL-22 inhibits epidermal differentiation and induces 
proinflammatory gene expression and migration of human keratinocytes. J Immunol. 174:3695-3702.
29. Sa SM, Valdez PA, Wu J, et al. 2007. The effects of IL-20 subfamily cytokines on reconstituted human 
epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in 
psoriasis. J Immunol. 178:2229-2240.
30. Gunther C, Bello-Fernandez C, Kopp T, et al. 2005. CCL18 is expressed in atopic dermatitis and me­
diates skin homing of human memory T cells. J Immunol. 174:1723-1728.
31. McCully ML, Ladell K, Hakobyan S, et al. 2012. Epidermis instructs skin homing receptor expression in 
human T cells. Blood. 120:4591-4598.
32. Giustlzieri ML, Mascia F, Frezzolini A, et al. 2001. Keratinocytes from patients with atopic dermatitis 
and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J 
Allergy Clin Immunol. 107:871-877.
33. Peters JH, Tjabringa GS, Fasse E, et al. 2013. Co-culture of healthy human keratinocytes and T-cells 
promotes keratinocyte chemokine production and RORgammat-positive IL-17 producing T-cell popu- 
lations. J Dermatol Sci. 69:44-53.
34. Trautmann A, Akdis M, Kleemann D, et al. 2000. T cell-mediated Fas-induced keratinocyte apoptosis 
plays a key pathogenetic role in eczematous dermatitis. J Clin Invest. 106:25-35.
35. Nickoloff BJ, Kunkel SL, Burdick M & Strieter, RM. 1995. Severe combined immunodeficiency mouse 
and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol. 146:580-588.
36. Gilha, A, et al. 2002. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: 
induction of psoriasis by cells with natural killer receptors. J Invest Dermatol. 119:384-391.
37. Ma HL, Liang S, Li J, et al. 2008 IL-22 is required for Th17 cell-mediated pathology in a mouse model 
of psoriasis-like skin inflammation. J Clin Invest. 118:597-607.
38. Boyman O, Hefti HP, Conrad C, et al. 2004. Spontaneous development of psoriasis in a new ani­
mal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med. 
199:731-736.
39. Di Meglio P. & Duarte J.H. CD8 T Cells and IFN-gamma emerge as critical playersfor psoriasis in a novel 
model of mouse psoriasiform skin inflammation. J Invest Dermatol. 2013;133:871-874.
40. Hijnen D, Knol EF, Gent YY, et al. 2013. CD8(+) T cells in the lesional skin of atopic dermatitis and 
psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. J Invest Dermatol. 
133:973-979.
41. Guttman-Yassky E, Nograles KE & Krueger JG. 2011. Contrasting pathogenesis of atopic derma­
titis and psoriasis—part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 
127:1420-1432.
42. de Jongh GJ, Zeeuwen PL, Kucharekova M, et al. 2005. High expression levels of keratinocyte antimi- 
crobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol. 125:1163-1173.
43. Livak KJ & Schmittgen TD. 2001. Anaiysis of relative gene expression data using real-time quantitative 
PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402-408.
110
3D infiammatory skin model
Supplemental Figures
Supplemental Figure 5.1 (a) Protein expression of CD4 and CD69 on isolated naive T-celis by flow 
cytometry before and after stimulation with antiCD3/CD28 beads for 6 hours. (b) Absence of CD4+ 
T-cells in skin equivalents when using unstimulated T-cells. (c) mRNA expression of T-cells present in the 
dermis of the skin equivalents after 2 and 4 days of migration. Expression is relative to IFNO (N=3 T-cell 
donors, mean ± SEM).
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Supplemental Figure 5.2 (a) Flow 
cytometry analysis of CD4 and CD69 
expression on (non-) polarized T-cells 
at 5 days of culture and subsequent 
stimulation with antiCD3/CD28 beads 
for 6 hours. (b) Keratinocyte mRNA 
expression levels of PI3 and KRT16 
after 4 days of T-cell migration of 
Th1, Th2 and Th 17 cells as compared 
to non-polarized T-cells (N=3 T-cell 
donors; mean ± SEM). (c) Lack of 
hBD-2 protein expression in skin 
equivalents with non-polarized and 
Th2 cells. (d) Filaggrin and involucrin 
protein expression in skin equivalents 
with non-polarized, Thl and Th 17 
cells (e) Keratinocyte mRNA 
expression levels of the psoriasis- 
associated genes KRT16 and LCE3A 
in untreated (T-cell), ATRA and CsA 
treated infiammatory skin equivalents 
(N=3 T-cell donors; mean ± SEM). (f) 
Keratinocyte mRNA expression levels 
in control skin equivalents, untreated 
(T-cell) and Infliximab-treated (Inflix) 
infiammatory skin equivalents (N=3 
T-cell donors; mean ± SEM).
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Supplemental Tables
Supplemental Table 5.1: Gene and protein nomenclature
HUGO gene 
symbol
Protein Description
Epidermal proliferation / Differentiation markers
MKI67 Ki67 Antigen identified by monoclonal antibody Ki-67
FLG Filaggrin Pro-filaggrin
IVL Invoiucrin Invoiucrin
~ ' ' ” - " ~ -----
Keratinocyte-associated disease markers
DEFB4 hBD-2 Human beta defensin-2
S100A7 Psoriasin S100 calcium binding protein A7
S100A8 MRP-8 S100 calcium binding protein A8
KRT16 Keratin 16 (KRT16) Keratin 16
LCE3A LCE3A Late cornified envelope 3A
Pl3 Elafin/skalp Peptidase inhibitor 3, skin-derived
NELL2 NELL2 Nel-like 2
CA2 CA2 Carbonic anhydrase-2
Pro-inflammatory mediators
IL4 IL-4 lnterleukin-4
IL5 IL-5 lnterleukin-5
IL6 IL-6 lnterleukin-6
IL8 (CXCL8) IL-8 lnterleukin-8
IL17 IL-17 lnterleukin-17
IL22 IL-22 lnterleukin-22
IL23 IL-23 lnterleukin-25
TNF TNF-a Tumor necrosis factor-alpha
IFNG IFN-y Interferon-gamma
CXCL10 CXCL10 Chemokine (C-X-C motif) ligand 10
CCL2 CCL2 Chemokine (C-C motif) ligand 2
CSF2 GM-CSF Granulocyte macrophage colony stimulating factor
T-cell markers
CD4 CD4 T-cell surface glycoprotein CD4
CD69 CD69 Early activation antigen CD69
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Supplemental Table 5.2: Antibodies used in immunohistochemistry and flow  cytometry
Antibody Manufacturer Dilution
CD4; 4B12 DAKO, Fleverlee, Belgium 1 50
Ki-67; MIB-1 DAKO, Fleverlee, Belgium 1 50
pAb to beta 2 defensin Abcam, Cambrigde, UK 1 200
Keratin 16; LL025 Novacastra, Newcastle-On Tyne, UK 1 50
SKALP/Elafin Wingens et al. 1998 1 500
Filaggrin; BT-165 Biomedical Technologies, Stoughton, MA 1 6000
Involucrin; Mon150 Van Duijnhoven et al. 1992 1 10
CD3; UCHT1 DAKO, Fleverlee, Belgium 1 50
CD4; MT310 DAKO, Fleverlee, Belgium 1 50
CD69; TP1.55/3 BD-Biosciences, Breda, The Netherlands 1 50
5
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Abstract
Topical application of coal tar is one of the oldest therapies for atopic dermatitis (AD), a T helper
2 (Th2)-lymphocyte mediated skin disease associated with loss-of-function mutations in the skin 
barrier gene, filaggrin (FLG). Despite its longstanding clinical use and efficacy, the molecular 
mechanism of coal tar therapy is unknown. Using organotypic skin models with primary 
keratinocytes from AD patients and Controls, we found coal tar to activate the aryl hydrocarbon 
receptor (AhR) resulting in induction of epidermal differentiation. AhR knockdown by siRNA 
completely abrogated this effect. Coal tar restored filaggrin expression in FIG-haploinsufficient 
keratinocytes to wild type levels, and counteracted Th2-cytokine-mediated downregulation of 
expression of skin barrier proteins. In AD patients, coal tar completely restored expression of 
major skin barrier proteins, including filaggrin. Using organotypic skin models stimulated with 
Th2-cytokines IL-4 and IL-13, we found coal tar to diminish spongiosis, apoptosis and CCL26 
expression, all AD hallmarks. Coal tar interfered with Th2-cytokine signaling via dephosphorylation 
of STAT6, most likely due to AhR-regulated activation of the Nrf2 anti-oxidative stress pathway. 
The therapeutic effect of AhR activation herein described opens a new avenue to reconsider the 
AhR as a pharmacological target potentially leading to the development of mechanism-based 
drugs for AD.
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Introduction
Atopic dermatitis (AD) is a common inflammatory skin disease which has both genetic and 
environmental factors to its etiology. The pathogenesis is thought to be driven by cells of the 
adaptive immune system, mainly T helper 2 (Th2) lymphocytes. Cytokines derived thereof, such 
as IL-4, IL-5 and IL-13 contribute to disease symptoms in a STAT6 dependent fashion. Clinical 
and histopathological features include erythema, itch, loss of skin barrier function, intercellular 
epidermal edema (spongiosis) and keratinocyte apoptosis. The disease is considered to be initiated 
by abnormal exposure to external triggers (e.g. allergens) which could be due to an impaired 
skin barrier function as exemplified by loss-of-function mutations in the filaggrin (FLG) gene l2. 
Recent work has demonstrated that not only FLG haploinsufficiency (observed in > 25% of AD 
patients) or complete deficiency (as in ichthyosis vulgaris patients) is associated with AD, but also 
the quantity of FLG repeats determines the risk for developing AD 3. Therefore, upregulation of 
filaggrin expression in AD patients might be of clinical significance. Besides the FLG association in 
AD, other main skin barrier proteins, as involucrin and loricrin, are known to be downregulated 
in AD by IL-4 and IL-13 via STAT6 signaling pathways 4. Constitutive expression of STAT6 in 
mice leads to decreased expression of epidermal barrier proteins and subsequent development of 
allergie skin inflammation 5. Furthermore, variation in a newly discovered terminal differentiation 
protein called, hornerin, and decreased protein expression levels thereof have been associated 
with AD 5' 7. A recent replication study, however, did not find a significant association of the 
hornerin variation and AD 8. Collectively, these data underscore the contribution and biological 
interaction of skin barrier biology and immune mechanisms in the pathophysiology of AD.
Most of the currently used therapies for AD target the immune system (corticosteroids, 
calcineurin inhibitors, UVB irradiation), whereas emollients are used as an adjuvant to improve 
skin barrier function. Topical application of tar is an effective AD therapy, reducing inflammation 
and itch, and has been used to treat skin diseases for more than 2000 years. Coal tar contains 
over 10,000 different organic compounds, which has precluded identification of its molecular 
mode of action, and has hampered pharmacological investigation or drug development of its 
active ingredients.
Coal tar consists of a wide range of polycyclic aromatic hydrocarbons (PAFI's)9. Keratinocytes 
metabolize and detoxify internalized PAH's via CYP450 enzymes as indicated by their high levels 
in skin of coal tar-treated individuals10. The CYP450 enzymes are induced by activation of the aryl 
hydrocarbon receptor (AhR)11. The AhR is a cytoplasmic transcription factor which translocates 
to the nucleus upon ligand recognition 12, where it binds to specific motifs in the DNA, known as 
xenobiotic response elements (XREs)13. The recent discovery of endogenous AhR ligands revealed 
a physiological role of the AhR in cell behavior and development. The AhR was found to be 
crucial in regulating development of lymphoid cells 14 and the induction of regulatory T cells 
1S' 16. Recently, the environmental pollutant and AhR ligand, tetrachloro-dibenzo-dioxin (TCDD), 
has been described to induce epidermal differentiation thereby providing an explanation for the 
occurrence of chloracne 17. So far, no endogenous AhR ligands have been described that affect 
epidermal gene expression programs.
Here we studied the effects of coal tar exposure on the epidermal aspects of AD and show 
that coal tar activates the AhR signaling pathway resulting in enhanced epidermal differentiation, 
increased levels of filaggrin, and inhibition of the IL-4/STAT6 signaling pathway using submerged 
cultured human keratinocytes, human organotypic skin models and AD patients. These results 
indicate coal tar to enhance skin barrier function and to dampen the keratinocyte response to the
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major cytokines involved in AD. These findings indicate a key roie for the AhR signaling pathway 
in the molecular mechanism by which the oldest known drug in dermatology corrects epidermal 
abnormalities in a common skin disease.
Materials and Methods 
Coal tar formulations
Pix Lithantracis (medicinal coal tar) obtained from BUFA (Spruyt-Hillen, Ijsselstein, The Netherlands) 
was added to keratinocyte differentiation medium supplemented with 0.5 mg/mL delipidized 
BSA at an initial concentration of 2 %  (v/v). After overnight vortexing at room temperature, the 
saturated coal tar suspension was centrifuged and the supernatant was sterilized by 0.2 mm 
filtration. This solution was diluted 10 times in culture medium to obtain the highest, non-toxic 
concentration (this condition was furtherdesignated as the '2 % ' concentration in all experiments). 
Further dilutions in culture medium were made thereof. Coal tar is known to be composed of 
a large number (>10,000) of organic compounds, many of which are non-polar and practically 
insoluble in aqueous solution. The presence of delipidized BSA in the medium is likely to have 
facilitated the solubility of part of the non-polar fraction, but no attempt was made to quantify 
the fraction of the crude coal tar that was actually dissolved.
Toxicity testing
Cellular toxicity was measured using cell supernatant and LDH analysis according to manufactures 
recommendations (Roche). Percentage of cell death was relative to 1 %  Triton-X/PBS treated 
keratinocytes which was set at 100%.
Submerged keratinocyte culture
Keratinocytes were isolated from human abdominal skin derived from donors who underwent 
surgery for abdominal wall correction as previously described 19. For submerged culture, 
keratinocytes were cultured in keratinocyte growth medium (Lonza) and differentiated by 
depletion of growth factors. Coal tar was supplemented during the differentiation phase at 
indicated concentration series.
Skin equivalent development
Human skin equivalents were generated using de-epidermised dermis as described previously and 
seeded with 105 human primary keratinocytes 19. Skin equivalents were cultured submerged for 
three days after which the medium level was lowered and equivalents were cultured at the air- 
liquid interface at indicated time points in the presence of coal tar as indicated.
Skin morphology and stainings
6 pm sections were obtained from paraffin-embedded, formalin-fixed skin equivalents or skin 
biopsies and stained with Hematoxylin and Eosin (H&E). Indirect immunoperoxidase technique 
with avidin-biotin complex enhancement (Vectastain Laboratories) was used to analyze epidermal 
differentiation. Antibodies against filaggrin (1:6000; Biomedical Technologies), loricrin (1:500; 
BabCO), involucrin (1:50; Mon150; generated by our lab), and hornerin (antibody was raised 
against full-length recombinant HRNR-repeat domains, 1:200) were used. For translocation of 
AhR and Nrf2 (1:200, Santa Cruz), direct immunofluorescent labeling was performed using Alexa
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Fluor 488 conjugate in conjuction with fluorescence microscopy, and fluorescence intensity of 
nuclei and cytoplasm was measured by ImageJ software. The average mean Fl nucleus:cytoplasm 
ratio of 10 cells per experinnental condition was calculated from three keratinocyte donors. 
Preincubation of 2 pg AhR human recombinant protein (Abnova) with a 1:200 dilution of AhR 
antibody for 1 hour at room temperature was performed prior to incubation with the cell cultures 
to determine antibody specificity.
Transcriptional analysis
Epidermis was separated from the skin equivalents by dispase (Roche) treatment for 2 hours 
at 4°C. Total RNA from epidermis and cultured keratinocytes was isolated using TRIzol reagent 
(Life Technologies, Inc.) and a microprep kit (Qiagen). Dnase I treated (Invitrogen) and reverse 
transcribed reaction products were analyzed using the MyiQ Single-Color Real-Time Detection 
System for quantification with SYBR Green and melting curve analysis (Bio-Rad Laboratories). 
Expression of target genes was normalized to expression of the housekeeping gene human 
ribosomal phosphoprotein PO (RPLPO) in the same sample. Relative mRNA expression levels were 
calculated using the AA-Ct method.
si RNA knockdown
Keratinocytes were grown to 60% confluency and 500 nM of smartpool AhR targeting or non- 
targeting siRNA (Accell Dharmacon) was added for 48 hours. Subsequently, culture medium was 
refreshed supplemented with siRNA for another 24 hours. Thereafter, keratinocytes were allowed 
to differentiate for 48 hours in the presence of coal tar. Cells were harvested for transcriptional 
analysis as described above.
Clinical studies
Three AD patients hospitalized to receive coal tar treatment in our medical centre were included 
in the study. Coal tar treatment consisted of application of 5%  crude coal tar ointment (pix 
lithantracis in zinc oxide paste) to the affected body area, twice daily. 3mm biopsies were taken 
under local anesthesia from lesional skin prior to treatment and on day 3 and 7 of treatment. 
Biopsies were taken from the centre of active lesions avoiding blisters or wounds.
FLG mutation analysis
Genomic DNA was extracted from saliva samples using the Oragene kit (DNA Genotek Inc) 
according to the manufacturer's protocol. For the analysis of the p.R501X (c.1501C>T) and 
c.2282del4 mutations the following primers: FilHI F3/RPT1P6 and RPT1 P7/RPT2P1, respectively. 
DNA (50 ng) was diluted in PCR reaction buffer containing 1.6 mM MgCI2 and Platinum Taq 
Polymerase (Invitrogen). PCR conditions were as follows: 94°C for 5 min; 35 cycles of 94°C for 
30 s, 58°C for 45 s, 72°C for 75 s; final extension step at 72°C for 7 min. The amplified PCR 
products were resolved on a 1.5% agarose gel, purified by using the Nucleospin Gel and PCR 
Clean-up kit (Bioké) and sequenced using dye termination chemistry on a 3730 DNA analyzer 
(Applied Biosystems).
Western blot analysis
Keratinocytes or epidermal sheets from skin equivalents separated by dispase treatment, were 
lysed in RIPA lysis buffer. After one cycle of freeze/thawing, the lysates were centrifuges for 
10 minutes at 4 degrees Celsius, maximum speed. The supernatant was used for involucrin
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immunoblotting. The total protein concentration of the supernatant was determined and a total 
of 12.5 pg protein was loaded for each sample. The pellet containing the insoluble fraction was 
resuspended in sample buffer, sonicated, and boiled for 5 minutes and used for filaggrin and 
loricrin detection. For submerged cultured keratinocyte lysates, actin antibody (Sigma) was used 
to control equal protein loading. To control equal loading of the insoluble fraction from skin 
equivalent epidermis, Coomassie Blue staining of gels and Ponceau S staining of blots was used 
(data not shown). Prior to immunoblotting, proteins were separated by SDS page and transferred 
to PVDF membranes using the NuPAGE system (Life Technologies). LumiGLO (Cell Signaling 
Technology) was used for chemiluminescent detection by the Bio-Rad Universal Flood Gel Imager 
(Bio-Rad Laboratories). STAT6 phosphorylation was analyzed in primary human keratinocytes 
after IL-4 and IL-13 stimulation as described previously 18 with coal tar supplemented in the 
culture medium at indicated time periods.
Statistics
Data are given as mean ± SEM of at least three biological replicates. Statistical analysis of qPCR 
data was performed on ACt values using commercially available software (PASW Statistics 18). 
One-way analysis of variance, followed by Bonferroni post hoc testing, and two-sided paired 
t-tests were performed. P< 0.05 was considered statistically significant.
Study approval
The study was approved by the local medical ethical committee and conducted according to 
the Declaration of Helsinki principles. Informed consent was obtained from all patients and 
individuals.
Results
AhR regulates coal tar-induced epidermal gene and protein expression
First, we investigated the potential of coal tartoactivate the AhR using cultured adult primary human 
keratinocytes. A coal tar formulation was prepared in culture medium and various concentrations 
were tested for toxicity. Following 48 hours of treatment, none of the concentrations tested 
resulted in enhanced cell death (Supplemental Figure 6.1a). In a variety of cells, it has been 
shown that upon ligand-binding, the AhR translocates to the nucleus. We indeed observed that 
coal tar caused the AhR to relocate from the cytoplasm to the nucleus within 4 hours (Figure 
6.1a), and we found a significant increase of the AhR nucleus/cytoplasm ratio upon TCDD and 
coal tar stimulation which increased in time (Figure 6.1b). Preincubation of the antibody with 
recombinant AhR before immunofluorescence analysis completely eliminated nuclear staining 
of coal tar treated cells, which indicates the specificity of the immunofluorescence staining 
(Supplemental Figure 6.1b). We found a strong time and concentration dependent increase of 
expression of typical AhR responsive genes such as CYP1A1 and CYP1B1 in coal tar-treated 
keratinocytes, while expression of CYP2E1 (not an AhR target) was unaffected (Figure 6.1c and 
Supplemental Figure 6.2a). The response of keratinocytes to coal tar was of similar magnitude 
as the response to TCDD, a dioxin-like compound used as positive control. Besides the CYP450 
target gene expression, we also observed a highly significant and concentration dependent 
induction of the epidermal differentiation genes FLG, hornerin (HRNR) and involucrin (IVL) (Figure 
6.1d), all pivotal for barrier function and functionally related to AD 1-2-4’7. For these genes, the
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induction rate achieved by high and intermediate coal tar concentrations was even higher than 
that achieved by TCDD. Other epidermal differentiation genes as cystatin M/E (CST6), repetin 
(RPTN) and small proline rich protein 2A/B (SPRR2A/B) were also induced after coal tar treatment 
but to a lesser extent (Supplemental Figure 6.2b). The induced mRNA expression was confirmed at 
the protein level by staining of coal tar-treated and untreated keratinocytes cultured on coverslips 
(Figure 6.1e) and by Western blotting (Figure 6.1 f). Filaggrin protein expression in untreated 
keratinocytes was confined to a few multilayered foei, while in coal tar-treated keratinocytes, 
filaggrin expression was already present in large patches of the keratinocyte monolayer (Figure
6.1 g). These results indicate that coal tar treatment induced filaggrin expression at early stages 
of keratinocyte differentiation.
To confirm the regulatory role of the AhR signaling pathway in the coal tar-mediated induction 
of epidermal differentiation genes, we studied the coal tar response after siRNA mediated knock 
down of AHR in keratinocytes. As shown in Figure 6.1 h, a 79% decrease of AHR expression was 
achieved, together with a concomitant 82% decrease in expression of its classical target gene 
CYP1A1. AHR knockdown also caused a similar decrease of coal tar-induced FLG and HRNR gene 
expression (Figure 6.1i) and other terminal differentiation genes (Supplemental Table 6.1). The 
induction rate after coal tar treatment and subsequent inhibition by AHR knockdown was most 
pronounced in terminal differentiation genes with a reported xenobiotic response element in 
their promoter region ,7, such as FLG, HRNR and filaggrin family member-2 (FLG2). In contrast, 
the early differentiation marker keratin 10 or the basal keratinocyte markers keratin 5 and keratin
14, were not affected by coal tar stimulation or AhR knockdown. Altogether, these data show 
that coal tar induces epidermal differentiation which is regulated by the AhR signaling pathway.
Accelerated epidermal differentiation by coal tar treatment
Next, we used an organotypic human skin model (hereafter referred to as 'skin equivalents') to 
evaluate the effects of coal tar during epidermal morphogenesis. We have previously shown that 
skin equivalents can be used successfully to mimic many aspects of normal epidermis or diseased 
epidermis (e.g. psoriasis and AD)18-19. After 3 daysof submerged culture, the skin equivalents were 
lifted at the air-liquid interface and the culture medium was supplemented with coal tar. Already 
after 4 days of culture at the air-liquid interface, a fully developed epidermis was observed in coal 
tar-treated skin equivalents. The untreated skin equivalents required 10 days of air-exposure to 
generate a well developed epidermis (Figure 6.2a). From day 4 onwards, the epidermis of coal tar- 
treated skin equivalents continuously produced terminally differentiated cells, resulting in a very 
thick Iayer of stratum corneum at day 10 of culture at the air-liquid interface (Figure 6.2a; bracket). 
To further examine the differentiation process of coal tar-treated skin equivalents, we analyzed 
protein expression at several time points using immunohistochemistry. Terminal differentiation 
markers, which are normally expressed from day 6 of air-exposed culture onwards20, were already 
expressed at high levels at day 4 in coal tar-treated skin equivalents. Particularly, filaggrin, loricrin 
and hornerin were barely present in the Standard (control) cultures at day 4, while abundantly 
expressed in coal tar-treated skin equivalents (Figure 6.2b, c). Therefore, we conclude that coal 
tar treatment in vitro results in accelerated epidermal differentiation, accompanied by induced 
expression of terminal differentiation proteins.
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Figure 6.1 Coal tar induces epidermal differentiation via AhR signaling. (a) Immunofluorescence 
staining of AhR in coal tar-treated or untreated human primary keratinocytes. Nuclei were counterstained 
using DAPI. Pictures are representative of N=5 keratinocyte donors, scale bar = 100 pm. (b) Semi- 
quantitative analysis of nudear and cytoplasmic fluorescence intensity (Fl) measured by ImageJ software. * 
P<0.05, ** P<0.01, *** P <0.001, relative to untreated, barsindicate mean±SEM. N=3. (c)qPCR analysis 
of CYP450 mRNA expression levels after 48 hours stimulation with TCDD or a coal tar concentration 
series. Expression levels are relative to untreated (control) keratinocytes. * P <0.05, ** P<0.001, relative 
to untreated, bars indicate mean±SEM. N=3 in two replicate experiments. (d) mRNA expression levels 
of epidermal differentiation genes after 48 hours stimulation with TCDD or a coal tar concentration 
series. Expression levels are relative to untreated (control) keratinocytes. Bars indicate mean+SEM N=3 
in two replicate experiments. (e) Filaggrin and hornerin immunofluorescence staining of 2% coal tar 
treated or untreated keratinocytes. Nuclei were counterstained using DAPI. Pictures are representative 
of N=5 keratinocyte donors, scale bar = 100 pm. (f) Western blot analysis of filaggrin protein in lysates 
of coal tar treated and untreated keratinocytes of two keratinocyte donors, (g) Filaggrin staining of 2% 
coal tar treated or untreated keratinocytes. Nuclei were counterstained using hematoxylin. Pictures are 
representative of N=3 keratinocyte donors, scale bar = 100 pm. (h) AHR and CYP1A1 and (i) FLG and 
HRNR mRNA expression levels by qPCR analysis after siRNA-mediated AhR knockdown and subsequent 
2% coal tar stimulation. Expression levels are relative to mock-treated, coal tar-stimulated keratinocytes. 
Bars indicate mean±SEM. N=3.
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Figure 6.2 Accelerated epidermal differentiation by coal tar. (a) H&E staining of human skin 
equivalents cultured in presence or absence (control) of coal tar during the entire air-liquid interface 
culture. Bracket indicates the thickness of the stratum corneum. (b) Immunostaining of filaggrin, loricrin 
and hornerin of skin equivalents at day 4 of the air-liquid interface culture when cultured in presence 
or absence (control) of coal tar. Pictures are representative of N=3 keratinocyte donors, experiment 
replicated twice. All scale bars = 100 pm. (c) Filaggrin and loricrin western blotting of skin equivalents 
harvested on day 4 or day 10 of air-liquid interface culture, treated with or without coal tar during the 
entire culture period. Blot is a representative of N=3 keratinocyte donors.
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coal tar treatment coal tar treatment
untreated 3 days 7 days untreated 3 days 7 days
Figure 6.3 Restored filaggrin and hornerin protein expression by coal tar. Fluman skin equivalents 
generated from keratinocytes from AD patients harboring a heterozygous FLG mutation (FLG", N=3) 
and healthy control wild type (WT, N=3) keratinocytes were treated with coal tar during the last 3 days 
of air-liquid interface culture Skin equivalents were stained for (a) filaggrin and (b) hornerin protein 
Immunohistochemical analysis of (c) filaggrin and hornerin and (d) involucrin and loricrin protein 
expression in skin biopsies from AD patients (N=3) receiving coal tar therapy. All scale bars = 100 pm.
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Coal tar increases filaggrin expression in human skin equivalents and in lesional 
AD skin
Based on the observed association of AD with FLG haploinsufficiency and the increased risk 
of lower copy numbers of intragenic FLG repeats, it has been suggested that treatments 
resulting in increased filaggrin expression may have therapeutic value 3. To address this issue 
experimentally, we generated skin equivalents with keratinocytes from both healthy volunteers 
and atopic dermatitis patients, with a wild type genotype or heterozygous mutation in the FLG 
gene, respectively (Supplemental Table 6.2). During the last 3 days of culture we supplemented 
the culture medium with coal tar and evaluated whether coal tar would induce filaggrin in these 
patient-derived skin equivalents. Filaggrin protein expression in skin equivalents of heterozygous 
mutated keratinocytes was barely present in control conditions, whereas after coal tar treatment, 
filaggrin expression was evident in the granular layer of the epidermis (Figure 6.3a). Wild type 
keratinocytes responded stronger to coal tar treatment as expected since they have two intact FLG 
alleles. Since downregulated hornerin expression in AD might be important in the pathophysiology 
of the disease 1, we also evaluated hornerin protein expression and found coal tar-mediated 
upregulated hornerin expression similar to that of filaggrin (Figure 6.3b). To correlate our in vitro 
model to the in vivo situation, we obtained skin biopsies from AD patients before and during 
coal tar therapy. In lesional AD skin, expression of filaggrin and hornerin was markedly lower, 
discontinuous or even absent as compared to normal skin, as described previously 7. Already 
after 3 days of coal tar treatment, expression of these proteins was strongly induced in lesional 
AD skin, and after 7 days of coal tar therapy a continuous expression pattern was observed 
(Figure 6.3c), resembling that of normal skin. Other epidermal differentiation proteins were also 
analyzed and we found a strongly upregulated loricrin and involucrin protein expression both in 
vitro, and in vivo (Figure 6.3d) suggesting that AD patients may benefit from enhanced epidermal 
differentiation in general, leading to improved barrier function.
Coal tar normalizes histopathological and molecular hallmarks of atopic 
dermatitis in skin equivalents
Th2-cytokines like IL-4 and IL-13 induce spongiosis and apoptosis in skin equivalents probably 
via STAT6 signaling 1S. These cytokines were also shown to downregulate involucrin and loricrin 
expression via STAT6 4, and constitutive expression of STAT6 in transgenic mice leads to an 
increased risk of developing AD 5. We therefore stimulated skin equivalents with IL-4 and IL- 
13 to induce an AD phenotype in vitro, as previously described 18, and tested the effect of coal 
tar. Coal tar treatment prevented the occurrence of spongiosis and apoptosis, and could 'cure' 
these symptoms in a therapeutic experimental design; both simultaneous addition of Th2- 
cytokines and coal tar, and coal tar treatment after Th2 stimulation resulted in improvement of 
the phenotype (Figure 6.4a, b). Although Th2-cytokine mediated apoptosis was reported to be 
associated with increased expression of FAS 2\ we did not observe downregulated FAS levels 
after coal tar treatment (Figure 6.4c). In our skin equivalent model, we confirmed the reported 
4 Th2-cytokine mediated downregulation of epidermal differentiation proteins, and we found 
coal tar treatment to restore both mRNA (Figure 6.4d) and protein expression (Figure 6.4e, f). 
This was also confirmed in coal tar-treated AD patients in vivo (Figure 6.3d). Eosinophilia has 
been associated with AD and the degree of eosinophilia correlates with AD severity 22. CCL26, 
or eotaxin-3, a chemokine for eosinophils is upregulated in keratinocytes by IL-4 via the STAT6 
signaling pathway23. Our results have shown coal tar to diminish downstream effects of IL-4, and 
therefore we analyzed CCL26 levels in our AD skin equivalent model after coal tar treatment.
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Figure 6.4 Coal tar attenuates Th2-cytokine-induced AD hallmarks. (a) H&E staining of skin 
equivalents stimulated with Th2-cytokines for 3 days, or treated with coal tar thereafter (Th2-»coal tar) 
or simultaneously stimulated with Th2-cytokines and coal tar (Th2+coal tar). Closed arrowheads indicate 
spongiosis. Pictures are representative of N=3 keratinocyte donors, experiment replicated twice, scale 
bar = 100 pm. (b) TUNEL assay on matching skin equivalents as depicted in (a), showing apoptotic cells 
indicated by open arrow heads Scale bar = 100 pm (c) qPCR anaiysis of FA5 mRNA expression levels 
after Th2-cytokine stimulation and coal tar treatment. Expression levels are relative to untreated (control) 
keratinocytes, bars indicatc mean±SEM. N=3 (d) mRNA expression levels of epidermal differentiation 
genes after Th2-cytokine stimulation and coal tar treatment. Expression levels are relative to untreated 
(control) keratinocytes, bars indicate mean±SEM. N=3, *P<0.05, **P<0.01 (e) Immunostaining of loricrin 
and involucrin in skin equivalents stimulated with Th2-cytokines for 3 days, or treated with coal tar 
thereafter (Th2-»coal tar). Pictures are representative of N=3 keratinocyte donors, experiment replicated 
twice, scale bar = 100 pm. (f) Loricin, involucrin and filaggrin western blotting of skin equivalents depicted 
in (e). (g) CCL26 mRNA expression levels after Th2-cytokine stimulation and coal tar treatment by qPCR 
anaiysis. Expression levels are relative to untreated (control) keratinocytes, bars indicate mean±SEM. N=3, 
***P<0,001.
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The highly upregulated CCL26 expression levels in skin equivalents after Th2-cytokine stimulation 
were completely normalized after coal tar treatment (Figure 6.4g), indicating that coal tar directly 
targets the innate immune system by interfering with the keratinocyte response following Th2- 
cytokine stimulation.
Coal tar interferes with the Th2-cytokine mediated STAT6 signaling cascade
Since most of the aforementioned effects of Th2-cytokine stimulation in keratinocytes act via 
STAT6 signaling, we hypothesized that coal tar interferes with this signaling cascade. Both 
phosphorylated (pSTAT6) and total STAT6 levels were determined using Western blot analysis, 
which revealed that stimulation with IL-4 and IL-13 induced STAT6 phosphorylation in keratinocytes 
(Figure 6.5a). Thereafter, we supplemented Th2-cytokine-stimulated keratinocytes with coal tar 
for six hours and observed markedly reduced pSTAT6 levels in these cell lysates (Figure 6.5a). 
pSTAT6 is a known substrate for protein tyrosine phosphatase 1B (PTPN1)24. In addition, oxidative 
stress induced by Th2-cytokine stimulation in keratinocytes results in oxidative inactivation of 
PTPN1 and therefore sustained STAT6 phosphorylation 2S. We therefore hypothesized that the 
molecular mechanism of coal tar-mediated inhibition of STAT6 phosphorylation could - at least 
in part - act via inhibition of oxidative inactivation of PTPN1. The AhR is known as a sensor 
of the redox system against oxidative stress and regulates nuclear factor-erythroid 2-related 
factor-2 (Nrf2), a master switch of the redox machinery 26. We found coal tar to induce both 
nuclear translocation of Nrf2 (Figure 6.5b) and subsequent induction of its target gene, NAD(P) 
H quinone oxidoreductase 1 (NQ01) in keratinocytes (Figure 6.5c). Remarkably, no induction of 
NQ01 was observed in keratinocytes following TCDD exposure. Upon AhR knockdown (Figure 
6.5d), induction of NQOl expression was inhibited (Figure 6.5e) indicating the regulatory role of 
the AhR in Nrf2 mediated signaling in keratinocytes. Our data suggest that coal tar activates the 
anti-oxidative stress pathway via Nrf2 signaling which might inhibit Th2-induced oxidative stress 
resulting in STAT6 dephosphorylation and abrogation of the inflammatory Th2-mediated STAT6 
signaling cascade in keratinocytes (Figure 6.6).
Discussion
AD is a highly prevalent inflammatory skin disease caused by skin barrier dysfunction and 
chronic immune activation 27’28. No mechanism-based therapies are available for AD patients 
and treatment is mainly focused on symptom relief, predominantly targeting dry skin, itch and 
inflammation by emollients and corticosteroids. As the seminal work of the Mclean lab has 
underscored the importance of skin barrier abnormalities as an etiological factor in AD, we 
focused on the effects of coal tar on the epidermal biology of this disease. Our results reveal a key 
role for the AhR signaling pathway by improvement of the skin barrier function and interference 
with Th2-cytokine signaling and downstream pathological processes, thereby breaching the 
vicious circle of chronic inflammation.
The immunopathogenesis of AD has been studied directly on patients or in animal models 
based on allergie immune responses29'31. We have recently developed in vitro organotypic models 
for psoriasis and atopic dermatitis 1S' 19, and we showed that application of genetic techniques 
therein could be used to study epidermal aspects of diseases 32. Others showed that FLG 
knockdown in human skin equivalents could mimic AD skin by impaired epidermal differentiation 
and barrier dysfunction 33' 34. We have chosen keratinocyte-only human skin equivalents to
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Figure 6.5 STAT6 dephosporylation and Nrf2 activation by coal tar. (a) Western blot analysis of 
phosphorylated STAT6 (pSTAT6) and total STAT6 levels in lysates of two keratinocyte donors. Keratinocytes 
were stimulated for 12 hours with differentiation medium (-/-), Th2-cytokines (+/-) or 2% coal tar (-/+), 
and with Th2-cytokines during the first 6 hours and 2% coal tar subsequently added and stimulated 
for another 6 hours (+/+). (b) Immunofluorescence staining of Nrf2 in coal tar treated or untreated 
keratinocytes. Nuclei were counterstained using DAPI. Pictures are representative of N=3 keratinocyte 
donors, scale bar = 100 pm. (c) qPCR analysis of NRF2 and NQ01 mRNA expression levels in keratinocytes. 
Expression levels are relative to untreated (control) keratinocytes, * P=0.002 relative to control condition, 
bars indicate mean±SEM. N=3 (d) qPCR analysis AHR and NQ01 after siRNA-mediated AHR knockdown 
and subsequent coal tar stimulation by qPCR analysis. Expression levels are relative to mock-treated, coal 
tar-stimulated keratinocytes. * P=0.006, ** P= 0.032, bars indicate mean±SEM. N=3.
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Figure 6.6 Model of the molecular mechanism of coal tar therapy in AD. Th2-cytokines IL-4 and II- 
13 activate the 5TAT6 signaling cascade leading to downregulated expression of epidermal differentiation 
proteins, induction of the eosinophilic chemoattractant CCL26 and histopathological features such 
as spongiosis and apoptosis. Under normal conditions, PTPNI dephosphorylates STAT6 resulting in a 
regulatory feedback loop. However, oxidative stress caused by Th2-cytokines inactivates PTPN1, leading to 
sustained STAT6 signaling. Coal tar-mediated activation of the AhR signaling pathway leads to enhanced 
epidermal differentiation and possible improvement of epidermal barrier function, thereby attenuating 
allergen exposure and reducing inflammatory cues. Importantly, coal tar activates the AhR/Nrf2 signaling 
pathway enabling detoxification of reactive oxygen species. This may prevent the oxidative inactivation 
of PTPN1 and lead to decreased STAT6 signaling, normalization of skin barrier protein expression and 
downregulation of CCL26 expression.
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evaluate the effect of coal tar on the epidermis, thereby excluding possible effects of coal tar and 
subsequent AhR activation, on other cell types of the skin such as fibroblasts and immune cells, 
which in turn could affect epidermal processes. Genetic approaches to modify keratinocyte gene 
expression were introduced in this system by an siRNA knockdown approach to prove the role 
of the AhR or by the use of patient-derived keratinocytes harboring one FLG null allele. These 
findings illustrate the power of skin equivalents to study human skin diseases, which to a certain 
extent can replace mouse models.
In the early seventies, attempts were made to unravel the mechanism of action of coal tar 
therapy. Suppression of DNA synthesis35' 36, and induction of a granular layer using the mouse 
tail test 37' 38 have been reported. The latter already indicated effects of coal tar on epidermal 
differentiation. Since the discovery of FLG mutations in AD, it is now widely accepted that epidermal 
barrier dysfunction is key in the pathophysiology of AD. These new insights are strongly guiding 
current efforts in AD research and therapy development. The accelerated filaggrin expression and 
barrier function in fetal mouse skin due to dioxin-mediated AhR activation 17'39 suggested to us 
a potential role for the AhR in AD treatment. Here, we show coal tar to activate AhR signaling 
and found the AhR to regulate and induce epidermal differentiation, and to stimulate filaggrin 
expression in keratinocytes harboring a mono allelic FLG loss-of-function mutation. These findings 
may have a major impact on the reappraisal of coal tar therapy, which is gradually abandoned by 
many dermatologists, as it is considered obsolete due to cosmetic reasons, safety concerns and a 
hitherto unknown mechanism.
The AhR signaling pathway is currently of high interest. As it was previously only considered 
to be related to (immuno)toxicity, recent findings have underscored its physiological role. The AhR 
seems to be mostly involved in development and function of the immune system 40'44. Genetic 
approaches in mice, however, have also revealed that AhR signaling plays a role in epidermal 
(patho-)physiology. Deficiency or constitutive expression of AhR interaction partners ARNT45-46 
and Nrf2 47, respectively, has detrimental effects on epidermal differentiation and barrier function, 
whereas AhR transgenic mice develop inflammatory skin lesions with hyperkeratinization 4S. All 
these studies show that disturbance of normal AhR signaling, either by genetic approaches 
or TCDD exposure leads to epidermal abnormalities. Our study is the first to demonstrate the 
beneficial, therapeutic effects of AhR activation on epidermal differentiation and barrier function 
in a skin disease which is characterized by low levels of terminal differentiation proteins and 
therefore a poor barrier function. The therapeutic use of AhR ligands appears controversial in 
light of the complete ban of all AhR ligands by the pharmaceutical industry due to the widely 
known dioxin-related toxic effects of AhR activation. However, the recent interest in the AhR 
signaling pathway has led to a variety of reports describing diverse downstream effects by 
different exogenous and endogenous AhR agonists. It is therefore nowadays recognized that 
the specific ligand-receptor interaction determines the downstream effects of AhR activation and 
that it is not merely a matter of drug potency. Hence, CYP1A1 induction and/or AhR activation is 
not synonymous with dioxin-like toxicity.
Besides the improved epidermal differentiation and filaggrin induction by coal tar-mediated 
AhR activation, we made the exciting observation that coal tar normalizes histopathological 
and molecular hallmarks of AD, and we found STAT6 to be the key player in this process in 
keratinocytes. Although we were unable to directly measure the putative phosphatase (PTPN1) 
activity responsible for inactivating STAT6 activity 24 in keratinocytes, we do provide evidence 
that both upstream (Nrf2) and downstream pathways (STAT6) are affected by coal tar. Therefore, 
it is most likely that coal tar inhibits oxidative inactivation of PTPN1 and thereby attenuates
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STAT6 activation. The Th2 immune response as observed in atopic diseases like AD, is also driven 
by STAT6 via IL-4 induced maturation and development of Th2 cells 49-50. Based on our data 
we believe that the AhR has great potential as a pharmacological target in atopic or allergie 
diseases. Especially as it was shown that the AhR agonist FICZ (a tryptophan metabolite) 
suppresses eosinophilia, Th2-cytokine production and STAT6 activation in allergie asthma in mice 
5'. Moreover, PTPN1 deficiency results in exacerbated lung inflammation in mice due to early 
recruitment of leukocytes and elevated levels of lung CCL26 and Th2-cytokine levels52. Since coal 
tar metabolites are found in urine of patients receiving coal tar therapy 53 suggesting systemic 
entrance of coal tar components following topical application, the therapeutic success of coal tar 
therapy may, in addition to its epidermal effects, also rely on suppression of the immune response 
by dampening STAT6 activation in immune cells. The reported role of AhR in Treg development 
is likely to contribute to the therapeutic efficacy of coal tar in two major skin diseases, psoriasis 
and AD. The scope of our current investigations, however, was limited to epidermal aspects of 
AD and the effect of coal tar.
In addition to the recently uncovered role of Nrf2 in epidermal barrier function, its main 
function lies in the defense against oxidative stress and is therefore proposed as a potential 
pharmacological target for chemoprevention 54. Nrf2 has been linked to the AhR signaling 
pathway mostly in mice liver tissue after dioxin exposure55. Here we show coal tar, but not TCDD, 
to induce Nrf2 activation and subsequent expression of NQ01 in human keratinocytes. Upon 
knockdown of AhR, significantly less NQ01 was expressed indicating an interaction between 
AhR and Nrf2 in human keratinocytes. The discrepancy between the previously reported TCDD- 
induced NQ01 levels and the lack of such induction in keratinocytes is in itself not unprecedented 
and may be explained by species and cell type differences and ligand specific effects56. Therefore, 
the induction of a protective mechanism (NQ01 induction) in keratinocytes after coal tar exposure 
might explain the lack of toxicity and carcinogenicity 57 associated with medicinal use of coal tar, 
while AhR activation by TCDD leads to severe symptoms as chloracne, immunotoxicity and an 
increased cancer risk.
Although coal tar therapy is the oldest known dermatological treatment, questions are still 
raised about its safety and possible carcinogenicity 5S. A comprehensive study by Roelofzen et 
al. in 2010 57 did not find a relation between an increased risk for skin or non-skin malignancies 
and coal tar therapy in a large cohort of 13,200 psoriasis and eczema patients. AhR ligands are 
currently excluded from drug discovery and development pipelines due to the exposure-related 
toxicity and carcinogenicity of some of its known ligands, as dioxin and benzo-a-pyrene. The 
emerging evidence of a more physiological role of the AhR, and the therapeutic effect of AhR 
activation herein described, suggest that it might be the right time to reconsider whether it is 
justifiable to exclude the AhR as a pharmacological target.
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Supplemental Figures
Supplemental Figure 6.1 No toxic effects of coal tar formulations on primary human 
keratinocytes. (a) Keratinocytes were stimulated with various concentrations of the coal tar formulation 
for 48 hours and conditioned culture medium was assessed for the presence of lactate dehydrogenase. 
The percentage of cell death was relative to keratinocytes treated with 1% Triton-X/PBS, which was set 
at 100%. (b) Blocking of specific nudear AhR staining by human recombinant AhR protein in coal tar 
treated keratinocytes.
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Supplemental Figure 6.2 Additional mRNA expression analysis. (a) Time dependent CYP1A1 mRNA 
expression levels after stimulation with TCDD or a 2 %  coal tar formulation. Expression levels are relative 
to untreated (control) keratinocytes. (b) Induced mRNA expression levels of epidermal differentiation 
genes after 48 hours stimulation with TCDD or a coal tar concentration series. Expression levels are 
relative to untreated (control) keratinocytes. All bars indicate mean±SEM, N=3.
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Supplemental Tables
Supplemental Table 6.1: Epidermal differentiation levels after AhR knockdown
Gene Abbreviation Relative expression* 
(mean ± SD)
Pvalue**
Hornerin HRNR 0.46 ± 0.03 0.003
Filaggrin FLG 0.40 ± 0.07 0.002
Filaggrin family member-2 FLG2 0.14± 0.03 0.01
Small proline rich protein 2A/B SPRR2A/B 0.61 ± 0.05 0.01
Involucrin IVL 0.68 ± 0.06 0.02
Loricrin LOR 0.65 ± 0.09 0.03
Transglutaminase 1 TGM1 0.76 ±0.21 0.12
Cystatin M/E CST6 0.89 ± 0.21 0.44
Keratin 10 KRT10 1.70 ± 0.45 0.08
Keratin 14 KRT14 1.52 ± 0.10 0.08
Keratin 5 KRT5 1.32 ± 0.43 0.37
* Keratinocytes were stimulated with coal tar after AhR knockdown.
Expression levels are relative to mock-treated, coal tar-stimulated keratinocytes. 
** Pvalues in bold are considered statistically significant. N=3.
Supplemental Table 6.2: Filaggrin mutation analysis*
Patiënt status P-R501X (c.1501C>T) c.2282del4
Healthy (N=3) 1 1
Atopic dermatitis (N=3) 0 l 1
* Analysis for the two most common FLG mutations, p.R501X (c.1501 C>T) and c.2282del4.
Intact allele is depicted as ' 1 mutation as '0'.
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Abstract
p53 and p63 share extensive sequence and structure homology. p53 is frequently mutated in 
cancer, whereas mutations in p63 cause developmental disorders manifested in ectodermal 
dysplasia, limb defects and orofacial clefting. We have established primary adult skin keratinocytes 
from ectrodactyly, ectodermal dysplasia and cleft lip/palate (EEC) syndrome patients with p63 
mutations as an in vitro human model to study the disease mechanism in the skin of EEC patients. 
We show that these patiënt keratinocytes cultured either in submerged 2D cultures or in 3D skin 
equivalents have impaired epidermal differentiation and stratification. Treatment of these patiënt 
keratinocytes with the mutant p53-targeting compound APR-246/PRIMA-1MET (p53 reactivation 
and induction of massive apoptisis), that has been successfully tested in a phase l/ll clinical trial 
in cancer patients, partially but consistently rescued morphological features and gene expression 
during epidermal stratification in both 2D and 3D models. This rescue coincides with restoration 
of p63 target gene expression. Our data show that EEC patiënt keratinocytes with p63 mutations 
can be used for characterization of the abnormal molecular circuitry in patiënt skin and may open 
possibilities for the design of novel pharmacological treatment strategies for patients with mutant 
p6J?-assodated developmental abnormalities.
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Introduction
The p53 family of transcription factors p53, p63 and p73 share high sequence and structure 
homology, especially in their DNA-binding domains. p53 plays a key role in tumor suppression 
and is mutated in around 50% of human tumors whereas p63 is a master regulator during 
ectodermal and epidermal development2' 3. p63 is expressed as several isoforms with different 
N-terminal ends, the TA and AN isoforms, and different C-terminal ends, designated a, p, y, 8, 
and e 4. ANp63a is the major isoform expressed in the epidermis 5.
The key role of p63 in ectodermal and epidermal development has been demonstrated in 
animal models as well as in human developmental disorders. Disruption of p63 in mice and 
zebrafish causes severe epidermal and limb defects 2' 3’6. In humans, heterozygous mutations 
in p63 give rise to several clinical conditions with autosomal dominant inheritance 7. The three 
major characteristics of these developmental disorders are limb defects, orofacial clefting and 
ectodermal dysplasia (ED) which is comprised of defects in skin, hair, teeth, nails and several 
exocrine glands. Among these disorders, the ectrodactyly, ectodermal dysplasia and cleft lip/ 
palate (EEC) syndrome displays all three major hallmarks. p63 mutations associated with the EEC 
syndrome are point mutations in the DNA-binding domain affecting all isoforms. Some of the 
amino acid residues mutated in the EEC syndrome correspond to the tumor-associated hotspot 
mutations in p53; p63 R204 corresponds to p53 R175H, p63 R304 to p53 R273, and p63 R279 
to p53 R248 8. Another p63-associated disorder is the ankyloblepharon-ectodermal defects-cleft 
lip/palate (AEC) syndrome which differs from the EEC syndrome mainly by the severity of the skin 
phenotype, the occurrence of an eyelid fusion at birth and the absence of limb malformations. 
Mutations associated with the AEC syndrome are localized in the C-terminal SAM domain which 
is absent in the p53 protein 7-9.
The cellular mechanisms of epidermal differentiation and stratification controlled by p63 have 
mainly been studied in mouse models, including p63-deficient mice with or without rescue by 
p63 isoforms, and in mouse ES cells ’°'12. However, these studies are not able to illustrate the 
disease mechanism underlying the phenotypes caused by heterozygous p63 point mutations in 
humans4. Two knock-in models of p63 mutations have been reported so far, L514F for the AEC 
syndrome 13 and R279H for the EEC syndrome 14. The L514F mice fully recapitulate the human 
AEC syndrome with abnormalities in skin and craniofacial structures. In the R279H knock-in 
model, limb phenotypes resembling that of p63 knock-out mice have been observed, whereas 
skin phenotypes have not been reported. Furthermore, there is a clear clinical variability among 
EEC syndrome patients with p63 mutations1S, which suggests that individual genetic background 
is one of the important determinants for the phenotypes. Therefore, mouse models established 
so far are not appropriate platforms to uncover the molecular circuitry in the skin that is affected 
in the EEC syndrome and to perform drug screening.
The current therapy for disorders caused by p63 mutations is limited to cosmetic surgery. 
Opportunities for improved treatment may come from studies of the family member p53. Due to 
the important tumor suppressor function of p53 16'17, novel strategies for targeting p53 for cancer 
therapy have been intensively pursued. Several compounds have been reported to restore wild 
type function to mutant p53 and induce p53-dependent cell death 1S. Previously, we found that 
the low molecular weight compounds PRIMA-1 and APR-246/PRIMA-1MET (henceforth referred to 
as APR-246) restore conformation and tumor suppressor activity to mutant p53 ,9' 20. APR-246 
has recently been tested in a phase l/ll clinical trial in patients with hematological malignancies 
or hormone-refractory prostate cancer21. Interestingly, we found that APR-246 can restore the
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pro-apoptotic function to mutant TAp63y in tumor cells22. This suggests that APR-246-mediated 
rescue of mutants of the p53 family members involves a conserved molecular mechanism due to 
the extensive structural homology in the DNA-binding domains among these proteins. Therefore, 
APR-246 might be suitable as a lead compound to initiate development of new drugs targeting 
developmental and differentiation defects caused by p63 mutations, especially those located in 
the DNA-binding domain such as mutations involved in the EEC syndrome.
Here we established an in vitro model to study the disease mechanism of the skin phenotype 
of the EEC syndrome, namely keratinocytes obtained from EEC syndrome patients with p63 
mutations. These keratinocytes showed differentiation defects based on morphology and gene 
expression. We found that these defects were consistently rescued upon APR-246 treatment and 
this rescue coincided with enhanced p63 target gene expression.
Material and Methods 
Patiënt information
EEC patiënt 1 is a 29-year old woman who has a dry albino-like skin and white hair. She has 
dystrophic nails and absence of enamel in her teeth. She is anhydrotic and has dacrocystitis in 
her eyes that is probably caused by the nasolacrimal obstruction. She also has syndactyly in her 
hand and cleft lip and palate. She has a small dysplastic ears and hearing impairment, double 
sided hydronephrosis and narrowed urethra. She has frequent urinary tract infections. Mammary 
or nipple abnormalities have not been observed. It is reported that she carries a heterozygous 
R204W mutation in the p63 gene (van Bokhoven et al., Am J Hum Genet, 2001). EEC patiënt 2 is 
a 51-year old man, who has a very dry and scaling skin in the nose, back of the hands and back. 
He has a history of a malignant spinocellular epithelioma in his left hand that has been exposed 
to the sun because of his daily work outside. He has prosthesis, his nails are hypoplastic and 
he has no hair. He has corrected dacryostenosis and cleft lip and palate. He has syndactyly and 
ectrodactyly in his hands and feet. He also has several genito-urinary abnormalities: double pyelum 
and ureter on the right side, narrowed bladder neck, prostate hypertrophie and hypospadia. He 
has normal sweating and normal nipples. This patiënt has been reported to carry a heterozygous 
R279H mutation in the p63 gene (van Bokhoven and Brunner, Am J Hum Genet, 2002). EEC 
patiënt 3 is a 59-year old man who has a dry, but normal sweating skin. His hair is coarse and he 
carries prosthesis because of teeth problems. He has a corrected dycryostenosis on the left side 
and absence of Meibomian glands in the eye. He has ectrodactyly and syndactyly in one hand and 
foot. And he also has left sided cleft lip and palate. He suffers from hearing impairment because 
of narrowed ear canal and has a history of chronic otitis media and a cholesteatoma cyst. He also 
has several genito-urinary abnormalities: hypospadia, prostate hypotrophy, chronical interstitial 
nephritis and a broaden urethra. This patiënt has been reported to carry a heterozygous R304W 
mutation in the p63 gene (Celli et al., Cell 1999). All these three mutations are localized in the 
p63 DNA-binding domain. The AEC patiënt has been reported to carry a heterozygous T533P 
mutation in the SAM domain of p63 (McGrath et al., Human Mol Genet, 2001).
Ethical approval
All procedures for establishing and maintaining human primary keratinocytes were approved by 
the ethical committee of the Radboud University Nijmegen Medical Centre with the approval 
code CIV10-PR2004/132. Informed consent was obtained from all donors of a skin biopsy.
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Submerged human primary keratinocytes cultures
Skin biopsies were taken from the trunk of healthy volunteers or EEC syndrome patients with 
p63 R204W, R279H, R304W or T533P mutations to establish the primary keratinocyte culture. 
APR-246 was applied to keratinocytes during the proliferation stage (Supplemental Figure 7.3A), 
and differentiation was initiated by depleting growth factors. KGM consists of Keratinocyte Basal 
Medium, 0.15 mM Ca2+ (Lonza), supplemented with 0.1 mM ethanolamine (Sigma), 0.1 mM 
phosphoethanolamine (Sigma), bovine pituitary extract (0.4%) (Bio Whittaker), 10 ng/mL EGF 
(Sigma), 5 pg/mL insulin (Sigma), 0.5 pg/mL hydrocortisone (Calbiochem), 100U/ml_ penicillin 
(Gibco) and 100 pg/mL streptomycin (Gibco). For all experiments cells were grown in 6-well plates 
in KGM for 6 days and then treated with APR-246 every two days for three times (Figure S3A). 
Differentiation was induced by depletion of growth factors and cells were maintained for another 
7 days. The differentiation medium consists of KGM, 0.15 mM Ca2+ (Lonza), supplemented 
with 0.1 mM ethanolamine (Sigma), 0.1 mM phosphoethanolamine (Sigma), 100U/mL penicillin 
(Gibco) and 100 pg/mL streptomycin (Gibco). Cells were collected at differentiation day 0, 2, 4 
and 7 (Supplemental Figure 7.3A), and analyzed for gene and protein expression, using RT-qPCR, 
immunostaining, Western blotting and flow cytometry analysis.
RNA extraction and quantitative real-time (RT)-PCR
Cells were collected on day 0, and on days 2, 4 and 7 after induction of differentiation. RNA 
extraction and cDNA synthesis were carried out using the NucleoSpin RNA II kit (740955.50; 
MACHEREY-NAGEL, Düren, Germany) and iScript cDNA synthesis kit (Bio-Rad; 170-8891, CA, 
Hercules, USA). PCR primers (Supplemental Table 7.4) were designed using Primer3 (http://frodo. 
wi.mit.edu), and PCR reactions were performed in the 7500 Fast Real Time PCR System apparatus 
(Applied Biosystems) by using iQ SYBR Green Supermix (Biorad) according to the manufacturer's 
protocol. Fluman acidic ribosomal protein (hARP) and GUSB were used as a housekeeping gene 
to normalize the amount of cDNA. Differences in expression of each gene between wild type and 
mutant samples (relative expression) were calculated by the AACt method.
Western blotting
Cells were harvested, washed in phosphate-buffered saline (PBS) and lysed by 1X SDS buffer. Cell 
extracts were incubated for 5 min at 100 degrees Celcius followed by determination of protein 
concentration using the BSA assay (Pierce, CA, USA). Equal amounts of protein from each sample 
were subjected to SDS-polyacrylamide gel electrophoresis at 130V followed by electroblotting to 
nitrocellulose membranes. Membranes were blocked for 1 h with 5%  non-fat milk in PBS at room 
temperature and probed with primary antibodies. All antibodies were diluted in PBS containing 
5%  non-fat milk, and 0.05% Tween-20. Blots were visualized by ECL (Amersham Biosciences, 
Sweden). The following antibodies were used for Western blotting: rabbit polyclonal anti-Claudin
1 (717800, Invitrogen, USA), mouse monoclonal anti-p-actin (clone AC-15, Sigma, Sweden), and 
rabbit polyclonal anti-p63a (H129) (sc-8344, Santa Cruz Biotechnology, Inc).
Antibodies and immunofluorescence staining of submerged keratinocyte 
cultures
The following antibodies were used for immunofluorescence staining: goat polyclonal anti-K1 
(N-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse monoclonal anti-K10 (RKSE 
60; Progen Biotechnology, Heidelberg, Germany), mouse monoclonal anti-involucrin (19018; 
Sigma, Missouri, MO, USA), rabbit anti-human/mouse transglutaminase-1 (Santa Cruz), mouse
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monoclonal anti-keratin 14(LL002, Novocastra, Newcastle-upon-Tyne, UK), mouse monoclonal 
anti-filaggrin (BT-576, Biomedical Technologies Inc, Stoughton, MA), rabbit polyclonal anti-LCE2, 
goat anti- mouse secondary antibody conjugated with Alexa 488 (A11001; Invitrogen, California, 
CA, USA) and chicken anti-goat secondary antibody conjugated with Alexa 488 (A21467; 
Invitrogen, California, CA, USA). All cells were fixed in 4%  paraformaldehyde, washed in PBS, 
and permeabilized with 0.1% Triton X-100. Primary (1:100) and secondary antibodies (1:2000) 
were diluted in PBS containing 3%  BSA and incubated with samples at room temperature for 
60min. Between all steps, cells were washed in PBS 3 x 10min. Stained sections were mounted 
using Vectashield H-1000 containing DAPI stain (Vector Laboratories, CA, USA), and examined 
under a Zeiss Axioplan 2 fluorescence microscope equipped with an AxioCam HRm Camera (Carl 
Zeiss, Germany). The software used for analysis was Axio Vision 4.2.
Affymetrix exon expression array and data analysis
Keratinocytes established from five different normal individuals were used as Controls, and 
keratinocytes from R204W, R279H and R304W patients were cultured twice and used as replicas 
for each mutation. RNA was extracted from keratinocytes at differentiation day 2, and used 
to perform expression analyes using Human Exon 1.0 ST Array (Affymetrix) according to the 
manufacturer's protocol. Quality of total RNA was assessed using the Agilent 2100 Bioanalyzer 
(Agilent Technologies). Two microgram of total RNA was used for hybridization on the Gene 
Chip Human Exon 1.0 ST Array (Affymetrix) according to the manufacturer's protocol (Gene 
Chip Whole Transcript (WT) Sense Target Labeling Assay Manual). The Affymetrix fileswere first 
imported into Affymetrix Expression Console version 1.1 where control probes were extracted 
using the default RMA algorithm in order to perform quality analysis checks. The Area Under 
the Curve (AUC) of the Receiver Operator Characteristic was calculated using the positive and 
negative control probes. All arrays had AUC score above the empirically defined threshold of
0.85, indicating a good separation of positive Controls from negative Controls. Subsequently the 
cell-files were imported into Partek® (Partek® Genomic Suite software, version 6.4) for clustering 
analysis where only core exons were extracted and normalized using the RMA algorithm with GC 
background correction. Core transcript summaries were calculated using the mean intensities of 
the corresponding probe sets. The ANOVA model was applied on the log2 intensities and Pvalues 
for expression differences for the three pair wise comparisons of each of the individual patients 
versus the Controls were generated. In each comparison only genes with P< 0.05 were selected. 
Heatmap of differentially regulated genes was generated using MultiExperiment Viewer (MeV, 
http://www.tm4.org/mev/).
Data analysis of mRNA synthesis/accumulation
The RT-qPCR data were first plotted in a coordinate system displaying mRNA expression related 
to the corresponding mRNA levels in wile type p63 keratinocytes at day 0 versus time. Data 
points were then connected by the Cubic spline interpolation method (3rd order polynomial 
interpolation). The area under curve (AUC) was integrated, providing an estimation of the 
synthesis/accumulation of the corresponding mRNA transcript over time. The interpolation 
and integration procedures were performed by Microcal Origin 8.5 software (Origin Lab, 
Northhampton, MA, USA). Levels of the corresponding mRNA transcripts in the differentiating 
wild type p63 keratinocytes were set as 100%. Statistical analysis was performed by Statistica 10 
software (Stat Soft. Inc. OK, USA).
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Gene Ontology Annotations
Gene Ontology analysis on differentially expressed genes and genes mapped by the nearby 
binding sites was performed using DAVID Bioinformatics Resources (NIH) (http://david.abcc. 
ncifcrf.gov). Pvalue was obtained using default setting in DAVID without multiple testing.
Light microscopy
Cell morphology was examined using a Leica light microscope (DM IRB, magnification: 20X, 
Germany) and images were recorded at magnification: 3X (Canon camera, Japan).
Tet-on inducible p63 cells
The Tet-on inducible expression system established in SA0S2 cells described previously (Smeenk 
et al., 2008), was used to generate myc-tagged mouse ANp63a wild type and R304W mutant 
stable SAOS2 cell lines. After 18 hours of doxycyclin (Sigma-Aldrich) treatment at 0.2 pg/mL to 
induce expression of myc-ANp63a wild type and myc-ANp63a R304W mutant p63. APR-246 was 
supplemented in the culture medium at final concentrations of 25 pM and 50 pM for 24 hours.
Constructs and transactivation assays
The genomic region of the p63 binding site ADH7-BS1 was amplified by PCR using Gateway 
cloning primers and cloned into a modified ccdB-containing pGL3-Basic vector which contains 
a firefly luciferase reporter gene. To mutate the p63 binding motif, the most conserved cytosine 
and guanine bases were changed to adenosine. The ANp63a expression plasmid was described 
previously (Yang et al., 1998), and mutagenesis was carried out to introducé the R204W, R279H, 
R304W, L514F and T533P mutations. Transfection and luciferase assays in SAOS2 cells were 
performed as described (Rinne et al., 2008). APR-246 was added in the culture medium at final 
concentrations of 25 pM and 50 pM 24 hours after transfection. For transient EGFP reporter 
assays, SAOS2 cells were transfected with a reporter construct containing a p53/p63 consensus 
binding site in front of an EGFP reporter, along with the ANp63a mutant or wild type p63 plasmids 
described above. After 24 hours cells were treated with APR-246 at several concentrations. Cells 
were harvested by trypsinization after 20h incubation and analyzed by flow cytometry. GFP 
reporter expression was quantified as geometrie mean of the fluorescence and normalized to 
p63 expression levels as assessed by Western blotting.
Chromatin immunoprecipitation (ChIP)
SAOS2 cells carrying inducible p63 were cross-linked with 1 %  formaldehyde for 10 minutes, and 
chromatin was collected. Chromatin was sonicated using the Bioruptor sonicator (Diagenode) for 
16 minutes at high power, 30 seconds on, 30 seconds off. Antibodies H129 against p63 (Santa 
Cruz), and 8WG16 against RNAPII (Santa Cruz) were used in ChIP-qPCR experiments. For qPCR of 
ChIP analysis, one primer set was used for each tested binding region (Supplemental Table 7.4), 
and ChIP efficiency of certain binding sites was calculated using percentage of ChIPped DNA 
against input of chromatin. Occupancy used in ChIP experiment with SAOS2 cells was calculated 
using ChIP efficiency of the ADH7 BS1 region standardized by that of the chromosome 11 region.
TransAM DNA binding assays
SAOS2 cells were transfected with the ANp63 mutant or wild type p63 constructs described above. 
After 24 hours cells were treated with APR-246 at different concentrations. After 20h incubation 
cells were harvested by trypsinization and analyzed by flow cytometry. Total protein extracts were
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prepared using RIPA-like lysis buffer and then incubated in a 96-well plate coated with immobilized 
oligonucleotides that contains a p53/p63 consensus binding site (50-GGACATGCCCGGGCA 
TGTCC-30; TransAM kit, Active Motif, 41196, Rixensart, Belgium). Bound p63 protein was 
detected by a mouse monoclonal anti-p63antibody (4A4; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) followed by incubation with a secondary horseradish peroxidase-conjugated antibody. 
The signal was developed by TMB substrate followed by termination of the reaction by sulfuric 
acid and quantified by spectrophotometry (450 nm). All data were normalized to p63 expression 
levels according to Western blotting.
Flow cytometry
Keratinocytes were washed in PBS, re-suspended in 3 mL ice-cold PBS and fixed with 4 mL ice- 
cold ethanol which was added to the cells dropwise while vortexing. Cells were kept in the 
fixative for several days. Then cells were washed with ice-cold TgT buffer (0.01 %  Triton X-100; 
20mM Tris, pH 7.4; 150mM NaCL; 20% serum) and stained with anti-claudin-1 conjugated 
with Alexa Fluor 488 primary mouse monoclonal antibodies (Invitrogen, California, CA, USA), 
anti-involucrin Alexa Fluor 647 conjugated rabbit polyclonal antibodies (Bioss, Woburn, MA), 
anti-transglutaminase-1 PE-conjugated rabbit polyclonal antibodies (Antibodies online.com), 
anti-Cytokeratin -1 mouse monoclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) labelled with EasyLink APC/Cy7 conjugation kit (Abcam, Cambridge, UK), anti-Cytokeratin 
-10 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) mouse monoclonal antibodies labelled 
with Zenon Alexa Fluor 700 mouse IgG 1 labelling kit (Invitrogen, California, CA, USA). After
1 hs staining and subsequent washings samples were analysed on LSR II BD flow cytometer 
(BD Biosciences, San Jose, CA). Samples were analysed by FCS Express 3.0 software (De Novo 
Software, Los Angeles, CA).
Generation of human skin equivalents
Human skin equivalents were cultured submerged for three days in medium containing 5% 
serum, consisting of two parts Dulbecco's modified Eagle's medium and one part Ham's F12 
medium (both from Life Technologies, Inc.) supplemented with 5%  calf serum (Hyclone), 4 
mmol/L l-glutamine and 50 lU/mL penicillin or streptomycin (both from Life Technologies, Inc.), 
24.3 pg/mL adenine (Calbiochem), 1 pmol/L hydrocortisone (Merck KGaA), and 50 pg/mL 
ascorbic acid, 0.2 pmol/L insulin, 1.36 ng/mL triiodothyronine, and 10-10 mol/L cholera toxin 
(all from Sigma). Thereafter, the skin equivalents were cultured at the air-liquid interface for ten 
days in medium without serum, consisting of two parts Dulbecco's modified Eagle's medium and 
one part Ham's F12 medium (both from Life Technologies, Inc.) supplemented with 4 mmol/L 
l-glutamine and 50 lU/mL penicillin/streptomycin (both from Life Technologies, Inc.), 24.3 pg/mL 
adenine (Calbiochem), 1 mg/mL l-serine and 2 pg/mL l-carnitine (both from Sigma), bovine serum 
albumin lipid mix (25 pmol/L palmitic acid, 7 pmol/L arachidonic acid, 15 pmol/L linoleic acid, 
and 0.4 pg/mL vitamin E; all from Sigma), 1 pmol/L hydrocortisone (Merck KGaA), and 50 pg/mL 
ascorbic acid, 0.1 pmol/L insulin, 1.36 ng/mL triiodothyronine, 10-10 mol/L cholera toxin, 5 ng/mL 
keratinocyte growth factor, and 2 ng/mL epidermal growth factor (all from Sigma). APR-246 was 
added in the culture medium during the entire culture period at the air-liquid interface at a final 
concentration of 10 pM.
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Morphological and immunolabeling of human skin equivalents
Skin equivalents were fixed in buffered 4%  formalin for 4 hours, processed for routine histology, 
and embedded in paraffin. 6 pm sections were stained with hematoxylin and eosin (H&E) (Sigma) or 
processed for immunofluorescence or immunohistochemical staining. Primary antibodies against 
Keratin 10 (1:100; Sanbio, Uden, The Netherlands), Involucrin (1:50; Mon150; Sanbio), CysME 
(1:200; R&D), Keratin 14(1:50, Novocastra, Clone LL002), LCE-2 (1:1000) and Filaggrin (1:6000, 
Biomedical Technologies, clone BT-576) were fluorescently labeled with ALEXA 488 and ALEXA 
594, respectively. Primary antibody against ADH7 (Abcam) was used at a 1:200 dilution and the 
indirect immunoperoxidase technique with avidin-biotin complex enhancement (Vectastain) was 
used according to manufactures recommendations. Primary and secondary antibodies (1:200) 
were diluted in PBS containing 1 %  BSA and incubated at room temperature for 60min. Between 
all steps, cells were washed in PBS 3 x 5min. For immunofluorescence staining, nuclei were 
stained with DAPI and sections were mounted in Fluoromount-G (Southern Biotech). Hematoxylin 
(Sigma) was used to counterstain nuclei in ADH7 immunohistochemically stained sections, and 
sections were mounted with glycerol gelatin (Sigma).
Results
De-regulated transcription program in keratinocytes from EEC syndrome 
patients with p63 mutations during early epidermal differentiation
To study the epidermal defects in EEC syndrome patients with p63 mutations, we established 
keratinocyte cultures from the epidermis of patients carrying p63 mutations that are located in 
the DNA-binding domain of p63, R204W, R279H and R304W (henceforth referred to as R204W, 
R279H and R304W keratinocytes). Expression array analysis of these EEC patiënt keratinocytes 
grown in submerged 2D cultures was performed at early differentiation stage (day 2 after 
initiation of differentiation) to detect de-regulated gene expression caused by p63 mutations, as 
compared to keratinocytes from five normal Controls with wild type p63. As shown by exon array 
analysis, exons 3' to 14 but not exons 1-3 and 15 were expressed at a comparable level above the 
detection threshold, demonstrating that the ANp63a is the only isoform expressed at a high level 
in primary keratinocytes (Supplemental Figure 7.1C). The low expression, if any, of other isoforms 
was also confirmed by RNA-seq data from the ENCODE consortium 23 (Supplemental Figure 7.1A 
and B) as well as by our RNA polymerase II (RNAPII) ChIP-seq followed by qPCR analysis (ChlP- 
qPCR) at the p63 TA- and AN promoters (Supplemental Figure 7.1D). Hierarchical clustering 
analysis showed that gene expression patterns in the five normal Controls were relatively similar 
to each other, as compared to those of keratinocytes with p63 mutant R204W, R304W or R279H 
(Supplemental Figure 7.1 E). This indicates that the effect of p63 mutations on the transcription 
program is more substantial than influence of different genetic backgrounds. To identify 
aberrantly regulated genes common to the EEC syndrome and to minimize the effect of the 
genetic background of each individual patiënt, we analyzed expression profiles in keratinocytes 
from three EEC patients (Figure 7.1A). A total number of 328 genes (66 and 89 genes of which 
were up- and down-regulated more than 1,5-fold, respectively) showed significant and consistent 
changes in expression in all three mutant cells, henceforth referred to as differentially expressed 
genes (Figure 7.1A and B, Supplemental Table 7.1). The expression pattern in R279H cells was 
significantly different from those in R204W and R304W cells (Figure 7.1A, Supplemental Figure
7.1 E).
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We searched for p63 binding sites in the vicinity of the 328 differentially expressed genes 
using our previously reported p63 binding profiles 24, and identified 208 potential p63 target 
genes (60%) that have p63 binding sites (BS) within the gene itself or in a region within 25 kb 
of the gene body (Figure 7.1 B, Supplemental Table 7.2). Analysis using the DAVID bioinformatics 
tooi 25 revealed that specific Gene Ontology (GO) terms such as epithelium, tissue and organ 
development as well as neurogenesis were the most significant for the potential direct target 
genes (Supplemental Table 7.3). With independent RT-qPCR analysis in all three patients, 16 out 
of 20 genes were validated (Supplemental Table 7.1). One of such genes, Alcohol dehydrogenase 
7 (ADH7), encodes subclass IV alcohol hydrogenase 7 subunits and possibly plays a role in 
retinol oxidation in the retinoic acid biosynthesis pathway. The expression of ADH7 was almost 
completely lost in keratinocytes with mutations in the p63 DNA-binding domain associated with 
the EEC syndrome. Two p63 binding sites (BS1 and BS2) were found near the transcription start 
site of ADH7 (Figure 7.4A) 24, and p63 binding at these regions was confirmed by ChIP-qPCR 
analyses (Figure 7.1C). Transient transfection assays showed that the ADH7 BS1 was able to drive 
gene expression in a p63-dependent manner, and this activation was completely abolished by 
mutations in the p63 binding motif present in ADH7 BS1 (Figure 7.1D). Taken together, these 
data suggest that ADH7 is a p63 target gene.
Figure 7.1 Expression 
analysis of EEC patiënt 
keratinocytes carrying p63 
mutations identified ADH7 
as one of the potential p63 
target genes. (A) Overlap of 
differentially expressed genes in 
three EEC patiënt keratinocyte 
cultures compared to the 
Controls (ANOVA P<0.05). 
(B) The expression pattern of 
328 differentially regulated 
genes shown by heatmap. 
p63 binding sites represented 
in black bars are shown to the 
right of the heatmap (C) Two 
binding sites near ADH7 (BS1, 
BS2) were validated using ChlP- 
qPCR. A p63 binding site near 
IRF6 was used as the positive 
control and myoglobin exon 
2 and a no gene region on 
Chromosome 11 as negative 
Controls. (D) Transactivation 
by ANp63a through the wild 
type ADH7 BS1 and BS1 with 
mutated p63 binding motif.
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Morphological defects in keratinocytes carrying mutations in the p63 DNA- 
binding domain are rescued by APR-246
Having detected de-regulated gene expression in p63 mutant keratinocytes during early epidermal 
differentiation, we investigated whether these cells exhibit differentiation defects during epidermal 
stratification. Due to the different gene expression pattern in R279H keratinocytes compared to 
those in R204W and R304W keratinocytes (Figure 7.1A, Supplemental Figure 7.1E), we decided 
to only use R304W and R204W keratinocytes. Under proliferative conditions, the morphology 
of R204W and R304W keratinocytes in submerged 2D cultures was less homogenous and cells 
were larger and flatter (Supplemental Figure 7.2Ba and Bd) compared to the wild type p63 cells 
(Supplemental Figure 7.2Bg). On day 4 and day 7 after differentiation, wild type p63 cells started 
to form multi-layer structures (Supplemental Figure 7.2Bh and Bi), whereas many R204W and 
R304W keratinocytes were detached from the surface of the culture dish, and the remaining cells 
retained as a single-layer with largely unchanged morphology (Supplemental Figure 7.2Bb and 
Be). This difference in morphology suggested differentiation defects in the R204W and R304W 
cells.
Next, we investigated the possibility of pharmacological rescue of the observed differentiation 
defects. We hypothesized that the compound APR-246 that has been shown to target mutant 
p53 with amino acid substitutions in the DNA-binding domain and restore p53 tumor suppressor 
activity 19-20 would be a candidate compound for restoration of differentiation defects caused by 
corresponding mutations in the p63 DNA-binding domain. Thus, we treated keratinocytes carrying 
R204W and R304W mutations with 10 to 30 pM of APR-246 before initiating differentiation 
(Supplemental Figure 7.2A). On day 7 after initiation of differentiation, most of the APR-246- 
treated R204W and R304W keratinocytes remained attached to the surface of culture dish. 
Some cells changed to a flattened elongated morphology, started to establish cell-cell contacts, 
and formed multi-layer structures (Supplemental Figure 7.2Bc and Bf), resembling those seen 
in normally differentiating wild type p63 keratinocytes (Supplemental Figure 7.2Bi). Thus, these 
morphological changes in APR-246-treated keratinocytes suggest that APR-246 can at least 
partially restore differentiation in p63 mutant keratinocytes.
Restoration of expression of stratification markers in p63 mutant keratinocytes 
by APR-246
To investigate whether APR-246 can restore differentiation in p63 mutant keratinocytes at the 
molecular level, we performed immunofluorescence staining of differentiation markers in 2D 
cultures. Terminal differentiation markers such as involucrin and transglutaminase (TGM) were 
lowly expressed in mutant p63 R204W keratinocytes, and their expression was substantially 
enhanced upon APR-246 treatment, as assessed by immunofluorescence staining (Figure 7.2A) 
and Western blotting (Figure 7.2C). Suprabasal epidermal markers such as Keratin 1 (K1) and 
Keratin 10 (K10) were expressed at low levels in untreated R304W keratinocytes and also 
induced on differentiation day 7 after APR-246 treatment (Figure 7.2B). Of note, p63 expression 
in wild type keratinocytes was reduced during differentiation, which is consistent with previous 
findings 2’ 26. Treatment with APR-246 did not seem to influence p63 expression levels or to 
induce the TAp63 isoform in the mutant p63 keratinocytes (Figure 7.2C and Supplemental Figure
7.1 D). Quantitative analysis of protein expression in R304W cells by flow cytometry showed 
that expression of K1 was induced by APR-246 to an almost complete recovery as compared to 
wild type p63 cells, and that expression of K10 and TGM was also substantially rescued upon 
treatment with APR-246 (Supplemental Figure 7.3G, left panel).
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Figure 7.2 Differentiation marker expression in APR-246-treated EEC patiënt keratinocytes.
Control, R204W (A) and R304W (B) keratinocytes treated with APR-246 were stained for differentiation 
markers. R304W keratinocytes were collected on differentiation day 7. Nuclei were stained with DAPI 
in blue. (C) Protein lysates of control and R204W keratinocytes treated with APR-246 were analyzed by 
Western blotting for Involucrin, p63 and p-actin (loading control).
Restoration of differentiation marker gene expression was also confirmed at the mRNA level. 
In wild type cells, expression of all tested differentiation markers including KW  and CystatinM/E 
(CysME, an inhibitor of asparaginyl endopeptidase required for envelope maturation 27) were 
not significantly induced upon APR-246 treatment (Supplemental Figure 7.3A). In contrast, 
induction of K 70and CysME expression in R304W cells was consistent and statistically significant 
(Supplemental Figure 7.3A and C). Expression of some differentiation markers including K I0 and 
CysME was also increased in APR-246-treated R204W keratinocytes as compared to untreated 
cells, but the effect was less pronounced than in R304W cells (Supplemental Figure 7.3D). When 
the total level of detected mRNA during differentiation was compared, the expression of KI and 
KW  in APR-treated R304W cells almost reached the levels observed in the differentiating wild 
type p63 keratinocytes (Supplemental Figure 7.3G, right panel), whereas the rescue in R204 
was less substantial (Supplemental Figure 7.3G middle panel). Interestingly, the expression of 
differentiation markers was also slightly enhanced in an AEC keratinocyte cell line carrying the 
T533P mutation upon APR-246 treatment, to similar levels as in R204W cells (Supplemental 
Figure 7.3E).
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APR-246 treatment enhances transcription of p63 target genes
To understand the mechanism behind the rescue of mutant p63 by APR-246, we examined the 
effect of APR-246 on ADH7, one of the novel p63 target gene identified in our expression array 
anaiysis. ADH7 expression was undetectable at the proliferation stage and strongly induced 
when differentiation was initiated and this was almost completely lost in R204W and R304W 
keratinocytes (Figure 7.3A). Restoration of ADH7 expression was readily detected in APR-246- 
treated R304W keratinocytes, approximately 5-fold, and reached statistical significance at day
4, whereas the slight induction of ADH7 expression in APR-246-treated R204W keratinocytes 
was not statistically significant (Figure 7.3A). Rescue of expression was also observed for 
some other potential target genes identified in our expression array study, such as glutathione 
peroxidase 2 (GPX2) (Supplemental Figure 7.3B). To obtain an overview of APR-246 effects on 
gene expression, we assessed the total mRNA synthesis (or accumulation) of all the tested genes 
over time. Expression of many tested genes, including the novel target gene ADH7, GPX2 and 
differentiation markers, was partially rescued by APR-246 in a dose-dependent manner but to 
variable degrees (Supplemental Figure 7.3F, upper and middle panel). We also examined Claudin-1 
protein expression in R204W keratinocytes with or without APR-246 treatment. Claudin-1 was 
previously reported as a direct target gene of p63 and is involved in epidermal differentiation
2S. Expression of the Claudin-1 protein was enhanced in the APR-246-treated R204W cells after 
differentiation (Figure 7.3B and Supplemental Figure 7.3H). The overall rescue of all tested 
genes at the mRNA (Figure 7.3C, left panel) and the protein level (Figure 7.3C, right panel)
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Figure 7.3 Expression of p63 target genes 
upon APR-246 treatment. (A) RT-qPCR 
anaiysis of ADH7 expression at different 
stages of differentiation in R304W and 
R204W keratinocytes treated with APR-246. 
(B) APR-246-treated R204W keratinocytes 
were stained for Claudin-1 (green). Nuclei 
were stained with DAPI (blue). (C) A summary 
of induction of the mRNA (RT-qPCR, left 
panel) and proteins (flow cytometry, right 
panel) of all tested genes (GPX2, ADH7, K10, 
CysMe, IVL, and K1 for mRNA and K10, TGM, 
K1, Claudin-1, and IVL for protein) over 7-day 
differentiation is shown in the box-whisker 
plot. Expression levels of mRNA or protein in 
wild type p63 cells were set as 100%. Left 
panel, paired t-test between untreated cells 
and APR-246-treated cells shows a significant 
rescue in R304W keratinocytes (P = 0.025) 
but not in R204W keratinocytes (P = 0.22). 
Right panel, paired t-test showed significant 
rescue in R304W cells treated with 15 pM 
APR-246 compared to untreated cells (P =
0.0796, Wilcoxon matched pairs test).
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were calculated and summarized in the box-whisker plot. The gene expression in APR246-treated 
R304W keratinocytes was clearly induced, and more pronounced than in R204W cells (Figure 
7.3C). Consistent with the slightly enhanced expression of differentiation markers in AEC T533P 
keratinocytes (Supplemental Figure 7.3E), we also observed an induction of ADH7 expression in 
these cells (Supplemental Figure 7.3F, lower panel).
To further investigate the effect of APR-246 on p63 target genes, we tested transcription 
driven by either wild type or mutant p63 through ADH7 BS1 in transient transfection assays. 
Wild type p63 but not p63 mutants R204W, R279H, R304W and T533P activated transcription 
via ADH7 BS1 (Figure 7.4B, top panel). We observed a slight increase of transcription upon 
APR-246 treatment in mock or wild type p63 transfected cells. Interestingly, however, APR-246 
induced more pronounced enhancement of transcription at ADH7 BS1 in cells transfected with 
p63 mutants R204W, R279H, R304W and T533P and the enhancement of treatment with 30 
pM APR-246 was statistically significant (P= 0.03) (Figure 7.4B, lower panel). This is consistent 
with ability of APR-246 to induce expression of the EGFP reporter driven by a p53 consensus 
motif in the presence of mutant p63 (Figure 7.4E). These findings indicate that treatment of APR- 
246 has a stronger effect on p63 mutants than on wild type p63. To assess whether APR-246 
enhances DNA binding of mutant p63 to its target sequences, we performed ChIP-qPCR analysis 
in SAOS2 cells stably transfected with R304W mutant p63. In two independent SAOS2 R304W 
cell lines, we observed a moderate increase of DNA binding at both ADH7 binding sites at high 
concentrations of APR-246 (Figure 7.4C). This enhanced DNA binding induced by APR-246 was 
corroborated by the data from an in vitro DNA binding assay (TransAM) based on a synthetic p53/ 
p63 consensus sequence (Figure 7.4D).
APR-246 improves stratification in 3D human skin equivalents from p63 mutant 
keratinocytes
The partial but consistent APR-246-mediated rescue of keratinocyte differentiation in submerged 
2D culture prompted us to test the effect of APR-246 on differentiation/stratification in a 3D 
human skin model. Compared to human skin equivalents established from wild type p63 cells 
(Figure 7.5Aa and Ad), those established from R204W keratinocytes showed a thin and poorly 
stratified epidermis that lacked a granular layer and showed parakeratosis in the cornified layer 
(Figure 7.5Ab and Ae). Treatment of R204W human skin equivalents with 10 pM APR-246 at the 
air-liquid interface markedly improved epidermal morphology to a multilayered structure with 
a visible stratum spinosum. The stratum granulosum was still absent but the stratum corneum 
appeared more continuous (Figure 7.5Ac and Af).
To investigate whether differentiation was rescued in these skin equivalents, a panel of 
differentiation markers were tested by immunostaining. Expression of the epithelial marker 
Keratin 14 (K14) and proliferation marker Ki67 was not substantially affected in the basal layer 
of the R204W and R304W skin equivalents compared to that of the wild type cells, and also not 
affected by APR-246 (Supplemental Figure 7.4). Expression of both early (K10) and late (Involucrin, 
CysME, Late Cornified Envelope protein (LCE2) and Filaggrin) differentiation markers in R204W 
and R304W skin equivalents appeared irregular and discontinious as compared to wild type 
human skin equivalents. APR-246 treatment in R204W and R304W cells enhanced expression of 
these early and late differentiation markers (Figure 7.5B and Supplemental Figure 7.4). For K10, 
Involucrin and CysME, APR-246 treatment resulted in a continuous expression pattern resembling 
that of wild type epidermis, and for LCE2 and Filaggrin, the rescue was less pronounced. APR-246 
treatment did not seem to affect expression of tested markers in skin equivalents from the wild
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type keratinocytes (Supplemental Figure 7.4). Furthermore, protein expression of the novel p63 
target gene ADH7 was visible in wild type skin equivalents but almost undetectable in R204W 
skin equivalents (Figure 7.5Ag and Ah, respectively). Treatment with APR-246, however, resulted 
in enhanced ADH7 expression in R204W skin equivalents (Figure 7.5Ai).
Taken together, our results show that expression of both differentiation markers and p63 target 
genes was partially but consistently restored by APR-246 treatment.
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Figure 7.4 p63 binding sites at the promoter region of ADH7, and partial restoration of 
transactivation and DNA-binding to mutant p63 by APR-246. (A) ChIP-seq analysis in human 
primary keratinocytes (Kouwenhoven et al., PLoS Genet, 2010) was performed with two antibodies in 
three independent cell lines. A screenshot at the genomic locus of ADH7 shows two binding sites (BS1 
ad BS2) near the ADH7 promoter. The p63 binding motif in ADH7 BS1 was detected using p63scan 
(Kouwenhoven et al., PLoS Genet, 2010) and is indicated. (B) Top panel, ADH7 BS1-dependent gene 
expression was tested in a transfection assay in the presence of wild type p63 or p63 mutants. Lower 
panel, APR-246 treatment enhanced transactivation of p63 mutants in a dose-dependent manner at the 
ADH7 BS1 site. The activation by p63 without APR-246 treatment was set as 1. The enhancement on p63 
mutants was statistically significant (P= 0.03). (C) ChIP-qPCR analysis in two independent inducible p63 
R304W SAOS2 stable cell lines that are treated with 25pM and 50 pM of APR-246. Binding of R304W 
p63 to the ADH7 BS1 binding site was moderately induced by at high concentrations of APR-246. (D) In 
vitro DNA binding was assessed using an oligonudeotide with a p53/p63 consensus binding motif and a 
panel of EEC and AEC p63 mutants. (E) A panel of p63 EEC and AEC mutants were tested in a transient 
transfection assay using an EGFP reporter carrying a p53/p63 consensus binding site. Transfected cells 
were treated with increasing amounts of APR-246.
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Figure 7.5 Differentiation marker expression in APR-246-treated 3D human skin equivalents. (A)
Human skin equivalents generated from p63 wild type and R204W keratinocytes treated with APR-246 
at the air-liquid interface culture were stained with heamatoxylin/eosin (H&E) and an ADH7 antibody. (B) 
Proteins expression of K10, Involucrin and CysM/E was examined by immunofluorescence staining of skin 
equivalents generated from wild type keratinocytes and R204W and R304W keratinocytes which were 
treated with APR-246. Nuclei were stained with DAPI (blue). Bar = 50 pm.
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Discussion
Here we have established an in vitro model using primary skin keratinocytes from EEC patients 
with p63 mutations in 2D submerged cultures and in 3D human skin equivalents. Using this 
unique model, we identified distinct clusters of potential direct target genes of p63, and tested 
our hypothesis that the differentiation defects caused by p63 mutations may be rescued by the 
mutant p53-targeting compound APR-246.
The DNA binding-domains of p53 and p63 share extensive structural homology2, and amino 
acid residues in p63 that correspond to tumor-associated hotspot mutations in p53 are often 
mutated in human developmental disorders such as EEC29. Variousstrategies have been developed 
to target mutant p53 for cancer treatment. Small molecules that bind to mutant p53 and restore 
wild type function have been identified 30. In the current study, we asked whether one such 
compound, APR-246, could reactivate endogenous mutant p63 with amino acid substitutions in 
the DNA-binding domain in keratinocytes derived from patients with the EEC syndrome. Indeed, 
treatment with APR-246 resulted in significant rescue of morphology and gene expression in 
R304W and R204W keratinocytes during epidermal differentiation. We recently showed that 
APR-246 can restore DNA-binding, target gene expression and pro-apoptotic activity to mutant 
isoforms of TAp63y in human tumor cells22. As different isoforms of p63 may regulate distinct 
target genes, it can be envisaged that APR-246-mediated restoration of wild type function to 
different isoforms of mutant p63 expressed in various cell types may result in distinct biological 
consequences. Our finding that a potential novel anticancer drug against mutant p53 can be 
used to target mutations in another p53 family member in a developmental disease raises the 
interesting possibility of developing targeted therapy for phenotypically distinct diseases that are 
caused by a similar underlying molecular mechanism.
We examined expression of differentiation markers in different layers during stratification, 
including K1 and K10 as suprabasal epithelial markers, involucrin as a late-stage marker in the 
spinous layer, and TGM, CysME, LCE2 and Filaggrin as markers in the granular layer and in 
the terminally differentiated cells of the skin. The APR-246-mediated induction of expression 
of these markers in specific stratified epidermal layers in patiënt keratinocytes suggests that 
restoration of normal function to mutant p63 can rescue not only differentiation initiation but 
also differentiation at terminal stages.
We found that the p63 R304W mutant is more amenable to reactivation by APR-246 than the 
R204W mutant. This observation is in agreement with our previous study of APR-246-mediated 
rescue of pro-apoptotic activity in human tumor cell lines 22. The difference in the response to 
APR-246 might be due to the molecular nature of the two mutations. R304 in p63 corresponds 
to R273 in p53, a residue that makes direct contact with DNA. R273H mutant p53 retains wild 
type conformation to a large extent3'. R204 in p63 corresponds to p53 R175 that is important 
for the structural integrity of the DNA-binding domain. The p53 R175H mutant shows severe 
structural defects. The structural consequences of the R204W mutation in p63 are presumably 
similar to those of p53R175H mutation, and extensive unfolding may make APR-246-mediated 
rescue less efficient. However, we cannot exclude that the observed differences are due to 
inter-individual variation in the response to APR-246 that is unrelated to p63. Intriguingly, we 
also observed restoration of gene expression and DNA binding mediated by APR-246 for a p63 
mutation that is localized in the C-terminal SAM domain and associated with the AEC syndrome 
(Supplemental Figures 7.3E and G and 7.4D). This domain is not conserved in the p53 protein, 
and therefore the effect of APR-246 on this type of mutations has not been investigated so far.
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Previous studies suggest that the AEC mutations may affect the conformation of the p63 protein 
or protein-protein interactions of p63 with other co-factors to affect transactivation 32. Therefore, 
the rescue effect of APR-246 on these mutants may be due to stabilization of the overall protein 
conformation of p63 or by modulating critical protein-protein interactions.
Based on our expression analysis, we identified a cluster of potential target genes whose 
expression was de-regulated in p63 mutant keratinocytes. One of them is ADH7, a class IV alcohol 
hydrogenase that may be involved in the biosynthesis of retinoic acid that is important for cellular 
differentiation. The expression of ADH7 during early differentiation was almost completely lost in 
p63 mutant keratinocytes (Supplemental Table 7.1), indicating that p63 normally activates ADH7 
and that mutations in the p63 DNA-binding domain disrupt this regulation. Consistent with this 
notion, we found that wild type p63 normally binds to specific sites near the ADH7 promoter 
(Figure 7.1C) and activates transcription (Figure 7.1 D), whereas mutations in the DNA-binding 
domain of p63 abolished the transactivation (Figure 7.1D and 7.3C). Interestingly, another 
enzyme in the retinoic acid biosynthesis pathway, Retinal short-chain Dehydrogenase (retSDRI, 
also known as Dehydrogenase/reductase member3, DHR53) has recently been reported as a p63 
target gene and its expression was shown to be affected by EEC syndrome p63 mutations33. 
These data suggest that p63 plays a role in the retinoic acid biosynthesis pathway and that EEC 
syndrome mutations disrupt cellular differentiation mediated by retinoic acid during embryonic 
development. ADH7 and Claudin-1 are probably two among a number of p63 target genes that 
are up-regulated in APR-246-treated mutant p63 keratinocytes. Their up-regulation suggests that 
reactivation of p63-dependent transcription is the underlying mechanism of APR-246-mediated 
rescue. Thus, we demonstrate that APR-246 partially restores wild type function to endogenous 
mutant p63 in a physiological context where p63 is normally expressed at high levels and essential 
for epidermal differentiation. It will be of interest to identify other p63 target genes that are up- 
regulated upon APR-246 treatment in p63 mutant keratinocytes in a genome-wide scale.
Our findings may open new opportunities for drug screening and development of therapy for 
patients with developmental disorders associated with p63 mutations. This is relevant not only 
to EEC but also to ectodermal dysplasia, as APR-246 can target mutations associated with AEC, 
even though these mutations are not localized within the DNA-binding domain. AEC syndrome 
patients often suffer from severe skin phenotypes6. Further in vivo studies of APR-246-mediated 
rescue of mutant p63 at various embryonic stages will be of great interest for exploring such 
therapy options. Since the retinoic acid biosynthesis pathway is affected by p63 EEC syndrome 
mutations, retinoic acid and related compounds should also be further investigated for their effect 
on epithelial differentiation affected by p63 mutations. In conclusion, we have shown that the 
mutant p53-targeting compound APR-246 partially restores epidermal differentiation of primary 
adult keratinocytes derived from patients with p63 mutations, probably through restoration of 
p63 target gene expression. Our study provides a novel concept for development of treatment 
for the p63-related diseases. The notion of applying targeted therapy for phenotypically distinct 
diseases caused by similar molecular mechanisms could also be relevant to treatment of other 
diseases.
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Supplemental Figure 7.1 Exon expression array analysis of p63 in primary keratinocytes. (A)
Screenshot o f UCSC genome browser showing genomic structure of the p63 gene, TA and ANp63 
exons and p63 expression revealed by RNA-seq data in Normal Human Epithelial Keratinocytes (NHEK) 
from the ENCODE consortium (Consortium EP, et al., 2012, Nature 489:57-74). (B) Screenshot o f UCSC 
genome browser showing the C-terminal exons o f the p63 gene and expression o f p63 a , p, y, 8, and e 
isoforms revealed by RNA-seq data in Normal Human Epithelial Keratinocytes (NHEK) from the ENCODE 
consortium. (C) Exon array analysis using Affymetrix Exon Array of wild type p63, p63 R204W, R304W 
and R279H shows the expression of individual exons. Expression (log2) ratio at 6 is normally considered as 
the expression detection threshold (dotted line). The expression of p63 in patiënt keratinocytes is slightly 
higher than that in normal control cells. (D) RNAPII ChIP-seq was performed in w ild type keratinocytes 
during differentiation (left panel) and wild type and R304W keratinocytes w ith  and w ithout treatment 
o f APR-246 (right panel). Specific primers designed at the p63 TA or AN promoter were used to  detect 
whether any transcript was initiated at specific promoters. p-actin promoter was used as a positive control 
and primers designed at myoglobin exon 2 and at a no gene region on chromosome 11 were used as 
negative Controls. (E) Hierarchical clustering analysis of expression pattern of five normal control samples 
and three EEC patiënt keratinocytes.
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Supplemental Figure 7.2 
Morphology of EEC patiënt 
keratinocytes upon APR-246 
treatment. (A) Scheme for APR- 
246 treatment. Cells were plated 
and cultured in proliferation medium 
for six days, followed by APR-246 
treatment in the same medium every 
second day for three times. When 
cells were confluent, differentiation 
was initiated by using differentiation- 
promoting medium without growth 
factors. Cells were harvested at 
undifferentiation condition (day 0 
of differentiation) and on day 2, 4 
and 7 of differentiation. (B) The cell 
morphology of keratinocytes with 
or without APR-246 treatment was 
photographed on different stages 
of differentiation (day 0, 4, 7), with 
the same magnification. The border 
between the top and bottom cell 
layers is indicated by the black 
dashed line.
Supplemental Figure 7.3 Gene expression analysis in p63 mutant keratinocytes upon APR- 
246 treatment. (A) Expression of CysME and KW in keratinocytes with wild type or R304W mutant 
p63 treated with APR-246, was analyzed by quantitative RT-qPCR. The human acidic ribosomal protein 
(hARP) gene and GUSB were used as internal Controls. All analyses of gene expression were performed 
in duplicates and repeated three times. (B. C, D) Expression of CysME and KW in wild type, R304W, 
R204W and T533P keratinocytes was assessed by RT-qPCR. (E) Expression of GPX2 in wild type, R204W 
and R304W keratinocytes was analyzed by RT-qPCR. (F) Combined mRNA expression data for K1, K10, 
Involucrin, CysMe, ADH7 and GPX2 in R304W, R204W and T533P keratinocytes at all analyzed time 
points. Data are related to the expression levels of the corresponding mRNA in the normal keratinocytes 
(set to 100%) over the studied time period. (G) Left panel shows relative induction of the corresponding 
proteins detected by flow cytometry in R304W cells. Total protein induction in treated R304W cells over
7-day differentiation is depicted as a percentage of the protein level in differentiating wild type p63 
keratinocytes. Middle and right panels show induction of mRNA expression of the corresponding genes 
in R304W and R204W. Total mRNA induction over 7-day differentiation is depicted as a percentage of 
the mRNA level in differentiating wild type p63 keratinocytes. Black: untreated cells; gray: change in the 
expression as a result of the treatment with 30pM of APR-246; white: the difference between protein 
levels in treated R304W cells and that in the wild type p63 keratinocytes. (H) Western blotting analysis 
of Claudin-1 expression during differentiation in wild type cells and in R204W cells with and without 
treatment of APR-246.
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Supplemental Figure 7.4 Differentiation marker expression in APR-246-treated human 
skin equivalents. Skin equivalents generated from wild type keratinocytes and R204W and R304W 
keratinocytes which were treated w ith  APR-246 were examined by single immunofluorescence staining 
for protein expression of K14, LCE2 and Filaggrin or by double immunofluorescence staining of Filaggrin/ 
CysME, IVL/CysME and Ki67/CysME. The white dotted lines represent the dermis. Nuclei were stained 
w ith  DAPI (blue).
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Supplemental Table 7.1: Validation o f d iffe ren tia lly  regulated genes from  the  
expression array by qPCR
Array data Validation by qPCR
Genes Mutation Fold-change Fold-change SD
GPX2* R279H 28.0 37.7 6.1
R204W 25.5 35.3 8.3
R304W 12.9 8.2 0.4
ADH7* R279H 16.4 21.2 2.8
R204W 15.7 30.7 6.7
R304W 13.9 33.4 9.2
GBP6 R279H 15.1 9.6 1.8
R204W 9.1 7.6 3.0
R304W 8.2 2.6 0.6
CTSK* R279H 10.0 9.5 3.3
R204W 9.9 9.3 0.1
R304W 5.4 5.0 0.7
ETV4* R279H 3.4 2.2 1.2
R204W 3.0 2.1 0.1
R304W 3.4 2.9 0.8
FZD7 R279H 3.3 9.8 2.9
R204W 2.0 3.0 0.1
R304W 1.6 3.3 0.0
PORC R279H 2.8 3.2 0.9
R204W 2.2 2.7 0.0
R304W 2.5 5.4 0.2
CLDN7* R279H 1.9 3.3 1.0
R204W 1.7 1.2 0.0
R304W 1.7 1.7 0.0
IRF6* R279H 2.3 2.5 0.4
R204W 1.6 1.1 0.2
R304W 1.7 1.1 0.3
CTNNB R279H 1.9 1.7 0.4
R204W 1.6 2.5 0.6
R304W 1.4 3.5 0.0
7
* with a binding site nearby
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Supplemental Table 7.2: Differentially regulated genes (with or without a p63 binding site nearby) in keratinocytes established from R204W, 
R279H and R304W patients
GenelD Gene Function Fold-Change
(Control vs. 279H) (Control vs. R204W) (Control vs. R304W)
NM_001446 FABP7 fatty acid metabolic process -651,066 -76,451 -15,440
NM_000423 KRT2 epidermis development -5,721 -16,450 -36,358
NM_001001548 CD36 lipid metabolic process -7,623 -9,259 -22,309
NM_014033 METTL7A metabolic process -5,708 -5,198 -7,636
NM_005950 MT1G — -5,482 -6,426 -5,585
NM_033100 PCDH21 homophilic cell adhesion -8,398 -3,712 -4,331
NM_005951 MT1H biologicaLprocess -5,893 -5,403 -5,018
NM_018593 SLC16A10 transport -5,501 -4,457 -5,410
NM_004172 SLC1A3 neurotransmitter uptake -3,484 -3,198 -5,028
BC048796 TMEM116 | -3,874 -2,579 -4,529
NMJ45791 MGST1 glutathione metabolic process -4,575 -3,337 -2,772
NM_199328 CLDN8 calcium-independent cell-cell adhesion -2,887 -3,236 -3,413
NM_000361 THBD female pregnancy -4,131 -2,193 -3,088
NM_007069 HRASLS3 cell cycle -2,436 -3,713 -3,114
NM_002126 HLF transcription -4,387 -2,054 -2,799
NM_024302 MMP28 proteolysis -3,385 -2,917 -2,901
NR_002822 MGC72080 signal transduction -2,547 -3,504 -3,027
NM_002291 LAMB1 cell adhesion -2,835 -3,041 -2,970
NM_006486 FBLN1 . . . -3,707 -2,447 -2,547
NM_005220 DLX3 skeletal development -2,875 -2,453 -3,299
NM_013302 EEF2K translational elongation -4,562 -1,768 -2,089
NM_014897 ZNF652 transcription -3,688 -2,234 -2,436
NM_002166 ID2 negative regulation of transcription -2,894 -2,459 -2,998
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NM_012230 POMZP3 biologicaLprocess -1,975 -2,183 -3,797
AF269162 C21orf7 . . . -1,992 -2,695 -3,019
NM_001025199 CHI3L2 carbohydrate metabolic process -2,345 -2,382 -2,965
NM_000765 CYP3A7 electron transport -2,670 -1,873 -2,969
NM_014935 PLEKHA6 translation -2,186 -2,478 -2,833
NM_000313 PROS1 blood coagulation -2,898 -1,987 -2,555
AF435957 LOC130576 -2,472 -2,508 -2,356
NM_003944 SELENBP1 protein transport -2,666 -1,960 -2,696
NM_005391 PDK3 carbohydrate metabolic process -3,320 -1,710 -2,229
N M J76870 MT1M . . . -2,210 -2,274 -2,614
NM.007238 PXMP4 . . . -2,332 -2,010 -2,505
NM_005595 NFIA DNA replication -2,996 -1,899 -1,901
NM_006039 MRC2 transport -2,111 -2,594 -1,969
EF534355 ZNF57 transcription -2,981 -1,811 -1,841
NM_031455 CCDC3 . . . -2,820 -1,670 -2,077
NM_015278 SASH1 cell cycle -1,878 -2,395 -2,294
N M J 98524 TEX9 -2,473 -2,227 -1,805
BC063016 TMEM166 autophagy -2,205 -2,014 -2,241
NM.002718 PPP2R3A protein amino acid dephosphorylation -2,516 -1,786 -2,129
NM_002167 ID3 negative regulation of transcription -2,358 -1,893 -2,136
NM_015198 COBL . . . -2,041 -2,118 -2,227
N M J) 14068 PSORS1C1 . . . -2,187 -2,296 -1,828
NM_021220 OVOL2 transcription -2,458 -1,848 -1,798
NM_003429 ZNF85 transcription -2,123 -2,189 -1,792
NM_203422 LOC221091 . . . -2,771 -1,578 -1,590
N M J 77938 PH-4 protein metabolic process -1,949 -1,742 -2,237
NM_182663 RASSF5 apoptosis -1,918 -1,735 -2,034
NM_005170 ASCL2 in utero embryonic development -2,030 -1,666 -1,929
NM_020987 ANK3 protein targeting -2,309 -1,760 -1,549
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(Control vs. 279H) (Control vs. R204W) (Control vs. R304W)
. . . -2,293 -1,660 -1,649
NM_001104629 C4orf19 . . . -1,554 -2,380 -1,654
NM_000358 TGFBI cell adhesion -1,868 -1,838 -1,844
NM_152573 RASEF small GTPase mediated signal transduction -2,085 -1,835 -1,626
NMJD03708 RDH16 lipid metabolic process -1,797 -1,897 -1,833
NM_022817 PER2 transcription -2,016 -1,923 -1,578
NM_015691 WWC3 . . . -1,912 -1,805 -1,663
NM_054027 ANKH skeletal development -2,046 -1,700 -1,616
NM_005440 RND2 signal transduction -1,733 -1,616 -1,957
NM_005060 RORC transcription -1,769 -1,705 -1,807
NM_014615 KIAA0182 - -1,791 -1,659 -1,704
NM_002506 NGFB cell-cell signaling -1,630 -1,930 -1,550
NM_004502 HOXB7 regulation of transcription -1,764 -1,588 -1,700
NM_000847 GSTA3 response to stress -1,825 -1,703 -1,519
NM_001083962 TCF4 negative regulation of transcription -2,945 -1,608 -1,481
NM_006152 LRMP veside targeting -3,022 -1,376 -1,539
NM_003222 TFAP2C transcription -2,644 -1,754 -1,439
NM_015076 CDC2L6 protein amino acid phosphorylation -2,286 -1,484 -1,789
NR_002186 DKFZp586l1420 . . . -2,168 -1,332 -1,889
NM_006540 NCOA2 negative regulation of transcription -2,090 -1,734 -1,443
NM_020879 CCDC146 transcription -2,053 -1,491 -1,598
NM_020529 NFKBIA protein import into nucleus, translocation -2,159 -1,567 -1,398
NM_017460 CYP3A4 electron transport -1,762 -1,352 -1,978
NM_173554 C10orf107 . . . -1,438 -1,613 -2,032
AF086095 C3orf68 . . . -2,059 -1,373 -1,569
NM_004820 CYP7B1 electron transport -2,122 -1,570 -1,285
NM_000891 KCNJ2 ion transport -1,670 -1,498 -1,791
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NM_032427 MAML2 transcription -1,925 -1,476 -1,514
NM_152493 ZNF362 transcription -2,033 -1,354 -1,496
N M J 44628 TBC1D20 regulation of Rab GTPase activity -1,884 -1,516 -1,469
NM_004833 AIM2 immune response -1,302 -2,014 -1,547
NM_000546 TP53 response to tumor cell -1,780 -1,559 -1,493
NM_021648 TSPYL4 nucleosome assembly -1,767 -1,495 -1,530
NM_052897 MBD6 ... -1,946 -1,467 -1,376
NM_016513 ICK protein amino acid phosphorylation -2,018 -1,362 -1,383
NM_030756 TCF7L2 chromatin architecture -1,745 -1,403 -1,612
NM_025149 ACSF2 metabolic process -1,837 -1,418 -1,498
AY457143 BBS4 visual perception -1,894 -1,470 -1,374
NM_ 194278 C14orf43 transcription -2,006 -1,411 -1,319
NM_000940 PON3 response to external stimulus -1,452 -1,659 -1,615
NM_006806 BTG3 negative regulation of cell proliferation -1,629 -1,405 -1,657
NM_004067 CHN2 intracellular signaling cascade -1,833 -1,375 -1,480
N M J 78177 NMNAT3 biosynthetic process -1,446 -1,270 -1,958
BC012940 C9orf9 ... -1,655 -1,598 -1,420
NM_006813 PNRC1 transcription -1,696 -1,483 -1,486
NM_002611 PDK2 carbohydrate metabolic process -1,848 -1,448 -1,344
NM_032854 C0R06 ... -1,459 -1,632 -1,542
NM_138501 GPSN2 lipid metabolic process -1,680 -1,510 -1,412
NM_020899 ZBTB4 transcription -1,944 -1,379 -1,269
NM_002646 PIK3C2B cell communication -1,579 -1,475 -1,528
NM_001830 CLCN4 ion transport -1,431 -1,536 -1,608
NM_002775 HTRA1 regulation of cell growth -1,551 -1,434 -1,585
NM_020247 CABC1 ... -1,677 -1,434 -1,434
NM_197947 CLEC7A phagocytosis, recognition -1,468 -1,590 -1,461
NM_025231 ZSCAN16 transcription -1,552 -1,381 -1,568
NM_005585 SM AD 6 transcription -1,309 -1,435 -1,738
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(Control vs. 279H) (Control vs. R204W) (Control vs. R304W)
NM_024028 PCYOX1L . . . -1,531 -1,458 -1,482
NM_002501 NFIX DNA replication -1,797 -1,307 -1,345
NM_003722 TP63 response to tumor cell -1,682 -1,321 -1,432
NM_015905 TRIM24 transcription -1,713 -1,311 -1,369
NM_021625 TRPV4 ion transport -1,373 -1,286 -1,697
NM_032431 SYVN1 ubiquitin cycle -1,494 -1,477 -1,380
NM_144778 MBNL2 . . . -1,547 -1,497 -1,286
NM_130898 CREB3L4 regulation of transcription -1,529 -1,343 -1,418
AF461052 C16orf62 . . . -1,638 -1,334 -1,304
NM_001001396 ATP2B4 cation transport -1,543 -1,352 -1,305
NM_015113 ZZEF1 regulation of mitotis -1,562 -1,369 -1,246
NM.016143 NSFL1C . . . -1,546 -1,296 -1,314
NM_032999 GTF2I transcription -1,382 -1,372 -1,401
NM_031232 NECAB3 protein secretion -1,229 -1,501 -1,420
BX648576 LOC 100134934 . . . -1,373 -1,346 -1,410
NM_017649 CNNM2 ion transport -1,562 -1,281 -1,285
NM_015710 GLTSCR2 biologicaLprocess -1,585 -1,215 -1,326
NM_133265 AMOT actin cytoskeleton organization -1,280 -1,309 -1,508
NM_022553 VPS52 protein transport -1,351 -1,244 -1,493
NM_006312 NCOR2 regulation of transcription -1,333 -1,354 -1,393
NM_080752 ZSWIM3 . . . -1,275 -1,415 -1,389
BC071776 LOC554203 ___ -1,534 -1,260 -1,285
NM_016376 ANKFY1 . . . -1,391 -1,370 -1,250
NM_014793 LCMT2 tRNA processing -1,335 -1,342 -1,334
NM_000494 COL17A1 phosphate transport -1,478 -1,276 -1,252
NM_014516 CNOT3 regulation of transcription -1,450 -1,309 -1,242
NM_173362 RFESD electron transport -1,354 -1,426 -1,217
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NM_001105562 UBE4B apoptosis -1,391 -1,264 -1,315
NM_001040097 MOSPD3 heart development -1,223 -1,342 -1,382
NM_003170 SUPT6H chromatin remodeling -1,266 -1,398 -1,273
NM_152327 AK7 nudeobase, nucleoside, nucleotide -1,322 -1,221 -1,379
NM_003704 C4orf8 . . . -1,475 -1,219 -1,221
NM_000548 TSC2 endocytosis -1,244 -1,334 -1,324
NM_032230 C12orf26 . . . -1,367 -1,164 -1,344
BC005153 RPH3AL intracellular protein transport -1,248 -1,324 -1,285
BC070329 TRA@ cellular defense response -1,277 -1,207 -1,344
NM_145170 TTC18 . . . -1,331 -1,252 -1,234
NM_014649 SAFB2 transcription -1,247 -1,301 -1,262
NM_024741 ZNF408 transcription -1,308 -1,304 -1,197
NM_014002 IKBKE protein amino acid phosphorylation -1,195 -1,208 -1,357
NM_014859 RICH2 signal transduction -1,368 -1,231 -1,156
NM_005528 DNAJC4 protein folding -1,231 -1,239 -1,209
NM.012231 PRDM2 regulation of transcription -1,267 -1,139 -1,264
BC054869 C11orf70 . . . -1,260 -1,227 -1,171
NM_000109 DMD muscle contraction -1,188 -1,246 -1,203
NM_080861 SPSB3 intracellular signaling cascade -1,253 -1,200 -1,175
NM_020195 C14orf124 metabolic process -1,221 -1,139 -1,164
NR_002724 MBL1P1 . . . -1,077 -1,088 -1,043
NM_001039706 FU21062 . . . -1,063 -1,040 -1,085
NM.000808 GABRA3 ion transport 1,315 -3,044 -1,225
AK289489 NDUFA3 mitochondrial electron transport 1,498 -1,453 -1,452
NM_001024656 LOC554235 NADP catabolic process 1,231 -1,242 -1,225
NM_032785 AGBL4 proteolysis 1,173 -1,218 -1,172
NM_052909 PLEKHG4B regulation of Rho protein signal transduction 1,237 -1,189 -1,221
NM.004310 RHOH small GTPase mediated signal transduction 1,191 -1,151 -1,176
NM_004045 ATOX1 ion transport 1,455 -1,214 -1,324
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(Control vs. 279H) (Control vs. R204W) (Conlrol vs. R304W)
AK123417 FU41423 . . . 1,338 -1,214 -1,206
NM_174977 SEC14L4 transport 1,167 -1,115 -1,095
BC027856 FIGNL1 ATP metabolic process -1,875 1,463 1,404
NM_006936 SUM03 protein modification process -1,260 1,164 1,146
NM_017617 NOTCH1 regulation of transcription, DNA-dependent -1,413 1,280 1,241
NM_019605 SERTAD4 . . . 1,119 1,097 1,113
NM_024531 GPR172A . . . 1,255 1,162 1,113
NM_005612 REST transcription 1,162 1,231 1,179
NM_002455 MTX1 protein transport 1,302 1,128 1,146
NM_001079858 GPR64 signal transduction 1,279 1,168 1,155
BC012981 ANKS6 . . . 1,288 1,203 1,164
NM_004781 VAMP3 protein complex assembly 1,325 1,174 1,230
D87470 KIAA0280 . . . 1,223 1,250 1,269
NM_031280 MRPS15 translation 1,247 1,235 1,290
NM_020698 TMCC3 . . . 1,325 1,249 1,208
NM_003116 SPAG4 spermatogenesis 1,523 1,142 1,152
NM_002154 HSPA4 response to stress 1,232 1,447 1,139
NM_006080 SEMA3A multicellular organismal development 1,354 1,224 1,242
NM_032174 TOMM40L anion transport 1,341 1,292 1,191
DQ413176 ABLIM2 cytoskeleton organization and biogenesis 1,343 1,305 1,181
NM_032293 GARNL3 regulation signal transduction 1,358 1,214 1,320
NM_175073 APTX single strand break repair 1,367 1,259 1,271
NM_001042544 LTBP4 biologicaLprocess 1,338 1,298 1,269
NM_178508 C6orf1 . . . 1,434 1,225 1,281
NM_013337 TIMM22 protein transport 1,391 1,258 1,292
NM_017825 ADPRHL2 . . . 1,495 1,261 1,195
NM_173505 ANKRD29 | 1,516 1,218 1,244
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NM_016224 SNX9 cell communication 1,300 1,337 1,350
NM_032717 MAG1 metabolic process 1,471 1,302 1,226
NM_006875 PIM2 protein amino acid phosphorylation 1,339 1,494 1,230
NM_003149 STAC intracellular signaling cascade 1,582 1,268 1,254
NM_014698 TMEM63A ~ 1,484 1,312 1,357
NM_014705 DOCK4 ... 1,578 1,295 1,286
NM_194279 ISCA2 iron-sulfur cluster assembly 1,394 1,341 1,443
N M J 75866 UHMK1 cell cycle arrest 1,350 1,472 1,364
NM_024756 MMRN2 ... 1,431 1,242 1,552
NM_024577 SH3TC2 ... 1,562 1,358 1,313
AK129567 FU26056 ... 1,688 1,409 1,154
NMJJ32947 MST150 ... 1,791 1,207 1,300
NM_020453 ATP10D transport 1,491 1,512 1,314
NM_015660 GIMAP2 ... 1,534 1,461 1,353
NM_020429 SMURF1 protein modification process 1,628 1,421 1,299
NM_006212 PFKFB2 fructose 2,6-bisphosphate metabolic process 1,498 1,503 1,356
NM_000055 BCHE cocaine metabolic process 1,341 1,499 1,534
NM_006767 LZTR1 anatomical structure morphogenesis 1,571 1,282 1,530
NM_017547 FOXRED1 biological_process 1,550 1,438 1,420
N M J 38639 BCL2L12 apoptosis 1,547 1,403 1,465
NM_004059 CCBL1 amino acid derivative metabolic process 1,460 1,519 1,515
NM_152406 AFAP1L1 - 1,452 1,542 1,517
NM_014241 PTPLA protein amino acid dephosphorylation 1,602 1,619 1,316
NM_012318 LETM1 signal transduction 1,698 1,459 1,419
NM_015894 STMN3 intracellular signaling cascade 1,857 1,377 1,425
NM_015340 LARS2 leucyl-tRNA aminoacylation 1,314 1,682 1,687
NM_004073 PLK3 protein amino acid phosphorylation 1,983 1,276 1,442
NM_001975 EN02 glycolysis 1,773 1,481 1,462
NM_177949 ARMCX2 ... 1,474 1,557 1,693
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(Control vs. 279H) (Control vs. R204W) (Control vs. R304W)
NM_147780 CTSB proteolysis 1,916 1,327 1,519
NM_001109 ADAM8 proteolysis 1,964 1,331 1,477
NM.005429 VEGFC angiogenesis 1,912 1,420 1,458
NM_001904 CTNNB1 negative regulation of transcription 1,859 1,604 1,365
NM_003483 HMGA2 chromatin architecture 1,799 1,460 1,622
NM_178014 TUBB cell motility 1,467 1,589 1,836
NM_018023 YEATS2 regulation of transcription 1,318 1,765 1,918
NM_152312 GYLTL1B carbohydrate biosynthetic process 2,055 1,430 1,635
NM_006194 PAX9 transcription 2,300 1,397 1,487
NM_173477 USH1G sensory perception of sound 1,962 1,773 1,467
NM_172229 KREMEN2 Wnt receptor signaling pathway 2,254 1,502 1,449
NM_001259 CDK6 G1 phase of mitotic cell cycle 1,960 1,496 1,802
BC033095 HIST1H3D nudeosome assembly 1,483 1,889 1,925
NM_005017 PCYT1A phospholipid biosynthetic process 2,484 1,633 1,374
NM_016395 PTPLAD1 l-kappaB kinase / NF-kappaB cascade 2,404 1,836 1,375
NM_015589 SAMD4A positive regulation of translation 2,616 1,445 1,690
NM_001386 DPYSL2 nudeobase, nucleoside, nudeotide 2,332 2,061 1,496
NM_001141 ALOX15B electron transport 2,591 1,487 2,385
NM_032873 UBASH3B ... 3,321 1,494 2,397
NM_024864 MRM1 RNA processing 1,665 1,559 1,590
NM.002213 ITGB5 cell adhesion 1,679 1,594 1,590
NM_002345 LUM visual perception 1,774 1,545 1,593
NM_014670 BZW1 transcription 1,825 1,629 1,500
NM_001216 CA9 morphogenesis of an epithelium 2,047 1,502 1,503
NM_033631 LUZP1 electron transport 1,954 1,524 1,609
NM_020647 JPH1 muscle development 1,690 1,767 1,636
NM_021647 MFAP3L ... 1,746 1,725 1,673
Chapter 
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NM.022153 C10orf 54 — 1,598 1,941 1,614
NM_020211 RGMA neural tube dosure 2,132 1,579 1,638
NM_001307 CLDN7 calcium-independent cell-cell adhesion 1,944 1,683 1,743
NM_203296 TRIM7 . . . 1,826 1,978 1,568
NM_002350 LYN protein amino acid phosphorylation 2,307 1,561 1,583
NM_005114 HS3ST1 . . . 1,906 1,708 1,838
NM_001311 CRIP1 cell proliferation 2,024 1,819 1,694
NM_013437 LRP12 endocytosis 1,749 1,938 1,866
NM_006147 IRF6 transcription 2,324 1,604 1,674
NM_004572 PKP2 cell-cell adhesion 2,063 1,585 2,041
NM_001003828 PARVB cell adhesion 2,348 1,703 1,795
NM_000403 GALE carbohydrate metabolic process 2,045 2,088 1,736
NM_004963 GUCY2C cGMP biosynthetic process 2,100 1,908 1,862
NM_006257 PRKCQ regulation of cell growth 2,171 1,760 1,952
AK292053 PTAFR cytokine production 2,232 1,590 2,127
NM_001017402 LAMB3 cell adhesion 2,597 1,687 1,682
NM_207577 MAP6 -- 2,425 1,757 1,787
NM_007314 ABL2 protein modification process 2,922 1,531 1,560
NM_007312 HYAL1 carbohydrate metabolic process 2,339 2,226 1,505
NM_014505 KCNMB4 regulation of action potential 2,246 1,899 1,947
NM_024508 ZBED2 . . . 2,568 1,679 1,857
NM_174934 SCN4B ion transport 1,868 1,870 2,391
NM_003364 UPP1 nucleobase, nudeoside, nucleotide 2,554 1,817 1,778
NM_016445 PLEK2 translation 2,347 1,738 2,102
NM_002632 PGF angiogenesis 2,658 1,759 1,777
NM_014905 GLS glutamine catabolic process 2,537 1,737 1,925
NM_198336 INSIG1 lipid metabolic process 2,054 2,431 1,755
NM_144668 WDR66 . . . 2,264 1,894 2,085
NM_213604 ADAMTSL5 . . . 2,154 2,145 1,974
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(Control vs. 279H) (Control vs. R204VV) (Control vs. R304W)
NM_152666 PLD5 metabolic process 2,373 2,174 1,817
NM_021005 NR2F2 neuron migration 2,157 2,387 2,016
NM_004631 LRP8 proteolysis 2,291 2,078 2,234
. . . 2,64 1,522 2,500
NM_004403 DFNA5 sensory perception of sound 2,447 2,202 2,134
NM_003105 S0RL1 electron transport 2,948 1,533 2,310
NM_182767 SLC6A15 neurotransmitter transport 2,205 2,248 2,384
NM_003507 FZD7 G-protein coupled receptor protein signaling 3,293 2,008 1,582
NM_018092 NET02 . . . 1,763 2,363 3,044
NM_182948 PRKACB protein amino acid phosphorylation 2,575 2,254 2,387
NM.033518 SLC38A5 . . . 3,029 2,201 2,023
BC044246 TMEM200A 2,072 2,068 3,187
NM_022825 PORCN Wnt receptor signaling pathway 2,772 2,159 2,511
NM_145753 PHLDB2 . . . 2,833 1,930 2,837
NM_001033045 GPR155 intracellular signaling cascade 2,601 2,945 2,451
NM_080927 DCBLD2 cell adhesion 2,854 2,550 2,621
NM.005763 AASS electron transport 2,302 2,900 2,934
NM_003786 ABCC3 transport 3,004 2,324 2,826
NM_001040716 PC gluconeogenesis 2,846 2,931 2,390
NM_001920 DCN organ morphogenesis 2,658 3,091 2,452
NM_153687 IKIP induction of apoptosis 2,538 2,862 2,836
NM_020039 ACCN2 ion transport 2,807 2,739 2,705
NM_002279 KRT33B . . . 3,280 2,641 2,860
NM_000620 N0S1 electron transport 2,988 3,098 2,813
NM_175075 C8orf42 1,910 3,219 3,886
NM_058237 KIAA1622 | 2,853 2,710 3,549
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NM_058172 ANTXR2 — 2,961 3,316 2,914
AK292352 ODC1 kidney development 4,418 2,259 2,665
NM_016575 NT5DC3 . . . 3,468 2,517 3,541
NM_001986 ETV4 transcription 3,354 3,028 3,438
NM_005447 PAMCI protein targeting 4,237 2,769 3,026
NM_002659 PLAUR cell motility 5,675 2,123 2,967
NM_004473 FOXE1 negative regulation of transcription 4,743 2,972 3,218
NM_004633 IL1R2 immune response 4,700 2,693 3,711
NM_000576 IL1B angiogenesis 4,166 3,957 3,744
NM_004744 LRAT vitamin A metabolic process 6,374 2,828 2,736
NM_003914 CCNA1 cyclin-dependent protein kinase activity 4,802 3,624 3,519
NM_001248 ENTPD3 nucleoside diphosphate catabolic process 4,490 3,535 4,469
NM_014059 C13orf15 cyclin-dependent protein kinase activity 4,627 4,224 4,094
NM_016321 RHC6 cellular ion homeostasis 5,145 3,613 4,209
NM_003866 INPP4B signal transduction 6,573 3,074 3,533
NM_030666 SERPINB1 . . . 4,985 4,590 3,814
ENST00000278919 FEZ1 cell adhesion 5,498 4,127 4,891
NM_173080 SPRR4 keratinization 8,008 2,425 5,059
NM_019618 IL1F9 immune response 9,540 3,459 6,443
NM_004867 ITM2A - 7,192 7,328 6,522
NM_000396 CTSK proteolysis 9,983 9,905 5,428
NM_018159 NUDT11 . . . 7,674 10,582 10,739
NM_198460 GBP6 immune response 15,124 9,069 8,205
NM_000673 ADH7 ethanol oxidation 16,408 15,660 13,872
NM_002083 GPX2 response to oxidative stress 27,970 25,535 12,864
NM_002277 KRT31 epidermis development 26,436 32,941 29,003
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Supplemental Table 7.3: Gene Ontology analysis of differentially regulated genes
Differentially expressed genes (328) | Differentially expressed genes with BS (208)
GO term P value GO term P value
epithelium development 1.12E-4 neurogenesis 8.17E-4
neurogenesis 4.54E-4 epithelium development 8,25E-4
tissue development 7.38E-4 regulation of cell cycle 9.65E-4
organ development 8.96E-4 cell differentiation 0,001
response to  chemical stimulus 0,001 tissue development 0,002
regulation of epithelial cell differentiation 0,001 cellular developmental process 0,003
regulation of cell cycle 0,001 system development 0,003
system development 0,001 generation of neurons 0,003
morphogenesis o f an epithelium 0,001 response to  heat 0,003
multicellular organismal development 0,002 nervous system development 0,003
ectoderm development 0,002 epithelial cell differentiation 0,004
nervous system development 0,002 negative regulation of cell communication 0,006
response to  heat 0,002 ectoderm development 0,006
generation of neurons 0,003 keratinocyte proliferation 0,006
tissue morphogenesis 0,003 negative regulation of cellular process 0,006
Consistently up-regulated genes (66) Consistently up-regulated genes with BS (47)
GO term P value GO term P value
cell differentiation 0,010 neurogenesis 0,003
neurogenesis 0,010 nervous system development 0,004
cellular developmental process 0,014 regulation o f cell cycle 0,008
nervous system development 0,018 generation o f neurons 0,010
regulation of cell cycle 0,019 cell differentiation 0,013
system development 0,022 cellular developmental process 0,017
multicellular organismal development 0,023 system development 0,017
response to  wounding 0,024 neuron differentiation 0,020
response to  lipopolysaccharide 0,024 multicellular organismal process 0,029
generation o f neurons 0,029 anatomical structure development 0,030
response to  molecule o f bacterial origin 0,029 multicellular organismal development 0,030
blood coagulation 0,040 response to  wounding 0,037
coagulation 0,040 neuron development 0,047
anatomical structure development 0,040 regulation o f transcription, DNA-dependent 0,056
nitric oxide mediated signal transduction 0,043 developmental process 0,058
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Supplemental Table 7.3 (continued)
Consistently down-regulated genes (89) Consistently down-regulated genes with BS (56)
GO term P value GO term P value
organ development 1.70E-04 tissue development 4.68E-04
tissue development 1.77E-04 response to  heat 5.27E-04
epithelium development 5.57E-04 response to  temperature stimulus 0,002
response to  heat 0,002 organ development 0,002
system development 0,003 epithelium development 0,004
anatomical structure development 0,003 amine transport 0,004
multicellular organismal development 0,006 epithelial cell differentiation 0,007
response to  temperature stimulus 0,006 anatomical structure development 0,007
developmental process 0,009 response to  chemical stimulus 0,008
epidermis development 0,010 system development 0,010
ectoderm development 0,013 response to  sterol depletion 0,011
amine transport 0,016 epidermis development 0,015
anatomical structure morphogenesis 0,018 w ound healing 0,017
response to  sterol depletion 0,018 ectoderm development 0,019
response to  hypoxia 0,023 regulation o f biological quality 0,020
Supplemental Table 7.4: Primers used in quantita tive  RT-PCR analysis
Gene Sequence Gene Sequence
GXP2_F1 gcaaccaatttggacatcag GUSB_F agagtggtgctgaggattgg
GXP2_R1 ccaggacggacatacttgag GUSB_R ccctcatgctctagcgtgtc
GXP2_F2 ttcaggagacactgctggac KRT1_F gatgaaatcaacaagcggacaa
GXP2_R2 gaaaaggaaacaggcagagg KRT1_R tggtagagtgctgtaaggaaatcaatt
ADH7_F1 gagcagaagcaacccttctc KRT10_F tggttcaatgaaaagagcaagga
ADH7_R1 agattcctgtggccaaaatc KRT10_R gggattgtttcaaggccagtt
ADH7_F2 agatggcaacctttgcattag cystatin M/E_F tccgagacacgcacatcatc
ADH7_R2 tgccatcagccagtactcc cystatin M/E_R ccatctccatcgtcaggaagtac
ADH7_F3 tgctcaattcaggacaaagc Invol ucrin_F acttatttcgggtccgctaggt
ADH7_R3 ctcctgccactttggatctc lnvolucrin_R gagacatgtagagggacagagtcaag
hARP_F caccattgaaatcctgagtgatgt P63_TA_specific_F ttctggaacagcctatatgttcagtt
hARP_R tgacaagcccaaaggcgaag P63_TA_specific_R tcttctgatggttcatccacaaa
F = Forward primer 
R= Reverse primer
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will attract more immune cells to the skin which again will produce pro-inflammatory cytokines 
thereby completing the vicious circle of chronic inflammation. To study this process in vitro, we 
introduced activated CD4+ T cells into our normal skin equivalents and we found these T-cells 
to migrate into the dermis and towards the epidermis. The pro-inflammatory cytokines which 
they produced (e.g. TNF-cc, IFN-y, IL-22 and IL-17), induced the expression of many markers of 
disease in keratinocytes, predominantly associated with psoriasis (e.g. hBD-2, SKALP, keratin 16 
and S100A7). The expression of chemokines like CXCL10 and CCL2 appeared to be the initial 
response of the keratinocytes to the T-cells, thereby attracting more T-cells into the dermis to 
finally elicit a disease phenotype in the epidermis. Treatment of our model w ith anti-inflammatory 
drugs targeting either the keratinocytes (all-trans retinoic acid) or the T-cells (Cyclosporin A) 
reduced the inflammatory phenotype indicating the potential o f this model for drug screening 
purposes in a pre-clinical setting.
Treatment fo r inflammatory skin diseases like psoriasis and atopic dermatitis is aimed to reduce the 
inflammation. Often, topically applied corticosteroids, UVtherapy, orsystemic immunosuppressive 
drugs like cyclosporine or the more advanced 'biologicals' are used. However, one of the oldest 
known dermatological therapies is the topical application of coal tar. Although proven effective 
and safe, the use of coal tar in dermatological practice is declining due to safety concerns 
(polycyclic hydrocarbons), cosmetic reasons (smell, color) and the - until recently - unknown 
mechanism of action. Chapter 6 describes the study on the molecular mechanism of coal tar for 
atopic dermatitis. Atopic dermatitis is a Th2-mediated inflammatory skin disease probably caused 
by abnormal exposure to  external triggers (e.g. allergens) due to an impaired skin barrier function, 
as exemplified by loss-of-function mutations in the filaggrin (FLG) gene which are a major risk 
factor for atopic derm atitis4. We found coal tar to activate the aryl hydrocarbon receptor (AhR), 
a transcription factor known to mediate the effects of xenobiotics, including the well known 
environmental toxin, dioxin. Coal tar-dependent AhR activation leads to restored expression of 
filaggrin and other epidermal barrier proteins, and interferes w ith Th2-cytokine signaling and 
downstream pathological processes. These findings rehabilitate coal tar as a rational therapy 
and highlight the AhR as a viable drug target, potentially leading to mechanism-based drugs for 
inflammatory skin diseases.
The last part of this thesis involves a multidisciplinary research project to  study the effects of 
mutations in the p63 gene on epidermal development and the potential use of a small molecule 
to restore the function of mutated p63. Chapter 7 presents expression data of monolayer- 
cultured EEC-patient derived keratinocytes which indicate a deregulated transcription program 
during early epidermal differentiation. Within these differentially expressed genes we searched 
for new potential p63 target genes and found, amongst others, the expression of ADH7 
completely lost upon p63 mutation. ADH7 is involved in the retinoic acid biosynthesis pathway 
known to be important for epidermal differentiation 5. In line w ith this finding, expression 
of terminal differentiation proteins was reduced both in EEC-keratinocyte monolayers and in 
human skin equivalents generated from EEC keratinocytes. The latter also showed a poorly 
stratified epidermis w ith only few  cell layers. Treatment w ith the small molecule, APR-246, 
partially restored p63 target gene expression, keratinocyte terminal differentiation, and improved 
epidermal morphology in EEC skin equivalents. These findings may provide new opportunities for 
drug screening and therapeutic strategies to alleviate symptoms in patients w ith developmental 
disorders associated w ith p63 mutations.
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Future perspectives
Human skin equivalents in basic Science and pharmacoiogy
The studies described in this thesis are performed on skin equivalents generated from adult 
keratinocytes. However, limited availability of patient-derived keratinocytes is a major drawback 
fo r generating skin disease models and also in regenerative medicine. Using keratinocytes 
differentiated from embryonic stem (ES) cells or induced pluripotent stem cells (iPSC) might be 
a solution. Protocols fo r generating keratinocytes from both cell types are available and skin 
equivalents generated from human ES-derived keratinocytes 6, mouse or human iPSC-derived 
keratinocytes7' 8 show a stratified epithelium with normal expression of differentiation markers. 
Generation of iPSC from patients with genetic mutations, e.g epidermolysis bullosa 8 or EEC 
syndrome 9, has been described. This may provide a source of cells for regenerative therapy 
or development of disease models to  study newly developed therapeutics. The use of iPSCs 
circumvents concerns about the ethics of using ES cells and w ith the generation of patient- 
derived iPSCs from accessible organs like the skin, the effect of specific mutations on cellular 
development and function of difficult-to-biopsy organs like the cornea 9, hea rt10 or brain 11 can 
now be studied. In addition, iPSCs and ES cells are amenable for the correction of gene mutations. 
Patient-derived iPSCs may therefore be an ideal source for treatment of genetic disorders with 
autologous cells in the clinic. However, in case of allogenic iPSC or ES cells, the immunogenicity 
of ES or iPSC-derived engineered tissues should be considered, as rejection may occur. Recently, 
no differences were found in the rate of transplantation success when skin and bone marrow 
cells derived from iPSCs were compared w ith ES-cell-derived tissues in mice models. Immune 
responses to the transplanted tissues were virtually absent suggesting limited immunogenicity 
of transplanted cells differentiated from iPSCs and ES cells 12. Although pre-clinical studies seem 
promising and the field of stem cell research is developing at a high pace, it remains to  be seen 
whether iPSC-derived cells and tissues will reach routine clinical practice within the next decade.
Skin disease models should faithfully mimic disease characteristics to be used as a preclinical 
screening tooi in pharmacoiogy. As presented in this thesis, we have developed in vitro 3D skin 
models for wound healing (Chapter 4) and inflammatory skin diseases (Chapters 5 and 6). Both 
models show great potential, however, from a (patho-) physiological point of view, one critical 
mediator is missing. The presence of microbes in both wound healing and skin inflammation 
is a major trigger fo r keratinocyte activation and affects keratinocyte function. In vitro skin 
models colonized w ith bacterial strains have been described ,3' 14. For wound healing, the link 
w ith microbial colonization is obvious and bacterial colonization of our wound healing model 
would be instrumental to  study the effect of specific bacteria and antimicrobial molecules on the 
wound healing process in vitro. In chronic inflammatory skin diseases like psoriasis and atopic 
dermatitis the interaction between a genetic predisposition and the (micro) environment has a 
dominant role in the disease etiology. This is particularly evident for atopic dermatitis where loss- 
of-function mutations lead to a deficiency of the major barrier protein, filaggrin. The resulting 
impaired barrier function leads to an increased exposure to antigens/allergens which trigger 
an inflammatory response which further downregulates the production of skin barrier proteins 
leading to a vicious circle of inflammation. For psoriasis, such mechanism was also proposed by 
our group since a deletion of the LCE3B/C genes is a risk factor for psoriasis and these genes 
were shown to be upregulated during the skin barrier repair process 15. The absence o f these
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genes might therefore cause an insufficiënt barrier repair after skin injury leading to increased 
microbial exposure and sustained keratinocyte activation resulting in a chronic immune response. 
In both the psoriasis (Chapter 5) and atopic dermatitis model (Chapter 6) the main disease 
characteristic, epidermal hyperproliferation, is lacking. The trigger causing this feature has yet 
to be identified, and although immune cell-derived mediators like IL-22 have been suggested 16, 
the microbial community may also regulate this process, as it has been shown that commensal 
bacteria regulate keratinocyte response to pathogens by the production of antimicrobial peptides
17, and these peptides may have mitogenic properties in vitro 18'19. Little is known about this 
mechanism and introducing bacterial strains to our in vitro human skin equivalents would serve 
as a good model system to evaluate the effect of potential pathogens, or the imbalance between 
commensal bacteria and pathogens, on keratinocyte behavior.
We used our in vitro atopic dermatitis model to successfully unravel the molecular mechanism of 
coal tar, thereby providing new clues to develop mechanism-based drugs for inflammatory skin 
diseases characterized by disturbed epidermal differentiation. In vitro skin disease models are 
therefore highly suitable fo r drug target discovery. In case of classical therapies, the molecular 
mechanism of action can be studied, as we did for coal tar. Another effective, yet often forgotten, 
dermatological therapy is topical application of dithranol, or anthralin. This synthetic anthracene 
derivative has been shown to accumulate in keratinocyte mitochondria thereby inducing 
keratinocyte apoptosis and reducing epidermal hyperproliferation. However, since anthracene is 
a known ligand fo r the AhR, epidermal barrier protein expression as well as suppression of the 
immune system via AhR activation may also mediate its therapeutic effect. Both hypotheses can 
be studied in our disease models, either by the addition of disease-related cytokines (Chapter 6) 
or immune cells (Chapter 5).
To elucidate gene function or to unravel pathophysiological pathways, many modifications to 
the conventional 3D skin models have been described in this thesis. Addition of disease-specific 
cells or cytokines or gene transduction strategies have opened new avenues to -at least partially- 
omit the use of in vivo disease models. These studies will provide a platform for many scientists 
to investigate skin diseases using human cells organized in a 3D structure closely resembling 
disease characteristics. Although being time consuming to produce, and not amenable to  high 
throughput, in vitro skin disease models are a powerful tooi to move the field of keratinocyte 
biology forward and will aid in the identification of novel pathways for therapeutic strategies.
Aryl hydrocarbon receptor signaling in skin  -  'Right on TAR-get'
Cosmetic issues
The in vitro skin disease models developed by our lab have allowed us to reveal the molecular 
mechanism of coal tar therapy fo r atopic dermatitis (Chapter 6). Although providing a rationale 
for this therapy, which has been proven safe and non-carcinogenic 20, major cosmetic issues 
remain. Coal tar ointment is a dark brown product and the intense tar odor is experienced by 
many patients as unpleasant. Now that we know the effects of coal tar at the molecular and 
functional level, we aim to identify which (combination) of the myriad of compounds in coal 
tar mediates its therapeutic effects. In a pilot study we have isolated a fraction with favorable 
properties (colorless, less smell) that retained the desired in vitro biological effect of inducing the 
expression of epidermal differentiation proteins (Figure 8.1). The expression of the AhR target
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gene, CYP1A1 is often considered related to potential toxicity since this enzyme is involved in 
the rmetabolism of xenobiotics which may result in the production of harmful metabolites21. The 
coal tarfractions induced less CYP1A1 expression whilst still inducing the desired FLG expression.
350
CypiAl FLG HRNR
Figure 8.1 Biological activity of coal tar factions. Monolayer cultured keratinocytes were 
stimulated with culture medium (control), coal tar, partially purified coal tar (fraction 1 and 2). 
CYP1A1, filaggrin {FLG) and hornerin (HRNR) mRNA expression was measured using qPCR.
These encouraging data will be the starting point to answer the question: can we isolate active 
fractions that have biological activity but lack the obvious cosmetic drawbacks and safety 
concerns. As coal tar and extracts thereof are already approved and on the market, we may 
potentially generate a novel therapeutic preparation that could swiftly find its way to the clinic. 
Fractionation of coal tar will generate many samples to be tested for their biological activity. We 
therefore started w ith the development of a high-throughput assay in which a large number 
of samples can be tested. Since coal tar exerts its therapeutic effect by induction of epidermal 
barrier proteins, such as filaggrin, we are developing a cell-based ELISA that allows screening 
of a large numbers of samples, or combinations thereof, for their potential to induce filaggrin 
protein expression in cultured human keratinocytes. This screening method will be first of many 
in vitro experiments (as described in Chapters 1, 5 and 6) which will hopefully lead to candidate 
fractions w ith favourable in vitro biological properties (indicative for therapeutic success in 
patients w ith AD), acceptable cosmetic properties, and an improved safety profile which can be 
tested in human volunteers.
The AhR interactome
We found the induction of epidermal barrier genes to be highly dependent on AhR activation, 
as AHR knockdown inhibited the coal tar-mediated induction of epidermal gene expression 
(Chapter 6, Figure 1H-I). However, it is known that the AhR interacts w ith other transcription 
factors such as ARNT, Nrf2 and NFkB. In addition, activation of the EGFR pathway is known to 
abolish ARNT-mediated effects on epidermal differentiation 22. Since we have shown coal tar- 
mediated induction of epidermal differentiation in our skin equivalent models, which are cultured 
in the presence of EGF, it is unlikely that the EGFR pathway affects the coal tar-mediated AhR 
signaling. ARNT is the nuclear partner of the AhR and the AhR/ARNT complex is responsible 
fo r recognition and binding to xenobiotic response elements (XREs) in the genome. When such
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XREs are located in promoter regions of certain genes, binding of the AhR/ARNT complex can 
regulate gene expression 21. There are several XREs found in the promoter region of epidermal 
differentiation genes such as FLG, HRNR and some LCEs23. This is a strong indication that the 
coal tar-induced skin barrier gene expression is regulated via the AhR/ARNT complex. However, 
performing ARNT knockdown in keratinocytes to verify if coal tar exerts its effects via AhR/ 
ARNT dimerization and XRE recognition is crucial to  provide evidence for this literature-based 
hypothesis. This will be part of future research. W ith regard to Nrf2, we have shown that coal 
tar activates Nrf2 since nuclear translocation of Nrf2 occurred and target gene expression was 
induced upon coal tar stimulation of keratinocytes (Chapter 6, Figure 5B-D). Nrf2 is known to be 
involved in skin barrier development24 and knockdown experiments will be instrumental to study 
the effect of Nrf2 activation on the observed coal tar effects. To identify new AhR interaction 
partners in an unbiased approach, chromatin immunoprecipitation sequencing (CHiP-seq) may 
yield new insights in the intercellular signaling cascade in keratinocytes upon coal tar activation. 
The comparison between coal tar-treated and dioxin-treated keratinocytes in this experimental 
setup may yield a differential molecular signature, thereby explaining how the distinct effects of 
dioxin (toxic) versus coal tar (desired, therapeutic) are regulated by the same signaling pathway. 
This may also rehabilitate the AhR as a bona fide pharmacological target.
Receptor-ligand interaction
Until now, we used indirect studies to prove the ligand-receptor interaction between coal tar 
and the AhR. We have yet to investigate the biochemical properties of such interactions and 
need more detailed insights in the receptor pharmacology and binding properties of coal tar to 
the AhR. In collaboration w ith the laboratory of Prof. Gary Perdew (PennState University) and as 
part of a short term fellowship, I will investigate the ability of coal tar and its fractions to directly 
bind the AhR using electrophoretic mobility shift assays and reporter cell lines developed by the 
Perdew lab 25’ 26. From a pharmacological point of view it is important to know the potency of 
potential therapeutics. Therefore, binding affinity analysis27' 28 of coal tar and its fractions to the 
AhR will be performed prior to  clinical studies.
A t a certain point, in vivo studies will be needed to test the biological and toxicological effect 
of topically applied coal tar fractions. The mouse tail has a parakeratotic epidermis comparable to 
disturbed differentiation in human skin. Topical treatment may cause the mouse tail skin change 
from parakeratotic ("psoriatic" skin) to orthokeratotic (normally differentiated skin). This has 
been used as a read-out to  screen for topical drugs that improve epidermal differentiation 29_31. 
Using this model, the necessity of AhR signaling for the coal tar-mediated therapeutic effects can 
be studied in AhrAand wild type mice. The hairless SKH1 mice, an immunocompetent outbred 
strain is widely used in dermatological research due to the absence of h a ir32. To study the role 
of the AhR in the response to coal tar in vivo, it is important to realize that in mice there are 
different allelic forms of the AhR: Ah6 and Ahd, that express a high or low ligand affinity form 
of the AhR, respectively. Previous work by the Perdew lab indicated that SKH1 mice express the 
A /idform (low affinity) of the AhR 33. Therefore, to perform AhR ligand treatment experiments it 
is necessary to backcross the Ahballele (high affinity) onto the SKH1 background. This has been 
recently accomplished by Perdew and colleagues and the induction of AhR transcriptional activity 
by the high affinity endogenous ligand, FICZ, has been shown by induction of the AhR target 
gene Cyp1a1 (Figure 8.2). Thus, a mouse model has been developed that is responsive to AhR 
ligand exposure and will enable studies to investigate the role of the AhR in skin biology and 
pharmacology.
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■  SKH1 - A h b 
□  SKH1 WT (Ah") Figure 8.2 Response of Ahb-SKH1 mice 
to AhR ligand treatment. Stimulation of 
SKH1 transgenic mice expressing the high 
affinity AhR (Ah“) with the high affinity ligand
6-formylindolo[3,2-b]carbazole (FICZ) results 
in induced Cyp la 1 expression, while wildtype 
(WT) mice expressing the low affinity (Ah*) 
receptor show no Cyp1a1 response. Figure 
adapted by the courtesy of Prof. Perdew.
Safetv concerns
The observation that metabolites of coal tar are present in the urine of patients receiving topical 
coal tar treatment or consumers that used tar-containing shampoo, indicates systemic entrance 
o f coal tar components via penetration through the skin 34_36. In view of the health hazards 
associated w ith exposure to PAH, the use of coal tar in medicines and consumer products has 
declined over the years. The preparation of coal tar cream by pharmacists is now subject to 
strict regulations in The Netherlands, and is only available via a few  specialized companies and 
pharmacists. Indeed individual compounds present in coal tar were proven to be mutagenic in 
the Ames test and carcinogenic in experimental animals, and DNA adducts are found in coal tar- 
treated skin and white blood cel Is 35-37. However, the medical use of coal tar in dermatological 
practice was shown to be non-carcinogenic in humans, as a large epidemiological study revealed 
no increased risk of any type of cancer in patients receiving coal tar therapy w ith a follow-up time 
of 21 years20. Nevertheless, the acceptance of medicinal coal tar would be greatly enhanced if 
the levels of potentially harmful substances could be reduced.
Immune regulation bv AhR sianalina
The AhR has a dominant role in the regulation of Treg, Th17 and Th22 cell development, and is 
therefore an interesting target fo r immunosuppressive therapy. Activation of AhR by TCDD leads 
to induced Treg and repressed Th 17 development, while AhR activation by a different ligand 
resulted in the opposite e ffe c t3S. This induction of Treg cells alleviates experimentally-induced 
colitis 39 potentially by epigenetic regulation of FOXP3 and IL17 expression by altered DNA 
methylation status after TCDD exposure 40. Also in early stages of CD4+ T-cell regulation, AhR 
downregulates the control o f IL-17 and RORC expression 41. Most work on immune regulation 
has been performed using TCDD as model ligand. The known ligand-dependent effects of AhR 
activation makes it important to test other endogenous ligands fo r the potential effects, as these 
might be more physiologically and therapeutically relevant. Kynurenine, the first breakdown 
product in the IDO-dependenttryptophan degradation pathway, activates the AhR leading to the 
AhR-dependent generation o f Treg cells. Interestingly, kynureninase, an enzyme that catalyzes the 
conversion of kynurenine into anthracilic acid, is one of the most highly differentially upregulated 
genes in psoriasis 42. A decreased methylation status of the kynureninase gene was recently 
demonstrated in psoriatic skin which may have caused the elevated expression levels 43. One 
could speculate that the high levels of kynureninase deplete the kynurenine levels in skin vital for 
AhR-dependent Treg development, resulting in a shift towards a more pro-inflammatory milieu 
in psoriasis. This warrants further investigation as restored AhR activation (e.g. by coal tar) in 
psoriatic skin may provide a new therapeutic option to correct the distorted immune balance in
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psoriasis and other (auto)-immune diseases.
Coal tar treatment has long been used to treat psoriasis patients, often in combination with 
UV radiation and also known as the Goeckerman therapy. The exact mechanism of action in 
psoriasis is still unknown and nowadays coal tar is only used in difficult-to-treat psoriasis patients 
or patients w ith scalp psoriasis. The use of biologicals to treat psoriasis is ever rising and although 
being effective, safe and patient-friendly, the high costs of these drugs cause a significant burden 
on the public healthcare budget. For this reason, a demand for cheap yet effective therapies, 
such as coal tar therapy, will remain. The emerging data on the role of the AhR in the balance 
of the immune system, as indicated above, may provide a rationale for its mechanism of action 
in psoriasis. Recently, is was found that phenanthrene (present in coal tar) induces FOXP3 
methylation and conversion of Treg into Th2 cells, while dioxin epigenetically modifies IL17A 
and mediated the conversion of Treg to Th17 cells44 This would suggest that AhR activation 
by a compound present in coal tar can restore the balance of the Th 1 /Th 17 dominant milieu 
by inducing Th2 cells. This study also explains why dioxin (or TCDD) exposure leads to severe 
inflammation (by the conversion of Treg to Th 17 cells) and coal tar therapy has anti-inflammatory 
effects (induction of Treg). The study on the working mechanism of coal tar in psoriasis will be 
part of future research by our group.
Besides its role in T-cell development, the AhR appears to be involved in dendritic cell 
maturation and function. AhR activation contributes to the maintenance of the immature state 
o f human dendritic cells 45 and alters dendritic cell differentiation and innate functions 46. In 
food allergie responses, like peanut allergy, AhR activation suppressed the immune response 
initiation by affecting dendritic cells and their interaction with effector T cells47. Therefore, the 
immunosuppressive action of coal tar might be AhR-mediated via impaired dendritic cell function 
and this is subject of future research. The suppressive effect on dendritic cell function was also 
observed by Malassezia yeast metabolites. Malassezia metaboliteswereshown to be highly potent 
AhR activators48 and AhR activation by these metabolites in monocyte derived- dendritic cells, 
resulted in limited maturation, reduced secretion of the inflammatory cytokines and a decreased 
ability to induce alloreactive T-lymphocyte proliferation 49. This mechanism may be important 
fo r the pathophysiology of skin diseases associated w ith pathogenic Malassezia strains such as 
seborrheic dermatitis 50.
Seborrheic dermatitis is an inflammatory skin disease usually characterized by excessive 
scaling of the scalp, like dandruff. Suppression of dendritic cell function may favor survival of 
the yeast on inflamed skin. The effect of the yeast or its metabolites on the skin is still unknown, 
and therefore the causal relation between Malassezia yeasts and seborrheic dermatitis has 
yet to be identified. Based on the accelerated epidermal differentiation observed by coal-tar 
mediated AhR-activation in keratinocytes (Chapter 7), we hypothesized that the dandruff-like 
symptoms in seborrheic dermatitis are caused by Malassezia-induced AhR-activation leading to 
increased epidermal differentiation and desquamation. In a collaboration w ith the group of Prof. 
Magiatis (University of Athens, Greece) we are now studying the effect of the Malassezia-derived 
metabolites on keratinocyte behavior using the in vitro skin models described in this thesis. The 
recently published human mycobiome data supports our hypothesis that the AhR mediates the 
interaction between the microenvironment and the skin thereby regulating skin homeostasis, as 
it was found that our body is completely and almost solely covered by yeasts of the Malassezia 
genus 51. Human microbiome analysis also provide supporting information this hypothesis as we 
found that the skin microbiome is significantly altered upon superficial injury and subsequent
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mild inflammation 52. The composition of the microbial community may be crucial fo r restoring 
skin homeostasis. Atopic dermatitis skin is often infected by Staphylococcus aureus, and the 
presence of this pathogen is associated w ith disease exacerbations and therapeutic success53. 
As coal tar therapy in atopic dermatitis patients often results in long remission times in contrast 
to corticosteroids, we postulate that coal tar therapy causes a long-lasting and potentially AhR- 
mediated shift of the skin microbiome, thereby correcting the dysbiosis commonly found in atopic 
dermatitis skin. Longitudinal microbiome analysis of the skin of atopic dermatitis patients before 
and during treatment, after healing of the lesions and up to the point that a relapse occurs, will 
provide information about the role of the microbiome in disease onset.
Final considerations
"The biological significance of AhR activation is no longer a topic restricted to toxicology but 
has recently become an area of considerable interest in immunology and developmental biology. 
The study described in Chapter 6 of my thesis has underscored the therapeutic potential of AhR 
signaling in atopic dermatitis and has set the stage for rehabilitation of drugs targeting this 
receptor. With the aid of the skin models described here, it is my ambition to gain a deeper insight 
in the role of AhR in skin biology (Figure 8.3) and to develop novel therapeutics for infiammatory 
skin diseases".
Epidermis - Keratinocytes 
Immune system Proliferation/Apoptosis
Tcell development (Treg, Th 17) Differentiation/ Barnerfunction 
DC maturation and f  unction Pigmentation
Innate immune response
Figure 8.3 The proposed role of the AhR in skin homeostasis and disease. Triggers like UV radiation, 
xenobiotics, specific drugs (e.g. ketoconazole or coal tar), the micro/mycobiome (e.g. Malassezia species) 
or endogenous ligands (e.g. kynurenine) may activate the AhR in keratinocytes or resident immune cells 
(e.g. T-cells or dendritic cells (DC)) in the skin. Activation of the AhR signaling in keratinocytes affects 
keratinocytes proliferation, apoptosis and melanogenesis and induces terminal differentiation and barrier 
function. Innate immune responses may be altered by the interaction of the AhR w ith  the NFkB pathway. 
AhR activation in immune cells and keratinocytes leads to  differential responses based on the specific 
ligand-receptor interactions and appears to  be a tightly controlled process in which over-activation as 
well as inhibition may result in disturbed cell and tissue homeostasis and disease. Fine-tuning of the 
AhR signaling either by stimulation w ith  AhR ligands or inhibition by specific antagonists may have a 
therapeutic potential for infiammatory skin diseases.
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Samenvatting
De huid is een complex orgaan met vele celtypen en cel-cel interacties, dat de barrière vormt 
tussen ons lichaam en de omgeving. Gecontroleerde processen in de huid reguleren de groei 
(proliferatie) en differentiatie van de keratinocyten (opperhuidcellen). Uiteindelijk vormen de 
verschillende lagen in de epidermis (opperhuid) een compacte en ondoordringbare hoornlaag 
bestaande uit dode huidcellen. Naast een fysieke en chemische barrière, is er een tweede 
afweermechanisme aanwezig in de huid, namelijk de immuuncellen die behoren bij ons 
aangeboren immuunsysteem. De interactie tussen de keratinocyten en deze immuuncellen is van 
cruciaal belang om potentieel schadelijke stoffen te herkennen en deze te elimineren om ons 
zo te beschermen tegen ernstige en mogelijk levensbedreigende infecties. Een verstoring in de 
proliferatie of differentiatie van de keratinocyten, of in de immuunrespons, kan echter leiden to t 
ontstekingsziekten van de huid zoals atopisch eczeem of psoriasis.
Er is al jaren een grote vraag naar geschikte modellen om de normale huidbiologie en 
het ontstaan van huidziektes te bestuderen. De eerste gerapporteerde in vitro huidmodellen 
zijn gebaseerd op het kweken van één laag keratinocyten op plastic, ondergedompeld in 
kweekmedium. Maar aangezien onze huid bestaat uit meerdere cellagen en tevens blootgesteld 
is aan de lucht, zijn deze simpele celkweken niet goed te vergelijken met onze echte huid. Daarom 
probeert men in vitro huidmodellen te verbeteren en te verfijnen om zoveel mogelijk kenmerken 
en functies van de normale huid na te bootsen. Het kweken van huidcellen in hun oorspronkelijke 
3D vorm biedt een biologisch relevant en functioneel modelsysteem waarin vele eigenschappen 
van de huid onderzocht kunnen worden. De sterke gelijkenis met menselijke huid heeft geleid 
to t de invoering van humane huidequivalenten (3D huidmodellen) in toxicologisch onderzoek ter 
vervanging van proefdieren.
Ook in fundamenteel wetenschappelijk onderzoek kunnen huidequivalenten het gebruik 
van proefdieren vervangen, of op zijn minst verminderen en verfijnen. Met behulp van speciale 
technieken is het mogelijk om in een 3D huidmodel bepaalde genen uit te schakelen of juist 
verhoogd to t expressie te brengen. Hiermee kan de functie van een gen in het laboratorium 
bestudeerd worden zonder gebruik te maken van de traditionele en kostbare genetisch 
gemodificeerde (knock-out of transgene) muismodellen.
Het onderzoek beschreven in dit proefschrift omvat het maken én toepassen van in vitro 
3D huidmodellen ten behoeve van wetenschappelijk onderzoek naar basale huidbiologie, 
wondgenezing, ontstekingsprocessen van de huid, en geneesmiddelenontwikkeling.
De keratinocyten die gebruikt worden voor het maken van huidequivalenten zijn afkomstig van 
patiënten en/of gezonde vrijwilligers. Er kan echter maar een beperkte hoeveelheid humane 
keratinocyten geïsoleerd worden uit het kleine aantal huidbiopten dat van patiënten/vrijwilligers 
w ordt afgenomen. Om huidequivalenten te maken is niet alleen de hoeveelheid keratinocyten 
die men gebruikt bepalend voor de kwaliteit van de uiteindelijke 3D huidmodellen, maar ook 
de mate waarin de keratinocyten zich kunnen vermenigvuldigen tijdens de kweekperiode. 
Hoofdstuk 2 beschrijft de toepassing van een Rho-kinase remmer, Y-27632 genaamd, die 
de levensduur van keratinocyten afkomstig van volwassen vrijwilligers en patiënten succesvol 
verlengt. Deze toepassing was al eerder beschreven bij kweken van voorhuid keratinocyten. 
Echter, de eigenschappen en proliferatiecapaciteit van voorhuid keratinocyten verschilt van 
keratinocyten afkomstig van volwassen vrijwilligers. Voorhuid keratinocyten hebben stamcel-
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achtige eigenschappen en hebben daardoor een zeer lange levensduur. De huidequivalenten 
gemaakt van voorhuid keratinocyten vertonen dan ook hyperproliferatie en verhoogde expressie 
van bepaalde psoriasismarkers zoals keratine 16 , hBD-2 en SKALP. Deze keratinocyten zijn 
daarom minder geschikt om normale huidequivalenten te maken. Door het gebruik van Y-27632 
tijdens de kweekperiode waren we waren in staat om huidequivalenten te genereren met 
langdurig gekweekte keratinocyten afkomstig van volwassen vrijwilligers. Deze huidequivalenten 
leken zeer sterk op echte menselijke huid en hadden een normaal expressiepatroon wat betreft 
proliferatie en differentiatiemarkers. Deze huidequivalenten zijn vervolgens ook gebruikt om 
een psoriasis model te maken. Na stimulatie met psoriasisgeassocieerde ontstekingsmediatoren 
was de expressie van psoriasis markers, hBD-2 en SKALP sterk verhoogd. Bovendien werd de 
expressie van ontstekingsmediatoren (TNF, IL1B en CXCL8) niet beïnvloed door behandeling 
van de keratinocyten met Y-27632. Tevens werd een verhoogde efficiëntie van lentivirale 
gentransductie door toevoeging van Y-7632 aan het kweekmedium waargenomen. Daarnaast 
bleek de epidermale morfologie van de huidequivalenten gemaakt van lentivirale getransduceerde 
keratinocyten aanzienlijk verbeterd door toevoeging van Y-27632.
Hoofdstuk 3 beschrijft de rol van de cysteine proteaseremmer, cystatine M/E (CST6) tijdens het 
epidermale differentiatieproces. Gebaseerd op de zeer sterke verhoorning en ernstig verstoorde 
huidbarrière van muizen waarin het cystatine M/E gen is uitgeschakeld (Cstfr'- muizen), 
veronderstelden we dat C5T6een kandidaat-gen zou kunnen zijn voor huidaandoeningen waarin 
een verstoord verhoorningsproces leidt to t een zeer droge huid (ichthyosis). Mutatie analyse 
van het CS7"6-gen in een uitgebreide patiëntengroep met vormen van ichthyosis, waarvan het 
genetisch defect niet bekend was, leverde echter niets op. Om het effect van CST6 deficiëntie 
tijdens de vorming van de epidermis op te helderen hebben we daarom gebruik gemaakt van de 
verbeterde lentivirale knockdown strategie door toevoeging van Y-27632, zoals beschreven in 
hoofdstuk 1. Dat resulteerde in een 75-80% afname van CST6 mRNA en een totale afwezigheid 
van het cystatine M/E eiwit. Verrassenderwijs zorgde dit niet voor een verdikking van de 
epidermis en hoornlaag maar juist een gebrek aan een meerlagige epidermis. Hieruit kunnen we 
concluderen dat cystatine M/E expressie onmisbaar is voor de ontwikkeling van de epidermis, en 
dat het volledige tekort aan deze protease remmer in de huid waarschijnlijk niet samen gaat met 
het menselijk leven. De verschillen in uiterlijk tussen de Cst&' muizen en ons in vitro cystatine 
M/E deficiëntie model suggereert dat er sterke verschillen zijn tussen de menselijke huid en die 
van muizen en illustreert de kracht van humane huidequivalenten voor de analyse van de functie 
van bepaalde genen in de huid.
Wondgenezing is een belangrijk thema in de experimentele en klinische dermatologie. Veelvuldig 
wordt er gebruik gemaakt van proefdiermodellen om het effect van nieuw ontwikkelde 
wondbedekkers (in dit geval dermale matrices) op de wondgenezing te testen. Hoofdstuk 4 
beschrijft de ontwikkeling van een in vitro wondgenezingsmodel waarin verschillende dermale 
matrices getest kunnen worden. Hiervoor hebben we met een biopteur een wond gemaakt 
in onze humane huidequivalenten. Het ontstane gat hebben we vervolgens opgevuld met 
verschillende dermale matrices. Na 10 dagen was de wond in zijn geheel gesloten en was er 
een nieuwe epidermis over de wond waarneembaar. In dit model hebben we vervolgens twee 
verschillende soorten matrices getest: poreuze, op collageen gebaseerde matrix (Integra) en niet- 
poreuze matrices gemaakt van humaan bindweefsel (DED en Glyaderm). Het dichtgroeien van 
de verwonde epidermis (ofwel re-epithelialisatie) verliep het snelste over de niet-poreuze dermale
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matrix. Onze resultaten hebben we vervolgens gevalideerd in een muismodel, en ook daarin 
verliep de wondgenezing het beste door gebruik te maken van niet-poreuze dermale matrices. 
Met behulp van de lentivirale gentransductie strategie zoals beschreven in hoofdstuk 1, hebben 
we keratinocyten gelabeld met een fluorescente marker (eGFP) en daarvan huidequivalenten 
gemaakt. Na verwonding van de fluorescente huidequivalente waren we in staat om het re- 
epithelialisatie proces te volgen in de tijd met een standaard fluorescentiemicroscoop. Ons 
lichaam vormt normaal gesproken een bloedstolsel dat de wond bedekt en afsluit. Daarom 
hebben we het in vitro model verfijnd door een druppel bloed op de gecreëerde wond aan te 
brengen. Dit versnelde de wondgenezing aanzienlijk, waarschijnlijk door de vochtige omgeving 
en de stimulerende factoren die in het bloed aanwezig zijn.
Hoofdstuk 5 beschrijft de ontwikkeling van een 3D model van huidontsteking waarin de interactie 
tussen immuuncellen (in dit geval T-cellen) en keratinocyten geanalyseerd kan worden op kleine 
schaal. Bij een chronische ontsteking van de huid zoals psoriasis en eczeem is de interactie 
tussen keratinocyten en immuuncellen cruciaal voor het chronische aspect van de ziekte. Door 
een nog onbekende oorzaak produceren de immuuncellen in patiënten met psoriasis bepaalde 
ontstekingsmediatoren (cytokines) die vervolgens de keratinocyten aanzetten tot de productie 
van lokstoffen (chemokines) die hun beurt weer immuuncellen aantrekken. Deze chemokine 
productie zorgt ervoor dat er grote hoeveelheden immuuncellen de huid binnendringen. Die 
immuuncellen maken vervolgens weer cytokines die de keratinocyten activeren, waarna de vicieuze 
cirkel van chronische ontsteking rond is. Om dit proces te bestuderen hebben we geactiveerde 
CD4+ T-cellen in ons 3D huidmodel geïntroduceerd. Deze T-cellen produceerden cytokines die 
met name met psoriasis geassocieerd zijn (bijv. TNF-a, IFN-y, IL-22 en IL-17). De productie van 
chemokines bleek de eerste reactie van de keratinocyten op de aanwezigheid van T-cellen in ons 
3D huidmodel te zijn. Uiteindelijk waren vrijwel alle markers voor psoriatische huid in ons model 
aanwezig. Behandeling van het in vitro psoriasis model met ontstekingsremmende medicijnen 
(die al gebruikt worden om psoriasis te behandelen) verminderde de ontstekingswaarden, 
waardoor we kunnen stellen dat ons model geschikt is voor het testen van nieuwe medicijnen in 
een pre-klinische fase.
De behandeling van onstekingsziekten van de huid, zoals psoriasis en eczeem, is met name gericht 
op het remmen van de immuunrespons. Hiervoor worden voornamelijk corticosteroïdenzalf, UV 
straling of immunosuppresiva zoals cyclosporine of meer de geavanceerde 'biologicals' gebruikt. 
Echter, één van de oudste bekende dermatologische behandelingen is het aanbrengen van 
teerzalf op de huid. Ondanks dat dit een effectieve en veilig therapie is, neemt het gebruik van 
koolteer in de dermatologische praktijk af. Dit als gevolg van bezwaren omtrent de veiligheid 
(aanwezigheid van polycyclische koolwaterstoffen), cosmetische aspecten (geur en kleur), en 
het - to t voor kort - onbekende werkingsmechanisme. Hoofdstuk 6 beschrijft het onderzoek 
naar het moleculaire mechanisme van koolteer in atopisch eczeem. Atopisch eczeem is een Th2- 
gemedieerde ontstekingsziekte van de huid die waarschijnlijk veroorzaakt wordt door abnormale 
blootstelling aan omgevingsfactoren (bijvoorbeeld allergenen). Deze blootstelling kan optreden 
door een verminderde huidbarrière, in veel gevallen veroorzaakt door mutaties in het filaggrine 
gen. Deze mutaties zijn een belangrijke risicofactor voor het ontwikkelen van atopisch eczeem. 
Met ons onderzoek hebben wij aangetoond dat koolteer de zogenaamde arylkoolwaterstof 
receptor (AhR) activeert. Activatie van de AhR door koolteer leidt to t een verhoogde expressie 
van huidbarrière eiwitten waaronder filaggrine, en het herstel van de huidbarrière in atopisch
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eczeem patiënten. Daarnaast blijkt dat kooiteer de Th2-gemedieerde pathologische processen in 
de keratinocyten remde. Deze bevindingen rehabiliteren kooiteer als een verantwoorde therapie 
voor de behandeling van eczeem en leveren het bewijs dat de AhR een farmacologisch target is 
voor de ontwikkeling van nieuwe geneesmiddelen voor ontstekingsziekten van de huid.
Het laatste gedeelte van dit proefschrift beschrijft de resultaten van een multidisciplinair 
onderzoek naar de effecten van mutaties in het p63 gen op de ontwikkeling van de epidermis, 
en het gebruik van een 'small molecule drug' om de functie van het gemuteerde p63 eiwit 
te herstellen. De expressiedata van gekweekte keratinocyten afkomstig van EEC patiënten met 
p63 mutaties, zoals beschreven in hoofdstuk 7, laten zien dat p63 mutaties leidden to t een 
verstoorde gentranscriptie tijdens de vroege fase van epidermale differentiatie. Binnen deze 
groep van differentieel to t expressie gebrachte genen zijn we op zoek gegaan naar nieuwe 
potentiële p63 target genen. We vonden dat onder andere de expressie van ADH7 volledig 
afwezig was door de aanwezigheid van een p63 mutatie. ADH7 is betrokken bij de vorming 
van retinoïnezuur uit vitamine A en is belangrijk voor het epidermale differentiatie proces. We 
vonden dan ook een sterk verminderde expressie van terminale differentiatie eiwitten in zowel 
gekweekte EEC keratinocyten als in humane huidequivalenten gemaakt van EEC keratinocyten. 
De huidequivalenten van EEC keratinocyten waren gekenmerkt door een epidermis bestaande 
uit slechts enkele cellagen, de afwezigheid van een stratum granulosum en een slecht gevormd 
stratum corneum. Behandeling met de 'small molecule drug', APR-246, herstelde deels de p63 
target genexpressie alsook de terminale differentiatie van de keratinocyten. Daarnaast verbeterde 
de epidermale morfologie in EEC huidequivalenten door toevoeging van APR-246. Deze 
bevindingen bieden nieuwe mogelijkheden voor drug-screening en therapeutische strategieën 
om de symptomen bij patiënten met ontwikkelingsstoornissen geassocieerd met p63 mutaties 
te verminderen.
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Slotoverwegingen
1. In dit proefschrift zijn vele modificaties op de standaard 3D huidmodellen beschreven voor 
het ophelderen van specifieke genfuncties of voor het ontrafelen van ziekteprocessen. Door 
toevoeging van ziektespecifieke cellen of cytokines, of door het gebruik van geavanceerde 
gentransductie strategieën zijn er nieuwe wegen geopend om - althans gedeeltelijk - het 
gebruik van proefdiermodellen te vervangen. Deze studies bieden een platform voor vele 
wetenschappers om huidziekten te onderzoeken met behulp van 3D gekweekte menselijke 
huidcellen waarin vele kenmerken van de desbetreffende ziekte aanwezig zijn. Hoewel het 
een tijdrovende procedure is om deze 3D huidmodellen te vervaardigen, en ze niet op grote 
schaal geproduceerd kunnen worden, ben ik ervan overtuigd dat deze, in het laboratorium 
gekweekte, huidmodellen een krachtig hulpmiddel zijn voor het wetenschappelijk onderzoek 
naar de biologie van de huid, én dat ze waardevol kunnen bij de ontwikkeling van nieuwe 
geneesmiddelen.
2. Het belang van AhR activatie in het menselijk lichaam is niet langer een onderwerp wat zich 
beperkt to t de toxicologie, maar heeft recentelijk aan interesse gewonnen bij immunologen 
en ontwikkelingsbiologen. Het onderzoek beschreven in hoofdstuk 6 van mijn proefschrift 
onderstreept de kracht van AhR signalering voor de behandeling van atopisch eczeem, en 
heeft een weg gebaand voor de (her)-introductie van geneesmiddelen die gericht zijn op 
deze receptor. Met behulp van de huidmodellen beschreven in mijn proefschrift, is het mijn 
ambitie om de rol van de AhR in de biologie van de huid verder te bestuderen en om nieuwe 
therapieën te ontwikkelen voor ontstekingsziekten van de huid.
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Curriculum Vitae
Ellen van den Bogaard werd geboren op 17 juni 1984 te Balgoij (gemeente Wijchen). Na de HAVO 
op de Stedelijke Scholengemeenschap Nijmegen afgerond te hebben in 2001, begon zij aan de 
Hogere Laboratoriumopleiding aan de Hogeschool van Arnhem en Nijmegen met als specialisatie 
Cyto-Histopathologie. Voor haar afstudeerstage koos ze voor een research afdeling en kwam 
terecht op een project van de afdeling Longziekten (Prof. Richard Dekhuijzen, Radboudumc) en 
Matrix Biochemie (Dr. Toin van Kuppevelt, NCMLS) onder begeleiding van Theo Hafmans en Dr. 
Coen Ottenheijm. Daar deed zij onderzoek naar de rol van heparaansulfaten in het diafragma 
van COPD patiënten. Na de HLO werd in 2005 het schakeljaar voor de opleiding Biomedische 
Wetenschappen aan de Radboud Universiteit Nijmegen succesvol doorlopen, waarna zij in 2006 
startte met twee Masteropleidingen, Pathobiologie en Toxicologie. De afstudeerstage voor de 
Master Pathobiologie werd met zeer goed gevolg afgerond op de afdeling Dermatologie onder 
leiding van Prof. Joost Schalkwijk en Dr. Sandra Tjabringa. Deze onderzoeksstage was het begin 
van de ontwikkeling van het 3D inflammatoire huidmodel, zoals recentelijk gepubliceerd en 
beschreven in dit proefschrift. Voor haar onderzoekstage Toxicologie vertrok Ellen naar de afdeling 
Drug Delivery, Pharmaceutical Sciences division (King's College Londen, Verenigd Koninkrijk) om 
aldaar een in vitro alveolair model te ontwikkelen voor het testen van nieuwe luchtwegmedicatie. 
Deze stage leidde to t haar eerste wetenschappelijke publicatie. Na het afronden van beide Masters 
met het predicaat Cum Laude, was het tijd voor iets anders. In 2008 werkte zij gedurende 9 
maanden als study director bij NOTOX B.V. (nu WIL Research) te 's Hertogenbosch, waar zij 
proefdierstudies begeleidde ten behoeve van toxicologisch onderzoek van nieuwe chemicaliën. 
Maar de drang naar het wetenschappelijk onderzoek bleef en zij keerde in juni 2009 terug naar 
de afdeling Dermatologie (Radboudumc) om aan een project van de Brandwondenstichting 
te werken, in afwachting van een subsidie voor haar eigen promotieonderzoek. In juni 2010 
startte zij met haar promotieonderzoek onder begeleiding van Prof. Joost Schalkwijk en Prof. 
Irma Joosten, waar dit proefschrift het eindproduct van is. Tijdens haar promotieonderzoek heeft 
zij verschillende bachelor- en masterstudenten begeleid en haar werk op vele (inter)nationale 
congressen gepresenteerd. Hiervoor werden meerdere reissubsidies toegekend door (inter) 
nationale fondsen en voor haar presentaties op deze congressen ontving zij meerdere prijzen. 
In 2013 werd zij toegelaten to t de 'Academy for Future Leaders in Dermatology' georganiseerd 
door de European Society for Dermatological Research. Daarnaast heeft zij bijgedragen aan het 
project 'Onderzoeker in de klas' georganiseerd door Wetenschapsknooppunt van de Radboud 
Universiteit. Hiervoor heeft zij basisscholen bezocht om leerlingen te interesseren voor de 
wetenschap. Na goedkeuring van dit proefschrift, is zij in november 2013 voor drie maanden 
vertrokken naar de Verenigde Staten. Daar heeft zij onder begeleiding van Prof. Gary Perdew (Penn 
State University, PA) haar onderzoek naar de interactie tussen koolteer en de arylkoolwaterstof 
receptor voortgezet. Hiervoor ontving zij het Frye stipendium voor veelbelovende vrouwelijke 
onderzoekers van de Radboud Universiteit, en werd er een subsidie toegekend door het Ter 
Meulen fonds van de Koninklijke Nederlandse Akademie van Wetenschappen. Na terugkeer uit 
de Verenigde Staten heeft zij haar onderzoek naar de werking van teerzalf en de rol van de 
arylkoolwaterstof receptor in de huid voortgezet als post-doc aan de afdeling Dermatologie van 
het Radboudumc. Ellen is getrouwd met Leon van Haren en zij wonen in Overasselt.
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Zeer gewaardeerde lezer van dit proefschrift,
STOP met bladeren!
Naar alle waarschijnlijkheid heb je na ontvangst van mijn proefschrift uitvoerig de voor- en 
achterkant bestudeerd en de stellingen gelezen, de inhoudsopgave vluchtig doorgenomen 
en vervolgens de hoofdstukken na het bekijken van het voorblad overslagen, om daarna de 
Nederlandse samenvatting proberen te begrijpen (geeft niks als dat niet helemaal gelukt is). 
Het curriculum vitae wordt dan al wat leuker om te lezen en nu ben je aangekomen bij het 
dankwoord. Naar mijn mening is dit laatste afsluitende stuk net zo belangrijk als de complete 
inhoud van dit proefschrift. Aangezien ik normaal gesproken ook niet heel erg kort van stof 
ben, w ordt dit dan ook geen dankwoord van een paar schamele pagina's. Maar lees elk woord 
zorgvuldig want hier spreekt mijn hart:
Een proefschrift bij elkaar kweken, pipetteren en schrijven doet geen enkele AIO alleen, en ik 
dus ook niet. Vandaar dat een woord van dank op zijn plaats is voor diegenen die op welke 
manier dan ook hebben bijgedragen aan dit eindproduct. Maar om nu elke zin te beginnen of 
te eindigen met 'bedankt' is ook weer zo monotoon (en dat is niet echt mijn stijl) dus vanaf hier 
geen 'bedankt' meer, want als je hieronder vernoemt wordt dan geldt de volgende Brabantse 
uitdrukking: "Da ge bedankt zèt dè witte".
Ten eerste mijn promotoren Prof. Schalkwijk en Prof. Joosten, Beste Joost en Irma, een dikke 
drie jaar geleden zijn we begonnen aan een N4i AIO project om de genetisch risicofactoren 
voor psoriasis functioneel te analyseren in 3D huidmodellen. Nou, daar is uiteindelijk weinig van 
in dit proefschrift terecht gekomen. Sorry daarvoor ©. Maar in plaats daarvan hebben we wel 
ontzettend leuke en uitdagende projecten to t een goed einde gebracht met mooie publicaties 
to t gevolg.
Joost, het beperkte aantal zinnen in dit dankwoord doen geen recht aan de manier waarop jij 
mij onder je hoede hebt genomen. Ik voel me een bevoorrecht AIO dat ik in jouw  lab heb mogen 
werken. Je bent niet alleen een goede mentor en onderzoeker, maar bovenal een bijzonder 
mens. De manier waarop jij ons lab vorm en leiding geeft is naar mijn mening een voorbeeld voor 
velen. Jij hebt me alle kansen gegeven om een succesvol junior onderzoeker te worden. Naast 
een scherp oog bij het nakijken van manuscripten en je niet aflatende enthousiasme en interesse 
voor mijn onderzoek en mij als persoon, nam je de moeite om aanbevelingsbrieven te schrijven 
en mijn subsidieaanvragen kritisch te corrigeren. Aan congresbezoeken en buitenlandse tripjes 
geen gebrek de afgelopen drie jaar ©. De komende jaren als post-doc in jouw  lab worden een 
(wetenschappelijk-verantwoord) feestje, daar ben ik van overtuigd!
Irma, van een 50/50 samenwerking kwam uiteindelijk weinig terecht omdat mijn hart toch 
meer bij de dermatologie lag. Je hebt me alle vrijheid gegeven om mijn eigen ideeën vorm te geven 
maar je bleef wel altijd kritisch op hoe we die vraagstellingen zo efficiënt mogelijk op konden 
lossen. Waar ik vaak dacht: "dat testen we toch gewoon even snel in een experimentje", vroeg 
jij om meer onderbouwing en een doordacht plan. Ik ben hierdoor een kritischer onderzoeker 
geworden die nu wat vaker eerst denkt en de literatuur raadpleegt alvorens meteen het lab in te 
duiken. Ik hoop dat we in de toekomst elkaar nog vaak zullen tegenkomen.
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Co-promotor Patrick Zeeuwen, je bent mijn moleculaire vraagbaak geweest de afgelopen jaren. 
Mijn gebrek aan kennis hieraan werden ruimschoots door jou gecompenseerd. Jouw deur 
stond altijd open voor welke (al dan niet wetenschappelijk gerelateerde) vraag dan ook. Mijn 
manuscripten gingen standaard als laatste naar jou waarna jij er met de stofkam door ging. 
Geen tikfout, verkeerde referentie of foute figuurverwijzing ontsnapt aan jouw oog. Ik hoop 
ooit ook zo'n kritisch oog te ontwikkelen, maar zolang jij mijn buurman bent weet ik het wel! 
Als medevoetballiefhebber (wat doe je in hemelsnaam in de Goffert?) en mede boer-zoekt- 
vrouw criticaster/imitator hebben we op menig maandagmorgen, de zondag ervoor uitvoerig 
geanalyseerd. Jouw soms lekker platte, directe humor en scherpe opmerkingen maakt dat onze 
koffiepauzes en e-mailwisselingen nooit saai zijn. Fijn dat we de komende jaren collega's blijven.
Als hoofd van onze afdeling mag Prof. van de Kerkhof niet ontbreken in dit dankwoord. U heeft 
de juiste mix van patiëntenzorg, klinisch en experimenteel onderzoek op de afdeling Dermatologie 
samenbracht. De laagdrempeligheid die U siert en uitdraagt staat wat mij betreft aan de basis 
van het succes van de Nijmeegse Dermatologie. Iedereen is belangrijk in de organisatie en draagt 
zijn steentje bij aan het grotere geheel, het maakt dat wij de Dermatologie als 'onze' afdeling 
zien. Uw enthousiasme voor mijn onderzoek en met name voor het teeronderzoek heb ik als zeer 
prettig ervaren. Daarmee wil ook meteen de overige stafleden bedanken voor hun interesse en 
in het bijzonder Pieter van der Valk en zijn opvolgster Marijke Kamsteeg voor hun betrokkenheid 
bij het onderzoek naar de werking van teerzalf. Daarnaast mag ik natuurlijk huidig bewoner van 
mijn geboortedorp, Piet van Erp, niet vergeten. Jouw FACS kwaliteiten kwamen bijzonder goed 
van pas de afgelopen jaren en daarnaast is het leuk om op de hoogte te blijven van het reilen en 
zeilen in dat pittoreske durpke oan de Moas.
Van begeleiders gaan we over mede-AIO's, labmaatjes en (ex)-collega's. Ik kwam na mijn uitstapje 
in de industrie weer terug op het vertrouwde nest. En het was een warm bad waar ik in stapte 
door mede-AIO's Judith, Patrick J, Heleen, en later Helmi en Hanna, en post-docs Sandra, Jeroen 
en later Ferry. Hoewel we uiteenlopende projecten hadden was er altijd wel een gezamenlijke 
noemer te vinden en hebben we kunnen profiteren van eikaars expertise op het lab.
Judith, wat ben je toch een heerlijk mens! Zo optimistisch en altijd vrolijk zijn er maar weinig. 
Het lab werd stil toen jij vertrok... Woordgrapje-Patrick, zelfs in jouw  proefschrift konden ze niet 
ontbreken. Jouw lentivirus voorwerk heeft gezorgd voor drie artikelen in dit boekje, waarvoor 
mijn grote dank! Heleen, als roomies hebben we veel aan elkaar gehad. Ik bewonder jouw 
vermogen om in elk artikel een aanknopingspunt te vinden voor je eigen onderzoek. Jouw 
boekje wordt een killer-proefschrift en als die kleine straks maar half zo briljant is, dan komt hij/ 
zij er wel! Helmi, good luck with your path in Science and hopefully your new project will meet 
your expectations. Liebe Hannah, je was mijn student, werd mede-AIO, roomie, en bent nu mijn 
paranimf. Je bescheidenheid, gemeende interesse, gezelligheid en kweek-skills zijn een aanwinst 
voor ons lab en ik hoop dat je harde werk van het afgelopen jaar snel leidt to t een mooi paper. 
Je moet eerst zaaien om te oogsten! Jeroen, samen hebben we gewerkt aan het project voor de 
Brandwondenstichting en dit heeft geresulteerd in hoofdstuk 4 van dit boekje. Die wondgenezing 
is zo simpel nog niet en er bleek veel voor nodig om een goed model te creëren. Succes op de 
HAN, en je weet het: alle goede studenten onze kant op sturen! Sandra, onze samenwerking 
heeft uiteindelijk geresulteerd in hoofdstuk 5 en een mooi JID paper, waar we naar mijn mening 
allebei trots op kunnen zijn. Ferry, je kwam als post-doc op ons lab maar besloot al na een jaar over 
te stappen naar de gevreesde mannen-in-pak ©. Je was een moleculaire én gezellige aanwinst
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voor ons lab, maar nu hebben we Merel voor jou in de plaats gekregen. En Merel, jij past ook 
heel goed bij ons clubje! Van leuke collega's kun je er niet genoeg hebben. Jos, onze nieuwste 
aanwinst in het derma-lab. The coal tar story continues... Ik ben blij dat jij mijn eerste AIO bent 
om te begeleiden en ik weet zeker dat we een goed team gaan vormen voor de komende jaren. 
Naast een leuke collega ben je mede-Ajacied, en ook daarvan kan je er nooit genoeg hebben!
Dan als laatste de klinische onderzoekers, de meiden van de bieb ©. Het soort onderzoek 
dat we doen ligt soms mijlenver uiteen waardoor het lastig is om veel van eikaars onderzoek 
te begrijpen...maar dat maakt het er niet minder gezellig om! Succes met jullie promoties, 
trouwerijen en natuurlijk de opleiding tot dermatoloog... maar dat gaat zeker goed komen. Malou 
en Romy, is het nu klinisch onderzoek of experimentele dermatologie wat jullie bezig houdt? De 
categorie 'tussen wal en schip' past wel bij jullie. Knap hoe jullie dat weten te combineren. 
Daarnaast hebben we ontzettend veel gelachen tijdens de congressen die we samen bezocht 
hebben (ESDR's, de IID en de NVED niet te vergeten).
Waar zouden wij als AIO's zijn zonder de ondersteuning van analisten. Daarom een aparte alinea 
voor de steunpilaren van het lab. Diana, wat heb ik veel aan jou gehad. Die verrekte celbank 
die we gingen kweken voor de HLA-C expressie studies: 70 primaire cellijnen, verschillende 
groeisnelheden en cytokine stimulaties. En dan denk je dat je alles onder controle hebt... leggen 
de cellen het loodje. Alles opnieuw moeten doen... drie keer is scheepsrecht! Daarnaast hebben 
we samen het Y van columbus uitgevonden en ben jij altijd bereid geweest om weer één van mijn 
vele projectjes to t uitvoer te brengen. Ook is het altijd gezellig met jou in de kweek want er zijn 
altijd wel nieuwtjes, roddels of nieuwe collega's die uitvoerig besproken moeten worden. Het was 
een logische keuze om jou als paranimf te kiezen.
Het kweken van 3D huidmodellen gaat één op één samen met veel histologie en kleuringen. 
Ivonne en Mieke, jullie hebben veel van deze kleuringen voor mij uitgevoerd en prijken in vrijwel 
elk hoofdstuk van dit proefschrift. Kleuren is één ding maar het maken van goede microscopische 
opnamen is een ander vak, en ook daarin ben je een kei, Ivonne! Waar in veel publicaties foto's 
staan van baggerkwaliteit ben ik trots op onze publicaties voorzien van heldere en duidelijke foto's. 
Roelie, als ex-roomie en Elkie als new-roomie, het lab was/is kleurrijker door jullie aanwezigheid!
Alhoewel ik het meeste van mijn tijd op het lab van de Dermatologie heb doorgebracht, 
was de samenwerking met het Laboratorium voor Medische Immunologie de basis van mijn 
promotieonderzoek. Vanuit de staf was er altijd belangstelling voor mijn doen en laten. Hans 
(Koenen), we hebben uiteindelijk nog veel experimenten moeten doen om het 3D T-cel model op 
papier te krijgen voor de JID. Ik ben dan ook dankbaar dat je mij de mogelijkheid hebt gegeven 
om dit model verder uit te werken. Ondanks dat wij af en toe niet helemaal op dezelfde golflengte 
zaten, vind ik je een toffe kerel en waardeer ik je inzet en belangstelling voor mijn onderzoek. 
Die T-cellen in dat huidmodel moeten ergens vandaag komen en daarvoor ben ik veel dank 
verschuldigd aan Esther van Rijssen. Esther Fasse en Bram, ook de ELISA en Luminex analyses van 
die T-cellen waren zeer waardevol voor mij! Henk en Kjeld mogen ook zeker niet ontbreken in 
dit dankwoord. Mijn project ging in eerste instantie om de HLA-C analyse en typering van onze 
keratinocyt-celbank. De data liggen er... nu alleen nog een logisch verhaal om ze te verbinden. 
Hopelijk prijken onze namen op een toekomstig paper zodat jullie harde werk niet voor niets 
is geweest. Natuurlijk mag ik ook de mede-AIOs van het LMI niet vergeten, en in het bijzonder 
Elena en Sip. Onze onderzoeken hadden weinig raakvlakken maar op persoonlijk vlak was het 
altijd leuk! Veel succes met de afronding van jullie promotieonderzoek.
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In de afgelopen 3 jaar zijn er een aantal studenten de revue gepasseerd. Renso, jij was mijn eerste 
student en samen hebben we de functie van LCE genen tijdens de vorming van de huidbarrière 
bestudeerd. Jouw stage was een goede leerschool voor ons beiden! Carlin, we tried to improve 
the keratinocyte differentiation of induced pluripotent stem cells. Unfortunately, it was just too 
much to handle fo r the short period of your internship. It was nice to have you at our lab! Hanna, 
je kwam, zag en overwon. Heerlijk, zo'n zelfstandige student, fijn dat we nu collega's zijn! Sjoerd, 
jij kwam terecht in ons teerzalf onderzoek en met één weekje van uitleg was de klus geklaard. 
Daarnaast bleek je super-schrijver te zijn en had ik weinig tijd nodig om je verslag en scriptie te 
corrigeren. Ik besef dat ik het ontzettend heb getroffen met jullie als studenten. Heel veel succes 
met alles wat er in de toekomst op jullie pad komt.
Dit dankwoord zou niet compleet zijn zonder ook mijn overige collega's van de afdeling 
Dermatologie te bedanken. Medewerkers van het secretariaat, administratie, poli, ATB, onze 
medisch fotografen en arts-assistenten, ook voor jullie geldt die Brabantse uitdrukking!
Waar ben je als onderzoeker zonder goede samenwerkingsverbanden? In mijn ogen is het van 
onschatbare waarde om je krachten te bundelen en van eikaars kennis en expertise te profiteren. 
Samen sta je sterk! Het lab van Jo Zhou bleek een schot in de roos. Jo, thanks for giving me the 
opportunity to collaborate w ith you on the p63-PRIMA project. (PRIMA or APR-246...I still find 
PRIMA more fun to use ©). You invited me to the lab of Prof. Daniel Aberdam in Haifa, Israël, 
and introduced me to the wonders of stem cell culture. I truly hope that our collaboration will 
continue in the future. Evelyn, ook jou mag ik niet vergeten. De laatste loodjes voor het PNAS 
artikel waren zwaar en ik heb die PNAS reviewers vervloekt... maar wat ontzettend gaaf dat we 
daar in staan, mede dankzij jouw  extra werk! Heel veel succes met het laatste deel van jouw 
promotieonderzoek.
Het ontwikkelen van 3D huidmodellen levert veel interessante toepassingen op, zo ook die 
voor het onderzoek naar melanoom huidkanker. Samen met Stanleyson en Stephania van de 
afdeling Tumor Immunologie (onder leiding van Prof. Figdor) proberen we om deze ernstige vorm 
van kanker na te bootsten in een 3D huidmodel. It has been great working w ith you guys over the 
last years! Stanley, special thanks for the beautiful (p)STAT6 blots in our JCI paper, and Stephania, 
best of luck w ith your research project. Hopefully we will manage to create some form of multi- 
cellular 3D melanoma microenvironment.
Vaak zijn antilichamen voor die ene speciale kleuring simpelweg te bestellen. Maar er zijn 
uitzonderingen waarbij je afhankelijk bent van de vrijgevigheid van anderen. Prof. Schröder, dear 
Jens, thank you very much for kindly providing your hornerin antibodies to us and for being so 
enthusiastic and supportive about our coal tar studies.
Naast het werken op het Dermatologie en LMI lab heb ik het geluk gehad ook buiten de 
Nederlandse grenzen rond te kijken. Prof. Aberdam, dear Daniel, it was truly a pleasure joining 
your lab in Haifa and having a first taste on generating induced pluripotent stem cells. I wish you 
and Edith all the best and perhaps we will meet again at some Gordon conference ©.
Het teerzalf onderzoek bracht een nieuwe speler in ons dermatologische onderzoeksveld, 
de arylkoolwaterstof receptor. Er bleek weinig kennis in Nederland over deze obscure 'dioxine- 
receptor' maar in de US was wel een expert te vinden. Drie maanden Penn State University waren 
het gevolg van overzees e-mailverkeer. Prof. Perdew, dear Gary, it is hard to  put into words how 
much I appreciate the given opportunity to work in your lab and to learn all about the fascinating
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aspects of AhR pharmacology. Not only I was warmly welcomed by your lab (special thanks to 
Troy, Ann, Kelly, Tejas, lain, Kayla, Nate and Elif), but you also welcomed me into your home and 
family. The dinners, weekend entertainment, care packages, milk and beer supply provided by 
you and your lovely w ife Marcia (my surrogate mother) were much appreciated! I have gained 
so much in those three months. Hopefully this is only the start o f a long lasting collaboration 
and we will be able to produce some nice papers in the future. We have only seen the tip of the 
AhR-iceberg yet!
Van werk over naar vrienden. Want die kun je niet genoeg hebben wat mij betreft! Want 
naast werken is een lekker druk sociaal leven een echte uitlaatklep om even weg te zijn van de 
promotiestress (niet dat ik die gehad heb overigens ©). Kaat en Annemarie, onze werelden gingen 
na de basisschool uiteen maar wat is het fijn om te weten dat het altijd weer gezellig is als we 
elkaar spreken. Karin, Anne en Martine, van teamgenoten bij het korfbal to t sportmaatjes in de 
sportschool. Hoewel ik helaas afgehaakt ben op het laatst heb ik genoten van die uurtjes lekker 
zweten en vooral lachen! Marlien, we werden vriendinnen op de HAVO en beloofden trouw 
contact te houden. Dit bleek af en toe lastig met onze drukke agenda's maar de vriendschap houdt 
stand, ongeacht hoe lang we elkaar niet hebben gezien. Dan weet je dat je echte vriendinnen 
bent! Neeltje, onze eerste indruk van elkaar op de HLO was nou niet bepaald een goede basis 
voor een langdurige vriendschap. Maar een eerste indruk zegt niet alles zo blijkt maar weer. Na 
onze wilde HLO tijd gingen we naar de uni om BMW te studeren en uiteindelijk zijn we nu allebei 
(bijna) gepromoveerd. Fijn dat we altijd contact hebben gehouden en ik kom je zeker in Montana 
opzoeken. Anita, we kwamen elkaar in het schakeljaar van Biomedische wetenschappen tegen 
en het klikte meteen. Heerlijk, hoe wij zonder moeite uren achter elkaar volkletsen (jij wat meer 
aan het woord dan ik, voor de verandering... ©). En elke keer komen we to t dezelfde conclusie: 
dit moeten we vaker doen, dus bij deze nogmaals! Je bent één van de weinige van deze alinea 
die weet hoe het is om AIO te zijn, en het was dan ook heel fijn om samen de highs and lows van 
het promoveren te kunnen delen.
Mr. Milkshake_Henk, Kampioenen_Bernie en Vrij-gezelligejappie, onze voetbalmaatjes, wat 
is het toch fijn om in het weekend dat prachtige rood-wit gekleurde shirt met die drie sterren op 
de borst aan te mogen trekken, de auto in te stappen en richting Amsterdam te rijden. Lekker 
verstand op nul en (over het algemeen) genieten van mooi voetbal. WZAWZDB!!!
Beter een goede buur dan een verre vriend zeggen we weleens, maar je kan ze ook 
combineren natuurlijk! Buurtjes Willy en Jessica, jullie staan altijd voor ons klaar. Van ANWB 
naast de deur service to t hondenuitlaatservice en hangtafel hofleverancier, nummer 17 is van alle 
markten thuis! Daarnaast is het prettig om te weten dat als mijn experimenten uitlopen of als er 
een borrel is na het werk, er altijd iemand klaar staat om voor onze viervoeter te zorgen.
Dan het kletstrio, Marlies, Marieke en Haske, veel woorden ga ik niet aan jullie besteden 
want wij hebben geen woorden nodig om elkaar te begrijpen. Bedankt voor jullie vriendschap, in 
leuke en minder leuke tijden zijn wij er voor elkaar en het is zo ontzettend fijn om dat in je leven 
te hebben. Best Friends 4-life! Het kletstrio wordt dan vervolgens aangevuld met de mannen tot 
de kwats-app. Heren, jullie zijn geweldig! Platte humor, scherpe humor, voetbalhumor, grappige 
filmpjes en foute foto's. Het is elke dag weer een verrassing wat er voorbij zal komen op de what's 
app. Gezellig is het in ieder geval altijd, of dat nu bij iemand thuis op de bank is of in de kroeg. 
Ook al snappen jullie geen hout van wat ik elke dag op het lab uitvoer, interesse is er altijd van 
jullie kant. En ach, met een biertje erbij hoeven we het ook helemaal niet over werk te hebben. 
Drinkmaatjes 4-life © !
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Dit proefschrift is in deze vorm to t stand gekomen tijdens mijn verblijf in Amerika na vele uurtjes 
prutsen achter de laptop. Maar zonder de hulp van mijn naamgenoot, Ellen (Swinkels), was mij 
dit echt niet gelukt. De spoedcursus InDesign zorgde voor een vliegende start en jouw  grafisch 
inzicht en handigheid heeft mijn vier-seizoenenboom idee omgetoverd to t een super gave 
voorkant!
Werk, vrienden... tijd voorfamilie. Altijd was er belangstelling. Voor mijn onderzoek en alles wat 
me bezig hield. Hoe wasje dag vandaag? Zijn je experimenten gelukt? Waar ga je nu weer naar 
toe op reis? Moeten we je wegbrengen of heb je vervoer? Is er iets geregeld voor Bailey? Denk 
je wel goed aan jezelf? Is het niet allemaal een beetje veel, Ellen? Wat zeg je... naar Amerika... 
voor drie maanden?! Jullie oprechte interesse (al is het vaak allemaal abracadabra voor jullie) en 
goede zorgen hebben het de afgelopen drie jaar makkelijk gemaakt om me volledig op het werk 
te storten, wetende dat jullie achter ons staan.
Lieve schoonfamilie, Henny en Leny, Ramona en Sebas en natuurlijk die knapperds van 
petekindjes, Yitte en Hessel. Het geeft rust te weten dat je familie hebt om op terug te kunnen 
vallen, en vanaf dag 1 dat ik bij jullie binnenstapte heb ik me welkom en geliefd gevoeld. Jullie 
huis werd mijn tweede thuis.
Lieve Judith, mijn grote en verstandige zus, wat ben ik trots op jou en je nieuwbakken 
gezinnetje. Die kleine Finn is prachtige toevoeging aan onze familie. Heerlijk zo'n manneke erbij! 
Na een aantal zoekende jaren heb je jouw  geluk en rust gevonden bij Wilko. Het is geweldig om 
je zo gelukkig te zien!
Dan, pap en mam... ik ben dankbaar dat jullie ons geluk destijds verkozen boven dat van 
jullie zelf. Opgroeien met een thuis en een compleet gezin is wat elk kind gelukkig maakt. Jullie 
hebben mij alle kansen gegeven om te studeren en te worden wie ik nu ben. In alles hebben jullie 
me gesteund en ik ben dankbaar voor wat jullie mij hebben gegeven. Trots ben ik ook op het feit 
dat jullie uiteindelijk toch voor je eigen geluk hebben durven kiezen, én dat jullie gewoon naast 
elkaar op de voorste rij zullen zitten tijdens mijn promotie, vergezeld door jullie nieuwe partners. 
Fijn dat dit gewoon kan! Ik hou van jullie...
Collega's, vrienden, familie... liefde van mijn leven. Alles leuk en aardig dat promoveren en 
carrière maken, maar het leven zou eenzaam en leeg zijn zonder jou, lieve Leon. Ik hoef hier niet 
uit de doeken te doen wat jij voor mij betekent, want na 14 jaar samen weten wij wel wat we 
aan elkaar hebben. Lief en leed hebben we gedeeld en ik zou simpelweg niet weten wie of wat 
ik zonder jou zou zijn. Uitleggen wat ik zoal op het lab uitvoer of wat me bezighoudt is niet altijd 
makkelijk, maar je snapt wel dat onderzoek doen belangrijk voor mij is én dat het me gelukkig 
maakt, en dat is meer dan genoeg. We hebben een ontzettend fijn leven opgebouwd met lieve 
familie en vrienden, een mooi en warm thuis, met de leukste hond ter wereld die ons leven extra 
kleur geeft. Wie weet wat de toekomst ons nog meer voor moois zal brengen? Tot nu toe was 
het in ieder geval een feestje... en daar hou ik wel van!
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List of Abbreviations
2D tw o dimensional
3D three dimensional
AD atopic dermatitis
ADH7 alcohol dehydrogenase 7
AEC ankyloblepharon-ectodermal defects-cleft lip/palate
AhR aryl hydrocarbon receptor
AMP anti-microbial peptide
ARCI autosomal recessive congenital ichthyosis
ARNT aryl hydrocarbon receptor nuclear translocator
ATRA all-trans retinoic acid
bHLH basic helix-loop-helix
BS binding site
CA2 carbonic anhydrase-2
CA2+ calcium
CCHCR1 coiled-coil alpha-helical rod protein 1
CCL chemokine C-C M otif Ligand
CD cluster of differentiation
CDSN corneodesmosin
CE cornified envelope
CHiP-seq chromatin immunoprecipitation sequencing
CsA cyclosporin A
CST6 cystatin M/E
CTSL cathepsin L
CTSV cathepsin V
CXCL CXC chemokine ligand
CYP cytochrome P450
DC dendritic cell
DED de-epidermised dermis
DNA deoxyribonucleic acid
ECM extracellular matrix
ED ectrodermal dysplasia
EEC ectrodactyly-ectodermal dysplasia-cleft syndrome
EGF epidermal growth factor
EGFR epidermal growth factor receptor
eGFP enhanced green fluorescent protein
ELISA enzyme-linked immunosorbent assay
ES embryonic stem
FBXL19 F-box and leucine-rich repeat protein 19
FLG filaggrin
GM-CSF granulocyte-macrophage colony-stimulating factor
GO gene ontology
HAK human adult keratinocyte
hBD2 human beta defensin 2
HB-EGF heparin binding epidermal growth factor
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HFK human foreskin keratinocyte
HLA human leukocyte antigen
HRNR hornerin
HSE human skin equivalent
Hsp heat shock protein
IFN interferon
IgE immunoglobulin E
IL interleukin
iPSC induced pluripotent stem cell
ITGB1 beta 1 integrin
IVL involucrin
kb kilobase
KRT/K keratin
LCE late cornified envelope
LGMN legumain
MLPA multiplex ligation-dependent probe amplification
mRNA messenger RNA
MRP8 myeloid related protein 8
NELL2 NEL-like protein 2
NFk B nuclear factor kappa-light-chain-enhancer of activated B cells
NR nuclear hormone receptor
Nrf2 nuclear factor (erythroid-derived 2)-like 2
OAS 2'-5'-oligoadenylate synthetase 2
PAH polycyclic aromatic hydrocarbon
PD population doubling
PPAR peroxisome proliferator-activated receptors
PSORS psoriasis susceptibility locus
REL v-rel avian reticuloendotheliosis viral oncogene homolog
RNA ribonucleic acid
RNAi RNA interference
RNA-seq RNA sequencing
ROCK Rho-associated protein kinase
RPLPO ribosomal protein, large, PO
RPTN repetin
RT-qPCR real time quantitative polymerase chain reaction
S. aureus Staphylococcus aureus
shRNA short hairpin RNA
siRNA small interfering RNA
SKALP peptidase inhibitor 3 or skin-derived antileukoprotease or elafin
SPINK5 serine protease inhibitor Kazal-type 5
SPRR small proline rich repeat
STAT signal transducer and activator of transcription
TA trans activating
TARC thymus and activation-regulated chemokine
TCDD 2,3,7,8-tetrachlorodibenzodioxin
TGM/TGase transglutaminase
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TG F transforming growth factor
Th T helper
TNF-a tumor necrosis factor alpha
UV ultraviolet
XRE xenobiotic response element
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"In my thesis, 
many modifications to the 
conventional 3D skin models have 
been described, to elucidate gene function 
or to unravel pathophysiological pathways. 
These studies provide a platform for scientists to 
study skin diseases using human cells organized 
in a 3D structure and will open new  avenues to 
reduce the use o f  experimental animaI models. 
Although being time consuming to produce, and  
not amenable to high throughput, I believe that 
in vitro skin disease models are a pow erfu l 
tooi to move the field o f keratinocyte 
biology forward, and that they will 
aid in the developm ent o f novel 
therapeutic stra teg ies."
